

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 10 ROUTINE

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH				
001 ALAN AMINO	ALT/SGPT	CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE	15	%	OR	6.00	{GREATER}					
2025-001	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	17	124.588	4.995	4.01	106.000	143.000				
2025-001	8 OX.OF NADH	220 Medica E.	130 MEDICA	10	116.600	3.499	3.00	99.000	134.000				
2025-001	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	81	136.272	3.742	2.75	116.000	157.000				
2025-001	11 MOD. IFCC	184 INTEGRA	93 ROCHE	18	123.167	4.153	3.37	105.000	142.000				
2025-001	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	32	113.844	3.336	2.93	97.000	131.000				
2025-001	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	147.724	13.326	9.02	126.000	170.000				
2025-001	11 MOD. IFCC	203 ROCHE	93 ROCHE	45	124.956	3.105	2.49	106.000	144.000				
2025-001	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	21	134.444	5.166	3.84	114.000	155.000				
2025-001	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	21	145.500	4.566	3.14	124.000	167.000				
2025-001	12 IFCC witho	203 ROCHE	93 ROCHE	14	125.714	3.411	2.71	107.000	145.000				
2025-001	13 ALA &aKETO	165 VITROS	155 ALTV	130	122.194	3.334	2.73	104.000	141.000				
2025-002	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	17	282.750	12.316	4.36	240.000	325.000				
2025-002	8 OX.OF NADH	220 Medica E.	130 MEDICA	10	259.100	7.674	2.96	220.000	298.000				
2025-002	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	81	297.963	6.235	2.09	253.000	343.000				
2025-002	11 MOD. IFCC	184 INTEGRA	93 ROCHE	18	274.444	6.440	2.35	233.000	316.000				
2025-002	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	32	253.281	7.645	3.02	215.000	291.000				
2025-002	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	323.571	33.515	10.36	275.000	372.000				
2025-002	11 MOD. IFCC	203 ROCHE	93 ROCHE	45	279.867	7.323	2.62	238.000	322.000				
2025-002	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	21	322.250	9.554	2.96	274.000	371.000				
2025-002	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	21	289.333	7.986	2.76	246.000	333.000				
2025-002	12 IFCC witho	203 ROCHE	93 ROCHE	14	278.786	7.627	2.74	237.000	321.000				
2025-002	13 ALA &aKETO	165 VITROS	155 ALTV	130	260.258	5.890	2.26	221.000	299.000				
2025-003	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	17	358.176	25.657	7.16	304.000	412.000				
2025-003	8 OX.OF NADH	220 Medica E.	130 MEDICA	10	325.800	11.080	3.40	277.000	375.000				
2025-003	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	81	377.400	11.471	3.04	321.000	434.000				
2025-003	11 MOD. IFCC	184 INTEGRA	93 ROCHE	18	346.500	11.959	3.45	295.000	398.000				
2025-003	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	32	321.938	12.801	3.98	274.000	370.000				

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-003	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	29	404.241	50.505	12.49	344.000	465.000		
2025-003	11 MOD. IFCC	203	ROCHE	93	ROCHE	45	353.614	12.709	3.59	301.000	407.000		
2025-003	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	21	360.333	20.028	5.56	306.000	414.000		
2025-003	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	21	402.905	15.482	3.84	342.000	463.000		
2025-003	12 IFCC witho	203	ROCHE	93	ROCHE	14	355.786	10.564	2.97	302.000	409.000		
2025-003	13 ALA &aKETO	165	VITROS	155	ALTV	130	324.217	8.596	2.65	276.000	373.000		
001 ALAN AMINO ALT/SGPT		CLIA TEST ID #: 255		EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}									
2025-004	5 ENZ. 37 C	197	ARCHITECT	1	ABBOTT	17	67.824	2.503	3.69	58.000	78.000		
2025-004	8 OX.OF NADH	220	Medica E.	130	MEDICA	10	62.600	8.126	12.98	53.000	72.000		
2025-004	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	81	76.840	2.391	3.11	65.000	88.000		
2025-004	11 MOD. IFCC	184	INTEGRA	93	ROCHE	18	67.278	1.726	2.57	57.000	77.000		
2025-004	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	32	61.719	1.924	3.12	52.000	71.000		
2025-004	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	29	80.448	6.790	8.44	68.000	93.000		
2025-004	11 MOD. IFCC	203	ROCHE	93	ROCHE	45	68.091	1.716	2.52	58.000	78.000		
2025-004	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	21	79.571	2.173	2.73	68.000	92.000		
2025-004	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	21	79.778	1.030	1.29	68.000	92.000		
2025-004	12 IFCC witho	203	ROCHE	93	ROCHE	14	68.500	1.500	2.19	58.000	79.000		
2025-004	13 ALA &aKETO	165	VITROS	155	ALTV	130	66.276	1.787	2.70	56.000	76.000		
2025-005	5 ENZ. 37 C	197	ARCHITECT	1	ABBOTT	17	14.588	1.032	7.08	9.000	21.000		
2025-005	8 OX.OF NADH	220	Medica E.	130	MEDICA	10	17.200	1.536	8.93	11.000	23.000		
2025-005	11 MOD. IFCC	38	SIEMENS DI	143	SIEMENS	81	19.963	1.691	8.47	14.000	26.000		
2025-005	11 MOD. IFCC	184	INTEGRA	93	ROCHE	18	14.722	1.557	10.57	9.000	21.000		
2025-005	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	32	14.219	0.739	5.20	8.000	20.000		
2025-005	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	29	17.310	2.365	13.66	11.000	23.000		
2025-005	11 MOD. IFCC	203	ROCHE	93	ROCHE	45	14.889	1.251	8.40	9.000	21.000		
2025-005	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	21	25.333	2.981	11.77	19.000	31.000		
2025-005	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	21	18.400	1.562	8.49	12.000	24.000		
2025-005	12 IFCC witho	203	ROCHE	93	ROCHE	14	15.143	1.125	7.43	9.000	21.000		
2025-005	13 ALA &aKETO	165	VITROS	155	ALTV	130	12.754	0.773	6.06	7.000	19.000		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY      SUB: 10 ROUTINE      GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
002	ALBUMIN	CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 8 %						
2025-001	3	DYE BI-B.G	165	VITROS	63	KODAK	141	2.824	0.094	3.34	2.600	3.100
2025-001	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	27	2.985	0.104	3.50	2.700	3.200
2025-001	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	32	2.853	0.066	2.32	2.600	3.100
2025-001	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	30	2.933	0.137	4.69	2.700	3.200
2025-001	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	30	2.917	0.113	3.87	2.700	3.200
2025-001	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	2.960	0.066	2.24	2.700	3.200
2025-001	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	15	2.807	0.068	2.42	2.600	3.000
2025-001	3	DYE BI-B.G	203	ROCHE	93	ROCHE	59	2.998	0.075	2.49	2.800	3.200
2025-001	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	20	2.874	0.085	2.95	2.600	3.100
2025-001	3	DYE BI-B.G	220	Medica E.	130	MEDICA	11	2.982	0.083	2.79	2.700	3.200
2025-001	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	85	2.559	0.089	3.46	2.400	2.800
2025-001	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	85	2.525	0.043	1.71	2.300	2.700
2025-002	3	DYE BI-B.G	165	VITROS	63	KODAK	141	4.274	0.162	3.80	3.900	4.600
2025-002	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	27	4.281	0.107	2.51	3.900	4.600
2025-002	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	32	4.188	0.093	2.21	3.900	4.500
2025-002	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	30	4.193	0.148	3.54	3.900	4.500
2025-002	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	30	4.317	0.157	3.64	4.000	4.700
2025-002	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	4.350	0.128	2.95	4.000	4.700
2025-002	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	15	4.129	0.088	2.13	3.800	4.500
2025-002	3	DYE BI-B.G	203	ROCHE	93	ROCHE	59	4.300	0.104	2.42	4.000	4.600
2025-002	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	20	4.284	0.150	3.49	3.900	4.600
2025-002	3	DYE BI-B.G	220	Medica E.	130	MEDICA	11	4.473	0.154	3.45	4.100	4.800
2025-002	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	85	3.850	0.166	4.31	3.500	4.200
2025-002	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	85	3.876	0.118	3.04	3.600	4.200
2025-003	3	DYE BI-B.G	165	VITROS	63	KODAK	141	5.088	0.164	3.22	4.700	5.500
2025-003	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	27	4.938	0.124	2.52	4.500	5.300
2025-003	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	32	4.934	0.157	3.19	4.500	5.300

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-003	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	30	5.017	0.177	3.53	4.600	5.400
2025-003	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	30	4.870	0.172	3.52	4.500	5.300
2025-003	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	5.190	0.083	1.60	4.800	5.600
2025-003	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	15	4.740	0.268	5.65	4.400	5.100
2025-003	3	DYE BI-B.G	203	ROCHE	93	ROCHE	59	4.979	0.098	1.96	4.600	5.400
2025-003	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	20	5.015	0.190	3.80	4.600	5.400
2025-003	3	DYE BI-B.G	220	Medica E.	130	MEDICA	11	5.136	0.192	3.74	4.700	5.500
2025-003	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	85	4.633	0.130	2.81	4.300	5.000
2025-003	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	85	4.500	0.071	1.57	4.100	4.900
002 ALBUMIN		CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 8 %						
2025-004	3	DYE BI-B.G	165	VITROS	63	KODAK	141	2.291	0.082	3.58	2.100	2.500
2025-004	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	27	2.492	0.067	2.71	2.300	2.700
2025-004	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	32	2.347	0.066	2.82	2.200	2.500
2025-004	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	30	2.437	0.105	4.30	2.200	2.600
2025-004	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	30	2.450	0.096	3.91	2.300	2.600
2025-004	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	2.450	0.092	3.76	2.300	2.600
2025-004	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	15	2.287	0.062	2.70	2.100	2.500
2025-004	3	DYE BI-B.G	203	ROCHE	93	ROCHE	59	2.507	0.086	3.43	2.300	2.700
2025-004	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	20	2.350	0.067	2.85	2.200	2.500
2025-004	3	DYE BI-B.G	220	Medica E.	130	MEDICA	11	2.440	0.066	2.72	2.200	2.600
2025-004	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	85	2.100	0.071	3.37	1.900	2.300
2025-004	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	85	2.094	0.075	3.58	1.900	2.300
2025-005	3	DYE BI-B.G	165	VITROS	63	KODAK	141	1.822	0.065	3.56	1.700	2.000
2025-005	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	27	2.041	0.083	4.06	1.900	2.200
2025-005	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	32	1.897	0.053	2.79	1.700	2.000
2025-005	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	30	2.033	0.075	3.67	1.900	2.200
2025-005	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	30	1.970	0.078	3.96	1.800	2.100
2025-005	3	DYE BI-B.G	194	BIOLIS-24S	154	(IDG)	10	1.990	0.070	3.52	1.800	2.100
2025-005	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	15	1.827	0.044	2.42	1.700	2.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-005	3	DYE BI-B.G	203	ROCHE	93	ROCHE	59	2.048	0.065	3.17	1.900	2.200
2025-005	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	20	1.905	0.051	2.68	1.800	2.100
2025-005	3	DYE BI-B.G	220	Medica E.	130	MEDICA	11	1.927	0.075	3.89	1.800	2.100
2025-005	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	85	1.639	0.069	4.22	1.500	1.800
2025-005	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	85	1.625	0.043	2.66	1.500	1.800
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-001	3	COLORIMET.	184	INTEGRA	93	ROCHE	22	115.318	6.342	5.50	92.000	138.000
2025-001	3	COLORIMET.	203	ROCHE	93	ROCHE	41	115.390	5.079	4.40	92.000	138.000
2025-001	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	12	103.417	6.278	6.07	83.000	124.000
2025-001	6	KINETIC 37	165	VITROS	63	KODAK	141	112.886	7.041	6.24	90.000	135.000
2025-001	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	32	93.250	7.782	8.35	75.000	112.000
2025-001	10	IFCC	219	ATELLICA	143	SIEMENS	21	110.000	4.940	4.49	88.000	132.000
2025-001	11	Modified I	38	SIEMENS DI	143	SIEMENS	78	120.481	4.620	3.83	96.000	145.000
2025-001	11	Modified I	191	RX-SERIES	126	RANDOX	26	100.500	6.851	6.82	80.000	121.000
2025-001	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	101.545	7.037	6.93	81.000	122.000
2025-002	3	COLORIMET.	184	INTEGRA	93	ROCHE	22	241.524	8.644	3.58	193.000	290.000
2025-002	3	COLORIMET.	203	ROCHE	93	ROCHE	41	245.525	9.492	3.87	196.000	295.000
2025-002	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	12	223.167	26.761	11.99	179.000	268.000
2025-002	6	KINETIC 37	165	VITROS	63	KODAK	141	157.028	10.666	6.79	126.000	188.000
2025-002	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	32	198.219	16.509	8.33	159.000	238.000
2025-002	10	IFCC	219	ATELLICA	143	SIEMENS	21	235.100	10.922	4.65	188.000	282.000
2025-002	11	Modified I	38	SIEMENS DI	143	SIEMENS	78	256.662	8.171	3.18	205.000	308.000
2025-002	11	Modified I	191	RX-SERIES	126	RANDOX	26	204.000	14.686	7.20	163.000	245.000
2025-002	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	11	214.636	16.350	7.62	172.000	258.000
2025-003	3	COLORIMET.	184	INTEGRA	93	ROCHE	22	320.136	16.094	5.03	256.000	384.000
2025-003	3	COLORIMET.	203	ROCHE	93	ROCHE	41	319.650	14.944	4.68	256.000	384.000
2025-003	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	12	274.583	21.647	7.88	220.000	330.000
2025-003	6	KINETIC 37	165	VITROS	63	KODAK	141	162.429	11.271	6.94	130.000	195.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2025-003	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	32	256.094	19.646	7.67	205.000	307.000			
2025-003	10 IFCC	219 ATELLICA	143 SIEMENS	21	304.571	12.808	4.21	244.000	365.000			
2025-003	11 Modified I	38 SIEMENS DI	143 SIEMENS	78	335.039	10.667	3.18	268.000	402.000			
2025-003	11 Modified I	191 RX-SERIES	126 RANDOX	26	261.654	18.140	6.93	209.000	314.000			
2025-003	12 P NITRO PH	197 ARCHITECT	1 ABBOTT	11	275.455	17.931	6.51	220.000	331.000			
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275	EVALUATION CRITERIA: TARGET VALUE 20 %									
2025-004	3 COLORIMET.	184 INTEGRA	93 ROCHE	22	70.364	4.657	6.62	56.000	84.000			
2025-004	3 COLORIMET.	203 ROCHE	93 ROCHE	41	69.488	2.964	4.27	56.000	83.000			
2025-004	5 KINETIC 30	197 ARCHITECT	1 ABBOTT	12	62.083	3.570	5.75	50.000	75.000			
2025-004	6 KINETIC 37	165 VITROS	63 KODAK	141	80.186	4.846	6.04	64.000	96.000			
2025-004	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	32	55.031	4.825	8.77	44.000	66.000			
2025-004	10 IFCC	219 ATELLICA	143 SIEMENS	21	65.857	3.182	4.83	53.000	79.000			
2025-004	11 Modified I	38 SIEMENS DI	143 SIEMENS	78	72.273	3.716	5.14	58.000	87.000			
2025-004	11 Modified I	191 RX-SERIES	126 RANDOX	26	60.400	5.099	8.44	48.000	72.000			
2025-004	12 P NITRO PH	197 ARCHITECT	1 ABBOTT	11	60.909	4.601	7.55	49.000	73.000			
2025-005	3 COLORIMET.	184 INTEGRA	93 ROCHE	22	26.227	1.594	6.08	21.000	31.000			
2025-005	3 COLORIMET.	203 ROCHE	93 ROCHE	41	26.293	1.469	5.59	21.000	32.000			
2025-005	5 KINETIC 30	197 ARCHITECT	1 ABBOTT	12	22.917	1.656	7.23	18.000	28.000			
2025-005	6 KINETIC 37	165 VITROS	63 KODAK	141	40.298	3.031	7.52	32.000	48.000			
2025-005	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	32	19.750	2.031	10.28	16.000	24.000			
2025-005	10 IFCC	219 ATELLICA	143 SIEMENS	21	24.700	1.382	5.60	20.000	30.000			
2025-005	11 Modified I	38 SIEMENS DI	143 SIEMENS	78	27.091	2.788	10.29	22.000	33.000			
2025-005	11 Modified I	191 RX-SERIES	126 RANDOX	26	22.320	2.167	9.71	18.000	27.000			
2025-005	12 P NITRO PH	197 ARCHITECT	1 ABBOTT	11	22.727	2.093	9.21	18.000	27.000			
004	AMYLASE	CLIA TEST ID #: 285										
2025-001	3 ENZYM. 37C	165 VITROS	63 KODAK	87	76.814	5.310	6.91	61.000	92.000			
2025-001	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS	22	104.227	1.929	1.85	83.000	125.000			
2025-001	9 ENZ/COL.37	203 ROCHE	93 ROCHE	27	106.731	1.809	1.70	85.000	128.000			
2025-001	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN	15	82.000	4.648	5.67	66.000	98.000			

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-001	11 KINETIC	219	ATELLICA	143	SIEMENS	15	120.857	1.505	1.25	97.000	145.000	
004	AMYLASE	CLIA TEST ID #: 285				EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-002	3 ENZYM. 37C	165	VITROS	63	KODAK	87	162.471	7.040	4.33	130.000	195.000	
2025-002	4 HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	22	223.000	3.896	1.75	178.000	268.000	
2025-002	9 ENZ/COL.37	203	ROCHE	93	ROCHE	27	227.852	3.817	1.68	182.000	273.000	
2025-002	10 CNPG3	186	BECK. COUL	76	AU-BECKMAN	15	176.067	9.637	5.47	141.000	211.000	
2025-002	11 KINETIC	219	ATELLICA	143	SIEMENS	15	256.933	8.062	3.14	206.000	308.000	
2025-003	3 ENZYM. 37C	165	VITROS	63	KODAK	87	206.471	6.953	3.37	165.000	248.000	
2025-003	4 HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	22	289.000	5.947	2.06	231.000	347.000	
2025-003	9 ENZ/COL.37	203	ROCHE	93	ROCHE	27	296.154	5.868	1.98	237.000	355.000	
2025-003	10 CNPG3	186	BECK. COUL	76	AU-BECKMAN	15	227.267	10.736	4.72	182.000	273.000	
2025-003	11 KINETIC	219	ATELLICA	143	SIEMENS	15	334.667	4.756	1.42	268.000	402.000	
2025-004	3 ENZYM. 37C	165	VITROS	63	KODAK	87	48.103	5.142	10.69	38.000	58.000	
2025-004	4 HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	22	61.136	1.013	1.66	49.000	73.000	
2025-004	9 ENZ/COL.37	203	ROCHE	93	ROCHE	27	64.038	1.480	2.31	51.000	77.000	
2025-004	10 CNPG3	186	BECK. COUL	76	AU-BECKMAN	15	48.533	2.849	5.87	39.000	58.000	
2025-004	11 KINETIC	219	ATELLICA	143	SIEMENS	15	71.933	1.181	1.64	58.000	86.000	
2025-005	3 ENZYM. 37C	165	VITROS	63	KODAK	87	30.183	0.521	1.73	24.000	36.000	
2025-005	4 HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	22	22.273	0.808	3.63	18.000	27.000	
2025-005	9 ENZ/COL.37	203	ROCHE	93	ROCHE	27	25.385	0.684	2.69	20.000	30.000	
2025-005	10 CNPG3	186	BECK. COUL	76	AU-BECKMAN	15	17.067	1.611	9.44	14.000	20.000	
2025-005	11 KINETIC	219	ATELLICA	143	SIEMENS	15	27.467	1.258	4.58	22.000	33.000	
005	ASP. AMINO AST/SGOT	CLIA TEST ID #: 295				EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}						
2025-001	1 ASPAR&KETO	165	VITROS	63	KODAK	138	181.854	6.041	3.32	155.000	209.000	
2025-001	1 ASPAR&KETO	220	Medica E.	130	MEDICA	11	141.273	4.750	3.36	120.000	162.000	
2025-001	5 ENZYMA.37C	38	SIEMENS DI	143	SIEMENS	86	151.541	4.709	3.11	129.000	174.000	
2025-001	11 MOD. IFCC	184	INTEGRA	93	ROCHE	20	158.526	5.175	3.26	135.000	182.000	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2025-001	11 MOD. IFCC	184 INTEGRA	93 ROCHE	20	177.667	2.494	1.40	151.000	204.000			
2025-001	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	33	135.250	5.190	3.84	115.000	156.000			
2025-001	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	183.310	12.619	6.88	156.000	211.000			
2025-001	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	177.667	2.494	1.40	151.000	204.000			
2025-001	11 MOD. IFCC	203 ROCHE	93 ROCHE	43	157.977	4.229	2.68	134.000	182.000			
2025-001	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	21	172.400	7.625	4.42	147.000	198.000			
2025-001	12 IFCC witho	203 ROCHE	93 ROCHE	13	157.385	4.306	2.74	134.000	181.000			
2025-001	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	160.071	14.543	9.09	136.000	184.000			
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295		EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}								
2025-002	1 ASPAR&KETO	165 VITROS	63 KODAK	138	412.044	15.108	3.67	350.000	474.000			
2025-002	1 ASPAR&KETO	220 Medica E.	130 MEDICA	11	293.273	6.969	2.38	249.000	337.000			
2025-002	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	86	316.282	7.957	2.52	269.000	364.000			
2025-002	11 MOD. IFCC	184 INTEGRA	93 ROCHE	20	392.000	25.020	6.38	333.000	451.000			
2025-002	11 MOD. IFCC	184 INTEGRA	93 ROCHE	20	324.263	11.493	3.54	276.000	373.000			
2025-002	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	33	276.375	11.810	4.27	235.000	318.000			
2025-002	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	392.000	25.020	6.38	333.000	451.000			
2025-002	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	375.071	28.216	7.52	319.000	431.000			
2025-002	11 MOD. IFCC	203 ROCHE	93 ROCHE	43	324.744	8.447	2.60	276.000	373.000			
2025-002	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	21	355.700	8.603	2.42	302.000	409.000			
2025-002	12 IFCC witho	203 ROCHE	93 ROCHE	13	321.308	8.552	2.66	273.000	370.000			
2025-002	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	336.286	32.312	9.61	286.000	387.000			
2025-003	1 ASPAR&KETO	165 VITROS	63 KODAK	138	535.681	28.712	5.36	455.000	616.000			
2025-003	1 ASPAR&KETO	220 Medica E.	130 MEDICA	11	355.273	14.130	3.98	302.000	409.000			
2025-003	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	86	397.106	14.079	3.55	338.000	457.000			
2025-003	11 MOD. IFCC	184 INTEGRA	93 ROCHE	20	394.300	20.859	5.29	335.000	453.000			
2025-003	11 MOD. IFCC	184 INTEGRA	93 ROCHE	20	522.333	18.838	3.61	444.000	601.000			
2025-003	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	33	342.788	16.139	4.71	291.000	394.000			
2025-003	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	457.621	42.925	9.38	389.000	526.000			
2025-003	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	522.333	18.838	3.61	444.000	601.000			



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2025-003	11 MOD. IFCC	203 ROCHE	93 ROCHE	43	400.071	16.878	4.22	340.000	460.000			
2025-003	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	21	434.238	14.609	3.36	369.000	499.000			
2025-003	12 IFCC witho	203 ROCHE	93 ROCHE	13	399.154	16.224	4.06	339.000	459.000			
2025-003	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	397.500	40.562	10.20	338.000	457.000			
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295	EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}									
2025-004	1 ASPAR&KETO	165 VITROS	63 KODAK	138	108.175	3.857	3.57	92.000	124.000			
2025-004	1 ASPAR&KETO	220 Medica E.	130 MEDICA	11	88.100	2.948	3.35	75.000	101.000			
2025-004	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	86	93.647	2.730	2.92	80.000	108.000			
2025-004	11 MOD. IFCC	184 INTEGRA	93 ROCHE	20	105.000	3.742	3.56	89.000	121.000			
2025-004	11 MOD. IFCC	184 INTEGRA	93 ROCHE	20	97.263	3.258	3.35	83.000	112.000			
2025-004	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	33	82.355	2.509	3.05	70.000	95.000			
2025-004	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	105.000	3.742	3.56	89.000	121.000			
2025-004	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	111.621	8.252	7.39	95.000	128.000			
2025-004	11 MOD. IFCC	203 ROCHE	93 ROCHE	43	96.930	2.654	2.74	82.000	111.000			
2025-004	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	21	106.143	2.965	2.79	90.000	122.000			
2025-004	12 IFCC witho	203 ROCHE	93 ROCHE	13	95.769	2.118	2.21	81.000	110.000			
2025-004	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	98.714	8.672	8.78	84.000	114.000			
2025-005	1 ASPAR&KETO	165 VITROS	63 KODAK	138	44.210	2.090	4.73	38.000	51.000			
2025-005	1 ASPAR&KETO	220 Medica E.	130 MEDICA	11	37.273	1.763	4.73	31.000	43.000			
2025-005	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	86	39.376	2.425	6.16	33.000	45.000			
2025-005	11 MOD. IFCC	184 INTEGRA	93 ROCHE	20	39.300	2.170	5.52	33.000	45.000			
2025-005	11 MOD. IFCC	184 INTEGRA	93 ROCHE	20	43.000	2.160	5.02	37.000	49.000			
2025-005	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	33	34.606	1.575	4.55	29.000	41.000			
2025-005	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	46.138	3.560	7.72	39.000	53.000			
2025-005	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	29	43.000	2.160	5.02	37.000	49.000			
2025-005	11 MOD. IFCC	203 ROCHE	93 ROCHE	43	39.884	1.185	2.97	34.000	46.000			
2025-005	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	21	44.200	1.661	3.76	38.000	51.000			
2025-005	12 IFCC witho	203 ROCHE	93 ROCHE	13	38.923	1.071	2.75	33.000	45.000			
2025-005	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	40.643	3.696	9.09	35.000	47.000			

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
006	BILIRUBIN, TOTAL	CLIA TEST ID #: 305	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}								
2025-001	1 BICHR.NO B	194 BIOLIS-24S	154 (IDG)		10	1.841	0.097	5.26	1.440	2.240	
2025-001	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS		83	2.242	0.114	5.08	1.790	2.690	
2025-001	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN		31	2.291	0.078	3.39	1.830	2.750	
2025-001	4 J-G WITH B	191 RX-SERIES	126 RANDOX		21	2.237	0.179	8.00	1.790	2.680	
2025-001	7 DIAZO-DYPH	165 VITROS	63 KODAK		139	2.261	0.120	5.29	1.810	2.710	
2025-001	13 AZOBIL.	184 INTEGRA	93 ROCHE		12	1.974	0.108	5.45	1.570	2.370	
2025-001	13 AZOBIL.	203 ROCHE	93 ROCHE		39	1.971	0.066	3.35	1.570	2.370	
2025-001	14 VANADATE	219 ATELLICA	143 SIEMENS		21	2.337	0.140	5.99	1.870	2.800	
2025-001	15 DCA 2,4	220 Medica E.	99 STAMBIO		10	2.610	0.271	10.36	2.090	3.130	
2025-001	18 COLORIMETR	184 INTEGRA	93 ROCHE		10	1.978	0.095	4.83	1.580	2.380	
2025-001	18 COLORIMETR	203 ROCHE	93 ROCHE		17	1.950	0.081	4.18	1.550	2.350	
2025-001	19 DIAZO W BL	197 ARCHITECT	1 ABBOTT		12	2.053	0.055	2.70	1.640	2.460	
2025-002	1 BICHR.NO B	194 BIOLIS-24S	154 (IDG)		10	4.341	0.217	5.00	3.470	5.210	
2025-002	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS		83	5.576	0.255	4.57	4.460	6.690	
2025-002	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN		31	5.331	0.171	3.20	4.260	6.400	
2025-002	4 J-G WITH B	191 RX-SERIES	126 RANDOX		21	5.554	0.322	5.79	4.440	6.670	
2025-002	7 DIAZO-DYPH	165 VITROS	63 KODAK		139	5.213	0.225	4.32	4.170	6.260	
2025-002	13 AZOBIL.	184 INTEGRA	93 ROCHE		12	4.888	0.112	2.30	3.910	5.870	
2025-002	13 AZOBIL.	203 ROCHE	93 ROCHE		39	4.811	0.167	3.47	3.850	5.770	
2025-002	14 VANADATE	219 ATELLICA	143 SIEMENS		21	5.742	0.424	7.38	4.590	6.890	
2025-002	15 DCA 2,4	220 Medica E.	99 STAMBIO		10	6.369	0.678	10.64	5.100	7.640	
2025-002	18 COLORIMETR	184 INTEGRA	93 ROCHE		10	4.809	0.250	5.20	3.850	5.770	
2025-002	18 COLORIMETR	203 ROCHE	93 ROCHE		17	4.782	0.187	3.91	3.830	5.740	
2025-002	19 DIAZO W BL	197 ARCHITECT	1 ABBOTT		12	4.758	0.136	2.86	3.810	5.710	
2025-003	1 BICHR.NO B	194 BIOLIS-24S	154 (IDG)		10	5.667	0.361	6.37	4.530	6.800	
2025-003	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS		83	7.355	0.293	3.98	5.880	8.830	
2025-003	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN		31	6.857	0.228	3.33	5.490	8.230	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2025-003	4 J-G WITH B	191 RX-SERIES	126 RANDOX		21	7.419	0.443	5.97	5.940	8.900	
2025-003	7 DIAZO-DYPH	165 VITROS	63 KODAK		139	6.817	0.286	4.20	5.450	8.180	
2025-003	13 AZOBIL.	184 INTEGRA	93 ROCHE		12	6.399	0.232	3.62	5.120	7.680	
2025-003	13 AZOBIL.	203 ROCHE	93 ROCHE		39	6.363	0.325	5.11	5.090	7.640	
2025-003	14 VANADATE	219 ATELLICA	143 SIEMENS		21	7.421	0.542	7.31	5.940	8.910	
2025-003	15 DCA 2,4	220 Medica E.	99 STAMBIO		10	8.179	0.930	11.36	6.540	9.810	
2025-003	18 COLORIMETR	184 INTEGRA	93 ROCHE		10	6.328	0.285	4.50	5.060	7.590	
2025-003	18 COLORIMETR	203 ROCHE	93 ROCHE		17	6.339	0.185	2.91	5.070	7.610	
2025-003	19 DIAZO W BL	197 ARCHITECT	1 ABBOTT		12	6.128	0.206	3.36	4.900	7.350	
006 BILIRUBIN, TOTAL		CLIA TEST ID #: 305		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}							
2025-004	1 BICHR.NO B	194 BIOLIS-24S	154 (IDG)		10	2.120	3.574	168.57	1.700	2.540	
2025-004	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS		83	1.071	0.074	6.90	0.670	1.470	
2025-004	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN		31	1.160	0.044	3.78	0.760	1.560	
2025-004	4 J-G WITH B	191 RX-SERIES	126 RANDOX		21	1.059	0.113	10.67	0.660	1.460	
2025-004	7 DIAZO-DYPH	165 VITROS	63 KODAK		139	1.105	0.091	8.24	0.710	1.510	
2025-004	13 AZOBIL.	184 INTEGRA	93 ROCHE		12	0.953	0.062	6.50	0.550	1.350	
2025-004	13 AZOBIL.	203 ROCHE	93 ROCHE		39	0.937	0.041	4.32	0.540	1.340	
2025-004	14 VANADATE	219 ATELLICA	143 SIEMENS		21	1.120	0.089	7.93	0.720	1.520	
2025-004	15 DCA 2,4	220 Medica E.	99 STAMBIO		10	1.237	0.184	14.88	0.840	1.640	
2025-004	18 COLORIMETR	184 INTEGRA	93 ROCHE		10	0.951	0.040	4.19	0.550	1.350	
2025-004	18 COLORIMETR	203 ROCHE	93 ROCHE		17	0.915	0.052	5.65	0.510	1.310	
2025-004	19 DIAZO W BL	197 ARCHITECT	1 ABBOTT		12	1.035	0.044	4.24	0.640	1.440	
2025-005	1 BICHR.NO B	194 BIOLIS-24S	154 (IDG)		10	0.121	0.018	14.53	0	0.520	
2025-005	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS		83	0.092	0.034	37.07	0	0.490	
2025-005	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN		31	0.101	0.007	6.82	0	0.500	
2025-005	4 J-G WITH B	191 RX-SERIES	126 RANDOX		21	0.124	0.078	62.55	0	0.520	
2025-005	7 DIAZO-DYPH	165 VITROS	63 KODAK		139	0.105	0.020	19.23	0	0.510	
2025-005	13 AZOBIL.	184 INTEGRA	93 ROCHE		12	0.106	0.057	53.65	0	0.510	
2025-005	13 AZOBIL.	203 ROCHE	93 ROCHE		39	0.157	0.024	15.38	0	0.560	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2025-005	14	VANADATE	219 ATELLICA	143	SIEMENS	21	0.162	0.021	13.15	0	0.560	
2025-005	15	DCA 2,4	220 Medica E.	99	STAMBIO	10	0.123	0.033	26.48	0	0.520	
2025-005	18	COLORIMETR	184 INTEGRA	93	ROCHE	10	0.131	0.041	31.00	0	0.530	
2025-005	18	COLORIMETR	203 ROCHE	93	ROCHE	17	0.124	0.055	44.05	0	0.520	
2025-005	19	DIAZO W BL	197 ARCHITECT	1	ABBOTT	12	0.100	0.000	0.00	0	0.500	
010	CALCIUM, TOTAL		CLIA TEST ID #: 345	EVALUATION CRITERIA: TARGET VALUE 1.00								
2025-001	3	ARSEN.-III	165 VITROS	63	KODAK	157	7.387	0.141	1.91	6.400	8.400	
2025-001	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	35	7.503	0.231	3.07	6.500	8.500	
2025-001	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	30	7.757	0.336	4.34	6.800	8.800	
2025-001	3	ARSEN.-III	194 BIOLIS-24S	154	(IDG)	10	7.900	0.155	1.96	6.900	8.900	
2025-001	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	11	7.491	0.138	1.84	6.500	8.500	
2025-001	5	CALC-NONFL	197 ARCHITECT	1	ABBOTT	10	7.440	0.136	1.82	6.400	8.400	
2025-001	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	86	7.380	0.178	2.41	6.400	8.400	
2025-001	8	CRESOLPHT.	184 INTEGRA	93	ROCHE	14	7.486	0.226	3.02	6.500	8.500	
2025-001	8	CRESOLPHT.	203 ROCHE	93	ROCHE	11	7.455	0.183	2.45	6.500	8.500	
2025-001	8	CRESOLPHT.	219 ATELLICA	143	SIEMENS	18	7.353	0.220	2.99	6.400	8.400	
2025-001	15	CA-NM-BAPT	184 INTEGRA	93	ROCHE	15	7.513	0.150	2.00	6.500	8.500	
2025-001	15	CA-NM-BAPT	203 ROCHE	93	ROCHE	47	7.513	0.173	2.31	6.500	8.500	
2025-002	3	ARSEN.-III	165 VITROS	63	KODAK	157	9.880	0.185	1.88	8.900	10.900	
2025-002	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	35	10.244	0.226	2.21	9.200	11.200	
2025-002	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	30	10.177	0.390	3.83	9.200	11.200	
2025-002	3	ARSEN.-III	194 BIOLIS-24S	154	(IDG)	10	10.440	0.262	2.51	9.400	11.400	
2025-002	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	11	10.100	0.176	1.74	9.100	11.100	
2025-002	5	CALC-NONFL	197 ARCHITECT	1	ABBOTT	10	10.200	0.440	4.32	9.200	11.200	
2025-002	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	86	9.838	0.254	2.59	8.800	10.800	
2025-002	8	CRESOLPHT.	184 INTEGRA	93	ROCHE	14	10.086	0.242	2.40	9.100	11.100	
2025-002	8	CRESOLPHT.	203 ROCHE	93	ROCHE	11	10.027	0.286	2.86	9.000	11.000	
2025-002	8	CRESOLPHT.	219 ATELLICA	143	SIEMENS	18	10.124	0.226	2.24	9.100	11.100	
2025-002	15	CA-NM-BAPT	184 INTEGRA	93	ROCHE	15	10.153	0.171	1.68	9.200	11.200	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2025-002	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	47	10.096	0.236	2.34	9.100	11.100			
010	CALCIUM, TOTAL	CLIA TEST ID #: 345	EVALUATION CRITERIA: TARGET VALUE 1.00									
2025-003	3 ARSEN.-III	165 VITROS	63 KODAK	157	11.115	0.200	1.80	10.100	12.100			
2025-003	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	35	11.729	0.301	2.57	10.700	12.700			
2025-003	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	30	11.762	0.368	3.13	10.800	12.800			
2025-003	3 ARSEN.-III	194 BIOLIS-24S	154 (IDG)	10	11.870	0.347	2.92	10.900	12.900			
2025-003	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	11	11.664	0.206	1.76	10.700	12.700			
2025-003	5 CALC-NONFL	197 ARCHITECT	1 ABBOTT	10	11.400	0.540	4.74	10.400	12.400			
2025-003	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	86	11.270	0.307	2.72	10.300	12.300			
2025-003	8 CRESOLPHT.	184 INTEGRA	93 ROCHE	14	11.579	0.273	2.36	10.600	12.600			
2025-003	8 CRESOLPHT.	203 ROCHE	93 ROCHE	11	11.473	0.299	2.60	10.500	12.500			
2025-003	8 CRESOLPHT.	219 ATELLICA	143 SIEMENS	18	11.633	0.424	3.65	10.600	12.600			
2025-003	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	15	11.553	0.212	1.84	10.600	12.600			
2025-003	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	47	11.563	0.243	2.10	10.600	12.600			
2025-004	3 ARSEN.-III	165 VITROS	63 KODAK	157	6.426	0.133	2.08	5.400	7.400			
2025-004	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	35	6.506	0.189	2.91	5.500	7.500			
2025-004	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	30	6.852	0.261	3.81	5.900	7.900			
2025-004	3 ARSEN.-III	194 BIOLIS-24S	154 (IDG)	10	6.980	0.140	2.01	6.000	8.000			
2025-004	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	11	6.527	0.121	1.86	5.500	7.500			
2025-004	5 CALC-NONFL	197 ARCHITECT	1 ABBOTT	10	6.460	0.150	2.32	5.500	7.500			
2025-004	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	86	6.545	0.221	3.38	5.500	7.500			
2025-004	8 CRESOLPHT.	184 INTEGRA	93 ROCHE	14	6.600	0.196	2.98	5.600	7.600			
2025-004	8 CRESOLPHT.	203 ROCHE	93 ROCHE	11	6.509	0.144	2.22	5.500	7.500			
2025-004	8 CRESOLPHT.	219 ATELLICA	143 SIEMENS	18	6.372	0.272	4.28	5.400	7.400			
2025-004	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	15	6.540	0.114	1.75	5.500	7.500			
2025-004	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	47	6.566	0.153	2.34	5.600	7.600			
2025-005	3 ARSEN.-III	165 VITROS	63 KODAK	157	5.601	0.134	2.40	4.600	6.600			
2025-005	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	35	5.679	0.166	2.92	4.700	6.700			

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-005	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	30	6.110	0.245	4.02	5.100	7.100
2025-005	3	ARSEN.-III	194	BIOLIS-24S	154	(IDG)	10	6.160	0.162	2.64	5.200	7.200
2025-005	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	11	5.736	0.123	2.14	4.700	6.700
2025-005	5	CALC-NONFL	197	ARCHITECT	1	ABBOTT	10	5.640	0.143	2.53	4.600	6.600
2025-005	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	86	5.793	0.182	3.15	4.800	6.800
2025-005	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	14	5.786	0.199	3.45	4.800	6.800
2025-005	8	CRESOLPHT.	203	ROCHE	93	ROCHE	11	5.691	0.131	2.30	4.700	6.700
2025-005	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	18	5.565	0.203	3.64	4.600	6.600
2025-005	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	15	5.753	0.120	2.09	4.800	6.800
2025-005	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	47	5.772	0.147	2.54	4.800	6.800
011	CHLORIDE	CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %								
2025-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	97.300	2.268	2.33	92.000	102.000
2025-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	98.000	2.345	2.39	93.000	103.000
2025-001	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	95.303	1.586	1.66	91.000	100.000
2025-001	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	16	98.625	1.409	1.43	94.000	104.000
2025-001	3	ISE DILUTE	203	ROCHE	93	ROCHE	60	93.900	2.211	2.35	89.000	99.000
2025-001	4	ISE UND-DI	165	VITROS	63	KODAK	62	96.145	1.925	2.00	91.000	101.000
2025-001	4	ISE UND-DI	165	VITROS	63	KODAK	62	95.857	3.182	3.32	91.000	101.000
2025-001	4	ISE UND-DI	165	VITROS	156	Kit 32	93	96.559	1.662	1.72	92.000	101.000
2025-001	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	30	95.933	2.943	3.07	91.000	101.000
2025-001	4	ISE UND-DI	220	Medica E.	130	MEDICA	14	94.000	1.604	1.71	89.000	99.000
2025-001	8	IMT	219	ATELLICA	143	SIEMENS	21	98.700	1.792	1.82	94.000	104.000
2025-001	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	85	95.554	1.772	1.85	91.000	100.000
2025-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	111.552	2.486	2.23	106.000	117.000
2025-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	115.500	5.220	4.52	110.000	121.000
2025-002	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	107.242	1.891	1.76	102.000	113.000
2025-002	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	16	110.188	1.073	0.97	105.000	116.000
2025-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	60	107.431	1.922	1.79	102.000	113.000
2025-002	4	ISE UND-DI	165	VITROS	63	KODAK	62	108.714	3.990	3.67	103.000	114.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-002	4	ISE UND-DI	165	VITROS	63	KODAK	62	107.581	2.144	1.99	102.000	113.000
2025-002	4	ISE UND-DI	165	VITROS	156	Kit 32	93	108.239	1.624	1.50	103.000	114.000
2025-002	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	30	109.267	3.463	3.17	104.000	115.000
2025-002	4	ISE UND-DI	220	Medica E.	130	MEDICA	14	111.429	2.871	2.58	106.000	117.000
2025-002	8	IMT	219	ATELLICA	143	SIEMENS	21	110.050	2.617	2.38	105.000	116.000
2025-002	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	85	111.529	2.199	1.97	106.000	117.000
011	CHLORIDE	CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %								
2025-003	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	120.500	3.304	2.74	114.000	127.000
2025-003	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	122.250	2.586	2.12	116.000	128.000
2025-003	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	113.844	2.373	2.08	108.000	120.000
2025-003	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	16	116.313	3.015	2.59	110.000	122.000
2025-003	3	ISE DILUTE	203	ROCHE	93	ROCHE	60	115.914	2.028	1.75	110.000	122.000
2025-003	4	ISE UND-DI	165	VITROS	63	KODAK	62	115.032	2.207	1.92	109.000	121.000
2025-003	4	ISE UND-DI	165	VITROS	63	KODAK	62	117.286	5.391	4.60	111.000	123.000
2025-003	4	ISE UND-DI	165	VITROS	156	Kit 32	93	115.559	1.823	1.58	110.000	121.000
2025-003	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	30	118.000	4.187	3.55	112.000	124.000
2025-003	4	ISE UND-DI	220	Medica E.	130	MEDICA	14	120.143	3.044	2.53	114.000	126.000
2025-003	8	IMT	219	ATELLICA	143	SIEMENS	21	116.952	1.618	1.38	111.000	123.000
2025-003	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	85	120.482	2.399	1.99	114.000	127.000
2025-004	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	91.733	2.205	2.40	87.000	96.000
2025-004	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	93.250	2.046	2.19	89.000	98.000
2025-004	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	90.531	1.250	1.38	86.000	95.000
2025-004	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	16	94.125	1.269	1.35	89.000	99.000
2025-004	3	ISE DILUTE	203	ROCHE	93	ROCHE	60	88.475	1.986	2.24	84.000	93.000
2025-004	4	ISE UND-DI	165	VITROS	63	KODAK	62	91.286	2.433	2.67	87.000	96.000
2025-004	4	ISE UND-DI	165	VITROS	63	KODAK	62	91.933	1.682	1.83	87.000	97.000
2025-004	4	ISE UND-DI	165	VITROS	156	Kit 32	93	92.505	1.604	1.73	88.000	97.000
2025-004	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	30	91.100	2.785	3.06	87.000	96.000
2025-004	4	ISE UND-DI	220	Medica E.	130	MEDICA	14	89.077	2.401	2.70	85.000	94.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-004	8	IMT	219	APELLICA	143	SIEMENS	21	93.286	1.608	1.72	89.000	98.000
2025-004	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	85	90.000	1.447	1.61	86.000	95.000
011	CHLORIDE	CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %								
2025-005	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	88.600	1.645	1.86	84.000	93.000
2025-005	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	89.000	1.871	2.10	85.000	93.000
2025-005	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	33	87.848	1.520	1.73	83.000	92.000
2025-005	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	16	91.500	1.061	1.16	87.000	96.000
2025-005	3	ISE DILUTE	203	ROCHE	93	ROCHE	60	85.220	1.949	2.29	81.000	89.000
2025-005	4	ISE UND-DI	165	VITROS	63	KODAK	62	89.279	1.631	1.83	85.000	94.000
2025-005	4	ISE UND-DI	165	VITROS	63	KODAK	62	88.000	2.070	2.35	84.000	92.000
2025-005	4	ISE UND-DI	165	VITROS	156	Kit 32	93	89.645	1.604	1.79	85.000	94.000
2025-005	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	30	87.700	3.206	3.66	83.000	92.000
2025-005	4	ISE UND-DI	220	Medica E.	130	MEDICA	14	85.500	2.413	2.82	81.000	90.000
2025-005	8	IMT	219	APELLICA	143	SIEMENS	21	90.650	1.878	2.07	86.000	95.000
2025-005	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	85	85.882	1.358	1.58	82.000	90.000
012	CHOLESTEROL, TOTAL	CLIA TEST ID #: 365		EVALUATION CRITERIA: TARGET VALUE 10 %								
2025-001	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	83	137.325	4.647	3.38	124.000	151.000
2025-001	1	ENZYMATIC	165	VITROS	63	KODAK	142	146.536	4.392	3.00	132.000	161.000
2025-001	1	ENZYMATIC	184	INTEGRA	93	ROCHE	13	145.538	5.227	3.59	131.000	160.000
2025-001	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	35	156.286	7.126	4.56	141.000	172.000
2025-001	1	ENZYMATIC	194	BIOLIS-24S	154	(IDG)	10	153.000	2.324	1.52	138.000	168.000
2025-001	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	12	144.417	3.639	2.52	130.000	159.000
2025-001	1	ENZYMATIC	203	ROCHE	93	ROCHE	21	148.100	3.300	2.23	133.000	163.000
2025-001	1	ENZYMATIC	220	Medica E.	130	MEDICA	12	150.833	4.079	2.70	136.000	166.000
2025-001	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	10	148.500	3.748	2.52	134.000	163.000
2025-001	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	31	143.067	2.645	1.85	129.000	157.000
2025-001	8	ENZYMATIC	203	ROCHE	93	ROCHE	18	147.333	3.266	2.22	133.000	162.000
2025-001	9	ENZYMATIC	203	ROCHE	93	ROCHE	14	147.071	3.615	2.46	132.000	162.000
2025-001	9	ENZYMATIC	219	APELLICA	143	SIEMENS	21	151.150	3.864	2.56	136.000	166.000



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
012	CHOLESTEROL, TOTAL	CLIA TEST ID #: 365	EVALUATION CRITERIA: TARGET VALUE 10 %									
2025-002	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS	83	177.699	5.665	3.19	160.000	195.000			
2025-002	1 ENZYMATI	165 VITROS	63 KODAK	142	203.014	7.050	3.47	183.000	223.000			
2025-002	1 ENZYMATI	184 INTEGRA	93 ROCHE	13	191.538	8.092	4.22	172.000	211.000			
2025-002	1 ENZYMATI	191 RX-SERIES	126 RANDOX	35	206.829	9.773	4.73	186.000	228.000			
2025-002	1 ENZYMATI	194 BIOLIS-24S	154 (IDG)	10	201.900	5.957	2.95	182.000	222.000			
2025-002	1 ENZYMATI	197 ARCHITECT	1 ABBOTT	12	190.500	4.330	2.27	171.000	210.000			
2025-002	1 ENZYMATI	203 ROCHE	93 ROCHE	21	194.619	6.351	3.26	175.000	214.000			
2025-002	1 ENZYMATI	220 Medica E.	130 MEDICA	12	200.250	7.224	3.61	180.000	220.000			
2025-002	5 FE-SALTS-N	197 ARCHITECT	1 ABBOTT	10	197.400	8.924	4.52	178.000	217.000			
2025-002	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN	31	188.567	3.461	1.84	170.000	207.000			
2025-002	8 ENZYMATI	203 ROCHE	93 ROCHE	18	194.722	6.090	3.13	175.000	214.000			
2025-002	9 ENZYMATI	203 ROCHE	93 ROCHE	14	194.857	4.809	2.47	175.000	214.000			
2025-002	9 ENZYMATI	219 ATELLICA	143 SIEMENS	21	203.000	4.690	2.31	183.000	223.000			
2025-003	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS	83	202.084	7.020	3.47	182.000	222.000			
2025-003	1 ENZYMATI	165 VITROS	63 KODAK	142	236.873	9.746	4.11	213.000	261.000			
2025-003	1 ENZYMATI	184 INTEGRA	93 ROCHE	13	216.077	10.277	4.76	194.000	238.000			
2025-003	1 ENZYMATI	191 RX-SERIES	126 RANDOX	35	237.771	12.449	5.24	214.000	262.000			
2025-003	1 ENZYMATI	194 BIOLIS-24S	154 (IDG)	10	232.000	5.745	2.48	209.000	255.000			
2025-003	1 ENZYMATI	197 ARCHITECT	1 ABBOTT	12	214.000	11.431	5.34	193.000	235.000			
2025-003	1 ENZYMATI	203 ROCHE	93 ROCHE	21	223.350	7.248	3.24	201.000	246.000			
2025-003	1 ENZYMATI	220 Medica E.	130 MEDICA	12	226.167	8.915	3.94	204.000	249.000			
2025-003	5 FE-SALTS-N	197 ARCHITECT	1 ABBOTT	10	217.000	8.911	4.11	195.000	239.000			
2025-003	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN	31	215.500	4.780	2.22	194.000	237.000			
2025-003	8 ENZYMATI	203 ROCHE	93 ROCHE	18	220.882	5.810	2.63	199.000	243.000			
2025-003	9 ENZYMATI	203 ROCHE	93 ROCHE	14	221.357	5.135	2.32	199.000	243.000			
2025-003	9 ENZYMATI	219 ATELLICA	143 SIEMENS	21	230.524	7.481	3.25	207.000	254.000			
2025-004	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS	83	122.622	3.856	3.14	110.000	135.000			

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2025-004	1 ENZYMATIC	165 VITROS	63 KODAK	142	126.443	3.957	3.13	114.000	139.000		
2025-004	1 ENZYMATIC	184 INTEGRA	93 ROCHE	13	128.923	5.850	4.54	116.000	142.000		
2025-004	1 ENZYMATIC	191 RX-SERIES	126 RANDOX	35	138.057	6.667	4.83	124.000	152.000		
2025-004	1 ENZYMATIC	194 BIOLIS-24S	154 (IDG)	10	137.000	3.033	2.21	123.000	151.000		
2025-004	1 ENZYMATIC	197 ARCHITECT	1 ABBOTT	12	128.417	3.378	2.63	116.000	141.000		
2025-004	1 ENZYMATIC	203 ROCHE	93 ROCHE	21	130.524	3.018	2.31	117.000	144.000		
2025-004	1 ENZYMATIC	220 Medica E.	130 MEDICA	12	135.000	5.527	4.09	122.000	149.000		
2025-004	5 FE-SALTS-N	197 ARCHITECT	1 ABBOTT	10	128.700	4.670	3.63	116.000	142.000		
2025-004	8 ENZYMATIC	186 BECK. COUL	76 AU-BECKMAN	31	126.100	2.468	1.96	113.000	139.000		
2025-004	8 ENZYMATIC	203 ROCHE	93 ROCHE	18	129.389	3.988	3.08	116.000	142.000		
2025-004	9 ENZYMATIC	203 ROCHE	93 ROCHE	14	129.357	2.467	1.91	116.000	142.000		
2025-004	9 ENZYMATIC	219 ATELLICA	143 SIEMENS	21	131.952	2.751	2.09	119.000	145.000		
012 CHOLESTEROL, TOTAL		CLIA TEST ID #: 365		EVALUATION CRITERIA: TARGET VALUE 10 %							
2025-005	1 ENZYMATIC	38 SIEMENS DI	143 SIEMENS	83	111.193	3.829	3.44	100.000	122.000		
2025-005	1 ENZYMATIC	165 VITROS	63 KODAK	142	108.761	4.094	3.76	98.000	120.000		
2025-005	1 ENZYMATIC	184 INTEGRA	93 ROCHE	13	115.000	4.915	4.27	104.000	127.000		
2025-005	1 ENZYMATIC	191 RX-SERIES	126 RANDOX	35	123.914	7.032	5.67	112.000	136.000		
2025-005	1 ENZYMATIC	194 BIOLIS-24S	154 (IDG)	10	122.600	2.615	2.13	110.000	135.000		
2025-005	1 ENZYMATIC	197 ARCHITECT	1 ABBOTT	12	114.917	2.691	2.34	103.000	126.000		
2025-005	1 ENZYMATIC	203 ROCHE	93 ROCHE	21	116.550	2.269	1.95	105.000	128.000		
2025-005	1 ENZYMATIC	220 Medica E.	130 MEDICA	12	121.417	5.139	4.23	109.000	134.000		
2025-005	5 FE-SALTS-N	197 ARCHITECT	1 ABBOTT	10	116.400	2.107	1.81	105.000	128.000		
2025-005	8 ENZYMATIC	186 BECK. COUL	76 AU-BECKMAN	31	112.774	2.536	2.25	101.000	124.000		
2025-005	8 ENZYMATIC	203 ROCHE	93 ROCHE	18	116.278	3.380	2.91	105.000	128.000		
2025-005	9 ENZYMATIC	203 ROCHE	93 ROCHE	14	114.929	2.251	1.96	103.000	126.000		
2025-005	9 ENZYMATIC	219 ATELLICA	143 SIEMENS	21	115.950	2.837	2.45	104.000	128.000		
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375		EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}							
2025-001	5 DEX.SUL/Mg	197 ARCHITECT	1 ABBOTT	11	52.955	2.527	4.77	42.400	63.500		
2025-001	11 ENC.-COLO.	165 VITROS	63 KODAK	139	51.209	2.794	5.46	41.000	61.500		
2025-001	11 ENC.-COLO.	184 INTEGRA	93 ROCHE	29	58.710	3.792	6.46	47.000	70.500		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-001	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	32	53.866	2.301	4.27	43.100	64.600	
2025-001	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	37	48.076	5.814	12.09	38.500	57.700	
2025-001	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	37	51.667	8.260	15.99	41.300	62.000	
2025-001	11 ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	37.778	2.299	6.08	30.200	45.300	
2025-001	11 ENC.-COLO.	203	ROCHE	93	ROCHE	50	57.808	2.484	4.30	46.200	69.400	
2025-001	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	20	55.526	3.032	5.46	44.400	66.600	
2025-001	11 ENC.-COLO.	220	Medica E.	130	MEDICA	12	47.583	3.013	6.33	38.100	57.100	
2025-001	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	52.833	2.409	4.56	42.300	63.400	
2025-001	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	81	54.916	2.218	4.04	43.900	65.900	
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375				EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}						
2025-002	5 DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	65.355	3.864	5.91	52.300	78.400	
2025-002	11 ENC.-COLO.	165	VITROS	63	KODAK	139	64.298	3.932	6.12	51.400	77.200	
2025-002	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	29	67.600	4.871	7.21	54.100	81.100	
2025-002	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	32	67.406	2.473	3.67	53.900	80.900	
2025-002	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	37	59.333	8.380	14.12	47.500	71.200	
2025-002	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	37	59.765	7.277	12.18	47.800	71.700	
2025-002	11 ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	48.333	3.197	6.61	38.700	58.000	
2025-002	11 ENC.-COLO.	203	ROCHE	93	ROCHE	50	67.262	3.142	4.67	53.800	80.700	
2025-002	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	20	69.284	3.834	5.53	55.400	83.100	
2025-002	11 ENC.-COLO.	220	Medica E.	130	MEDICA	12	61.667	3.520	5.71	49.300	74.000	
2025-002	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	66.167	3.362	5.08	52.900	79.400	
2025-002	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	81	57.957	2.692	4.64	46.400	69.500	
2025-003	5 DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	72.300	2.903	4.02	57.800	86.800	
2025-003	11 ENC.-COLO.	165	VITROS	63	KODAK	139	75.736	5.406	7.14	60.600	90.900	
2025-003	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	29	72.800	4.218	5.79	58.200	87.400	
2025-003	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	32	76.425	3.354	4.39	61.100	91.700	
2025-003	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	37	67.092	7.450	11.10	53.700	80.500	
2025-003	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	37	64.333	6.549	10.18	51.500	77.200	
2025-003	11 ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	53.889	4.306	7.99	43.100	64.700	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-003	11 ENC.-COLO.	203	ROCHE	93	ROCHE	50	72.773	3.407	4.68	58.200	87.300	
2025-003	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	20	77.395	3.922	5.07	61.900	92.900	
2025-003	11 ENC.-COLO.	220	Medica E.	130	MEDICA	12	68.583	4.152	6.05	54.900	82.300	
2025-003	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	71.500	4.368	6.11	57.200	85.800	
2025-003	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	81	59.219	2.493	4.21	47.400	71.100	
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375		EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}								
2025-004	5 DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	48.609	2.494	5.13	38.900	58.300	
2025-004	11 ENC.-COLO.	165	VITROS	63	KODAK	139	47.095	2.159	4.58	37.700	56.500	
2025-004	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	29	54.690	3.231	5.91	43.800	65.600	
2025-004	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	32	48.625	2.467	5.07	38.900	58.400	
2025-004	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	37	47.333	5.185	10.96	37.900	56.800	
2025-004	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	37	42.928	5.225	12.17	34.300	51.500	
2025-004	11 ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	34.667	2.261	6.52	27.700	41.600	
2025-004	11 ENC.-COLO.	203	ROCHE	93	ROCHE	50	53.952	2.523	4.68	43.200	64.700	
2025-004	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	20	50.335	3.036	6.03	40.300	60.400	
2025-004	11 ENC.-COLO.	220	Medica E.	130	MEDICA	12	43.636	1.823	4.18	34.900	52.400	
2025-004	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	48.083	2.139	4.45	38.500	57.700	
2025-004	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	81	53.728	1.991	3.71	43.000	64.500	
2025-005	5 DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	45.027	2.146	4.77	36.000	54.000	
2025-005	11 ENC.-COLO.	165	VITROS	63	KODAK	139	44.646	1.720	3.85	35.700	53.600	
2025-005	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	29	51.534	3.009	5.84	41.200	61.800	
2025-005	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	32	44.322	2.062	4.65	35.500	53.200	
2025-005	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	37	39.927	5.665	14.19	31.900	47.900	
2025-005	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	37	45.000	7.071	15.71	36.000	54.000	
2025-005	11 ENC.-COLO.	194	BIOLIS-24S	154	(IDG)	10	31.778	2.200	6.92	25.400	38.100	
2025-005	11 ENC.-COLO.	203	ROCHE	93	ROCHE	50	50.688	2.178	4.30	40.600	60.800	
2025-005	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	20	46.084	3.016	6.55	36.900	55.300	
2025-005	11 ENC.-COLO.	220	Medica E.	130	MEDICA	12	39.667	2.593	6.54	31.700	47.600	
2025-005	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	44.667	2.014	4.51	35.700	53.600	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-005	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	81	52.620	1.795	3.41	42.100	63.100		
014	CREATINE KINASE (CK)	CLIA TEST ID #: 385		EVALUATION CRITERIA: TARGET VALUE 20 %									
2025-001	3 KINETIC 37	165	VITROS	63	KODAK	72	148.352	10.634	7.17	119.000	178.000		
2025-001	3 KINETIC 37	165	VITROS	63	KODAK	72	183.000	3.317	1.81	146.000	220.000		
2025-001	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	155.529	10.239	6.58	124.000	187.000		
2025-001	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	16	176.500	6.275	3.56	141.000	212.000		
2025-001	8 Hexokinase	203	ROCHE	93	ROCHE	11	173.364	4.457	2.57	139.000	208.000		
2025-001	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	24	175.875	5.231	2.97	141.000	211.000		
2025-001	10 ENZYMATI-	203	ROCHE	93	ROCHE	14	175.786	5.401	3.07	141.000	211.000		
2025-002	3 KINETIC 37	165	VITROS	63	KODAK	72	400.500	8.958	2.24	320.000	481.000		
2025-002	3 KINETIC 37	165	VITROS	63	KODAK	72	276.310	18.376	6.65	221.000	332.000		
2025-002	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	351.941	19.975	5.68	282.000	422.000		
2025-002	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	16	394.375	9.656	2.45	316.000	473.000		
2025-002	8 Hexokinase	203	ROCHE	93	ROCHE	11	386.364	10.165	2.63	309.000	464.000		
2025-002	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	24	392.292	10.979	2.80	314.000	471.000		
2025-002	10 ENZYMATI-	203	ROCHE	93	ROCHE	14	393.857	9.523	2.42	315.000	473.000		
2025-003	3 KINETIC 37	165	VITROS	63	KODAK	72	312.833	22.010	7.04	250.000	375.000		
2025-003	3 KINETIC 37	165	VITROS	63	KODAK	72	505.750	11.322	2.24	405.000	607.000		
2025-003	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	447.647	28.253	6.31	358.000	537.000		
2025-003	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	16	505.375	16.389	3.24	404.000	606.000		
2025-003	8 Hexokinase	203	ROCHE	93	ROCHE	11	499.091	21.732	4.35	399.000	599.000		
2025-003	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	24	504.708	17.242	3.42	404.000	606.000		
2025-003	10 ENZYMATI-	203	ROCHE	93	ROCHE	14	503.500	13.653	2.71	403.000	604.000		
2025-004	3 KINETIC 37	165	VITROS	63	KODAK	72	102.500	3.041	2.97	82.000	123.000		
2025-004	3 KINETIC 37	165	VITROS	63	KODAK	72	84.694	5.847	6.90	68.000	102.000		
2025-004	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	85.000	5.636	6.63	68.000	102.000		
2025-004	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	16	98.867	1.996	2.02	79.000	119.000		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-004	8	Hexokinase	203	ROCHE	93	ROCHE	11	96.273	1.601	1.66	77.000	116.000
2025-004	9	SIEMENS	38	SIEMENS DI	143	SIEMENS	24	96.652	3.016	3.12	77.000	116.000
2025-004	10	ENZYMATIC-	203	ROCHE	93	ROCHE	14	96.857	2.030	2.10	77.000	116.000
014 CREATINE KINASE (CK)			CLIA TEST ID #: 385			EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-005	3	KINETIC 37	165	VITROS	63	KODAK	72	22.901	2.956	12.91	18.000	27.000
2025-005	3	KINETIC 37	165	VITROS	63	KODAK	72	26.000	0.707	2.72	21.000	31.000
2025-005	3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	19.471	1.538	7.90	16.000	23.000
2025-005	5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	16	23.750	2.704	11.39	19.000	29.000
2025-005	8	Hexokinase	203	ROCHE	93	ROCHE	11	23.364	0.771	3.30	19.000	28.000
2025-005	9	SIEMENS	38	SIEMENS DI	143	SIEMENS	24	21.792	2.843	13.05	17.000	26.000
2025-005	10	ENZYMATIC-	203	ROCHE	93	ROCHE	14	22.857	1.684	7.37	18.000	27.000
016 CREATININE			CLIA TEST ID #: 405			EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}						
2025-001	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	24	2.279	0.116	5.09	2.050	2.510
2025-001	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	2.578	0.104	4.05	2.320	2.840
2025-001	4	ENZYMATIC	220	Medica E.	130	MEDICA	14	2.626	0.069	2.64	2.360	2.890
2025-001	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	2.607	0.121	4.62	2.350	2.870
2025-001	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	35	2.569	0.084	3.27	2.310	2.830
2025-001	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	2.651	0.082	3.07	2.390	2.920
2025-001	6	KIN. ALK P	203	ROCHE	93	ROCHE	31	2.538	0.106	4.17	2.280	2.790
2025-001	6	KIN. ALK P	203	ROCHE	93	ROCHE	31	2.551	0.106	4.17	2.300	2.810
2025-001	8	IDMS-CREA	165	VITROS	63	KODAK	156	2.468	0.069	2.81	2.220	2.710
2025-001	9	MODIFIED	219	ATELLICA	143	SIEMENS	20	2.521	0.132	5.22	2.270	2.770
2025-001	9	MODIFIED	219	ATELLICA	143	SIEMENS	20	2.617	0.046	1.77	2.360	2.880
2025-001	10	JAFFE COMP	203	ROCHE	93	ROCHE	10	2.588	0.069	2.66	2.330	2.850
2025-001	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	80	2.699	0.088	3.25	2.430	2.970
2025-002	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	24	4.227	0.196	4.64	3.800	4.650
2025-002	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	4.793	0.192	4.02	4.310	5.270
2025-002	4	ENZYMATIC	220	Medica E.	130	MEDICA	14	5.096	0.151	2.97	4.590	5.610
2025-002	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	4.716	0.188	3.98	4.240	5.190

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2025-002	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	35	4.920	0.147	2.99	4.430	5.410			
2025-002	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	17	5.322	0.149	2.80	4.790	5.850			
2025-002	6 KIN. ALK P	203 ROCHE	93 ROCHE	31	4.654	0.223	4.80	4.190	5.120			
2025-002	6 KIN. ALK P	203 ROCHE	93 ROCHE	31	4.728	0.182	3.84	4.260	5.200			
2025-002	8 IDMS-CREA	165 VITROS	63 KODAK	156	4.418	0.116	2.61	3.980	4.860			
2025-002	9 MODIFIED	219 ATELLICA	143 SIEMENS	20	4.697	0.147	3.14	4.230	5.170			
2025-002	9 MODIFIED	219 ATELLICA	143 SIEMENS	20	4.907	0.263	5.36	4.420	5.400			
2025-002	10 JAFFE COMP	203 ROCHE	93 ROCHE	10	4.777	0.106	2.22	4.300	5.250			
2025-002	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS	80	5.123	0.163	3.18	4.610	5.640			
016 CREATININE		CLIA TEST ID #: 405	EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}									
2025-003	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	24	5.333	0.163	3.06	4.800	5.870			
2025-003	4 ENZYMATIC	203 ROCHE	93 ROCHE	12	5.883	0.275	4.68	5.300	6.470			
2025-003	4 ENZYMATIC	220 Medica E.	130 MEDICA	14	6.412	0.157	2.45	5.770	7.050			
2025-003	6 KIN. ALK P	184 INTEGRA	93 ROCHE	15	5.769	0.274	4.75	5.190	6.350			
2025-003	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	35	6.195	0.226	3.65	5.580	6.810			
2025-003	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	17	6.774	0.280	4.13	6.100	7.450			
2025-003	6 KIN. ALK P	203 ROCHE	93 ROCHE	31	5.770	0.210	3.65	5.190	6.350			
2025-003	6 KIN. ALK P	203 ROCHE	93 ROCHE	31	5.736	0.293	5.11	5.160	6.310			
2025-003	8 IDMS-CREA	165 VITROS	63 KODAK	156	5.317	0.153	2.87	4.780	5.850			
2025-003	9 MODIFIED	219 ATELLICA	143 SIEMENS	20	6.165	0.315	5.11	5.550	6.780			
2025-003	9 MODIFIED	219 ATELLICA	143 SIEMENS	20	5.763	0.097	1.69	5.190	6.340			
2025-003	10 JAFFE COMP	203 ROCHE	93 ROCHE	10	5.878	0.184	3.14	5.290	6.470			
2025-003	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS	80	6.535	0.199	3.05	5.880	7.190			
2025-004	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	24	1.565	0.114	7.27	1.370	1.770			
2025-004	4 ENZYMATIC	203 ROCHE	93 ROCHE	12	1.699	0.062	3.64	1.500	1.900			
2025-004	4 ENZYMATIC	220 Medica E.	130 MEDICA	14	1.769	0.045	2.52	1.570	1.970			
2025-004	6 KIN. ALK P	184 INTEGRA	93 ROCHE	15	1.749	0.081	4.61	1.550	1.950			
2025-004	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	35	1.689	0.055	3.26	1.490	1.890			
2025-004	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	17	1.668	0.058	3.51	1.470	1.870			

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-004	6	KIN. ALK P	203	ROCHE	93	ROCHE	31	1.722	0.081	4.68	1.520	1.920
2025-004	6	KIN. ALK P	203	ROCHE	93	ROCHE	31	1.697	0.071	4.18	1.500	1.900
2025-004	8	IDMS-CREA	165	VITROS	63	KODAK	156	1.656	0.050	3.00	1.460	1.860
2025-004	9	MODIFIED	219	ATELLICA	143	SIEMENS	20	1.733	0.012	0.72	1.530	1.930
2025-004	9	MODIFIED	219	ATELLICA	143	SIEMENS	20	1.669	0.115	6.87	1.470	1.870
2025-004	10	JAFFE COMP	203	ROCHE	93	ROCHE	10	1.711	0.036	2.13	1.510	1.910
2025-004	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	80	1.762	0.064	3.63	1.560	1.960
016	CREATININE	CLIA TEST ID #: 405				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}						
2025-005	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	24	0.913	0.090	9.81	0.710	1.110
2025-005	4	ENZYMATIC	203	ROCHE	93	ROCHE	12	0.898	0.040	4.48	0.700	1.100
2025-005	4	ENZYMATIC	220	Medica E.	130	MEDICA	14	0.971	0.040	4.15	0.770	1.170
2025-005	6	KIN. ALK P	184	INTEGRA	93	ROCHE	15	0.938	0.044	4.67	0.740	1.140
2025-005	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	35	0.880	0.039	4.46	0.680	1.080
2025-005	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	17	0.806	0.022	2.76	0.610	1.010
2025-005	6	KIN. ALK P	203	ROCHE	93	ROCHE	31	0.894	0.048	5.40	0.690	1.090
2025-005	6	KIN. ALK P	203	ROCHE	93	ROCHE	31	0.932	0.043	4.63	0.730	1.130
2025-005	8	IDMS-CREA	165	VITROS	63	KODAK	156	0.885	0.036	4.06	0.680	1.080
2025-005	9	MODIFIED	219	ATELLICA	143	SIEMENS	20	0.864	0.079	9.13	0.660	1.060
2025-005	9	MODIFIED	219	ATELLICA	143	SIEMENS	20	0.940	0.022	2.30	0.740	1.140
2025-005	10	JAFFE COMP	203	ROCHE	93	ROCHE	10	0.876	0.042	4.79	0.680	1.080
2025-005	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	80	0.847	0.068	7.99	0.650	1.050
017	GLUCOSE	CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}						
2025-001	3	GL. OXI. C	165	VITROS	63	KODAK	158	73.603	2.059	2.80	68.000	80.000
2025-001	3	GL. OXI. C	165	VITROS	63	KODAK	158	74.333	1.886	2.54	68.000	80.000
2025-001	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	87	79.598	2.597	3.26	73.000	86.000
2025-001	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	87	78.500	1.118	1.42	72.000	85.000
2025-001	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	75.600	1.744	2.31	70.000	82.000
2025-001	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	35	74.914	1.903	2.54	69.000	81.000
2025-001	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	28	79.000	3.559	4.51	73.000	85.000
2025-001	5	HEXOKINASE	203	ROCHE	93	ROCHE	36	74.972	1.590	2.12	69.000	81.000



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-001	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	74.900	2.737	3.65	69.000 81.000	
2025-001	6	HEXOKI. CO	220	Medica E.	130	MEDICA	14	77.357	1.913	2.47	71.000 84.000	
2025-001	12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	76.350	1.878	2.46	70.000 82.000	
2025-001	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	73.143	1.301	1.78	67.000 79.000	
2025-001	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	74.913	1.349	1.80	69.000 81.000	
2025-001	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	21	75.000	1.949	2.60	69.000 81.000	
017	GLUCOSE	CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}								
2025-002	3	GL. OXI. C	165	VITROS	63	KODAK	158	124.333	1.700	1.37	114.000 134.000	
2025-002	3	GL. OXI. C	165	VITROS	63	KODAK	158	124.962	3.164	2.53	115.000 135.000	
2025-002	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	87	132.000	4.123	3.12	121.000 143.000	
2025-002	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	87	130.686	3.835	2.93	120.000 141.000	
2025-002	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	125.900	3.145	2.50	116.000 136.000	
2025-002	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	35	123.800	3.223	2.60	114.000 134.000	
2025-002	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	28	127.481	5.181	4.06	117.000 138.000	
2025-002	5	HEXOKINASE	203	ROCHE	93	ROCHE	36	124.806	3.213	2.57	115.000 135.000	
2025-002	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	122.700	3.348	2.73	113.000 133.000	
2025-002	6	HEXOKI. CO	220	Medica E.	130	MEDICA	14	130.143	4.389	3.37	120.000 141.000	
2025-002	12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	126.500	3.170	2.51	116.000 137.000	
2025-002	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	122.154	2.032	1.66	112.000 132.000	
2025-002	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	124.870	2.419	1.94	115.000 135.000	
2025-002	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	21	123.300	2.917	2.37	113.000 133.000	
2025-003	3	GL. OXI. C	165	VITROS	63	KODAK	158	154.987	3.724	2.40	143.000 167.000	
2025-003	3	GL. OXI. C	165	VITROS	63	KODAK	158	149.833	3.804	2.54	138.000 162.000	
2025-003	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	87	159.271	4.633	2.91	147.000 172.000	
2025-003	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	87	157.000	2.550	1.62	144.000 170.000	
2025-003	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	153.300	4.473	2.92	141.000 166.000	
2025-003	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	35	150.735	3.109	2.06	139.000 163.000	
2025-003	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	28	155.185	6.622	4.27	143.000 168.000	
2025-003	5	HEXOKINASE	203	ROCHE	93	ROCHE	36	152.389	2.918	1.91	140.000 165.000	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-003	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	151.500	5.025	3.32	139.000	164.000
2025-003	6	HEXOKI. CO	220	Medica E.	130	MEDICA	14	158.846	2.567	1.62	146.000	172.000
2025-003	12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	155.000	4.050	2.61	143.000	167.000
2025-003	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	145.857	8.667	5.94	134.000	158.000
2025-003	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	152.591	4.418	2.90	140.000	165.000
2025-003	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	21	148.952	3.484	2.34	137.000	161.000
017	GLUCOSE	CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}								
2025-004	3	GL. OXI. C	165	VITROS	63	KODAK	158	57.833	2.034	3.52	52.000	64.000
2025-004	3	GL. OXI. C	165	VITROS	63	KODAK	158	53.519	1.587	2.97	48.000	60.000
2025-004	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	87	61.126	2.061	3.37	55.000	67.000
2025-004	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	87	60.500	0.866	1.43	55.000	67.000
2025-004	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	57.600	1.562	2.71	52.000	64.000
2025-004	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	35	56.588	1.353	2.39	51.000	63.000
2025-004	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	28	62.185	2.842	4.57	56.000	68.000
2025-004	5	HEXOKINASE	203	ROCHE	93	ROCHE	36	56.714	1.058	1.86	51.000	63.000
2025-004	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	58.700	2.369	4.03	53.000	65.000
2025-004	6	HEXOKI. CO	220	Medica E.	130	MEDICA	14	59.769	1.928	3.23	54.000	66.000
2025-004	12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	58.000	1.049	1.81	52.000	64.000
2025-004	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	55.286	1.097	1.98	49.000	61.000
2025-004	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	57.087	1.349	2.36	51.000	63.000
2025-004	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	21	57.143	1.807	3.16	51.000	63.000
2025-005	3	GL. OXI. C	165	VITROS	63	KODAK	158	36.795	1.125	3.06	31.000	43.000
2025-005	3	GL. OXI. C	165	VITROS	63	KODAK	158	41.167	2.339	5.68	35.000	47.000
2025-005	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	87	43.920	1.877	4.27	38.000	50.000
2025-005	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	87	44.000	0.707	1.61	38.000	50.000
2025-005	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	41.300	1.345	3.26	35.000	47.000
2025-005	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	35	40.500	1.118	2.76	35.000	47.000
2025-005	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	28	45.778	2.149	4.69	40.000	52.000
2025-005	5	HEXOKINASE	203	ROCHE	93	ROCHE	36	40.229	0.897	2.23	34.000	46.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-005	6	HEXOKI. CO	194	BIOLIS-24S	154	(IDG)	10	43.200	1.470	3.40	37.000	49.000
2025-005	6	HEXOKI. CO	220	Medica E.	130	MEDICA	14	43.000	2.449	5.70	37.000	49.000
2025-005	12	HEXOKINASE	184	INTEGRA	93	ROCHE	20	41.300	0.900	2.18	35.000	47.000
2025-005	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	39.286	0.700	1.78	33.000	45.000
2025-005	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	40.435	0.970	2.40	34.000	46.000
2025-005	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	21	41.250	1.445	3.50	35.000	47.000
018	IRON, TOTAL		CLIA TEST ID #: 425			EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-001	4	COULOMETR.	165	VITROS	63	KODAK	18	133.944	8.114	6.06	114.000	154.000
2025-002	4	COULOMETR.	165	VITROS	63	KODAK	18	267.333	14.000	5.24	227.000	307.000
2025-003	4	COULOMETR.	165	VITROS	63	KODAK	18	355.556	14.088	3.96	302.000	409.000
2025-004	4	COULOMETR.	165	VITROS	63	KODAK	18	92.778	5.959	6.42	79.000	107.000
2025-005	4	COULOMETR.	165	VITROS	63	KODAK	18	54.294	4.586	8.45	46.000	62.000
019	LACTASE DEHY. (LDH)		CLIA TEST ID #: 435									
2025-001	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	18	205.235	16.455	8.02	174.000	236.000
2025-001	6	NADH	203	ROCHE	93	ROCHE	28	258.556	9.347	3.61	220.000	297.000
2025-001	6	NADH	219	ATELLICA	143	SIEMENS	16	257.067	9.781	3.80	219.000	296.000
2025-001	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	32	245.594	7.968	3.24	209.000	282.000
2025-001	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	32	265.875	6.489	2.44	226.000	306.000
2025-001	9	LDH1	165	VITROS	63	KODAK	69	329.194	8.968	2.72	280.000	379.000
2025-002	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	18	430.765	35.891	8.33	366.000	495.000
2025-002	6	NADH	203	ROCHE	93	ROCHE	28	538.593	19.991	3.71	458.000	619.000
2025-002	6	NADH	219	ATELLICA	143	SIEMENS	16	523.267	16.555	3.16	445.000	602.000
2025-002	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	32	542.250	11.766	2.17	461.000	624.000
2025-002	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	32	521.531	17.161	3.29	443.000	600.000
2025-002	9	LDH1	165	VITROS	63	KODAK	69	660.824	28.273	4.28	562.000	760.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
019	LACTASE DEHY. (LDH)	CLIA TEST ID #: 435			EVALUATION CRITERIA: TARGET VALUE 15 %							
2025-003	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	18	554.294	39.830	7.19	471.000	637.000	
2025-003	6 NADH	203	ROCHE	93	ROCHE	28	694.357	36.552	5.26	590.000	799.000	
2025-003	6 NADH	219	ATELLICA	143	SIEMENS	16	663.000	24.014	3.62	564.000	762.000	
2025-003	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	32	675.844	22.399	3.31	574.000	777.000	
2025-003	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	32	676.375	20.524	3.03	575.000	778.000	
2025-003	9 LDH1	165	VITROS	63	KODAK	69	840.544	42.200	5.02	714.000	967.000	
2025-004	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	18	120.706	10.016	8.30	103.000	139.000	
2025-004	6 NADH	203	ROCHE	93	ROCHE	28	156.296	6.235	3.99	133.000	180.000	
2025-004	6 NADH	219	ATELLICA	143	SIEMENS	16	156.000	4.412	2.83	133.000	179.000	
2025-004	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	32	160.500	3.391	2.11	136.000	185.000	
2025-004	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	32	145.500	8.370	5.75	124.000	167.000	
2025-004	9 LDH1	165	VITROS	63	KODAK	69	198.000	6.543	3.30	168.000	228.000	
2025-005	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	18	44.765	4.052	9.05	38.000	51.000	
2025-005	6 NADH	203	ROCHE	93	ROCHE	28	58.630	2.696	4.60	50.000	67.000	
2025-005	6 NADH	219	ATELLICA	143	SIEMENS	16	57.200	3.563	6.23	49.000	66.000	
2025-005	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	32	52.281	5.697	10.90	44.000	60.000	
2025-005	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	32	60.500	2.062	3.41	51.000	70.000	
2025-005	9 LDH1	165	VITROS	63	KODAK	69	77.910	3.935	5.05	66.000	90.000	
021	MAGNESIUM	CLIA TEST ID #: 455										
2025-001	5 COLOR./K E	165	VITROS	63	KODAK	28	2.793	0.092	3.31	2.400	3.200	
2025-001	8 XYLIDYL B.	203	ROCHE	93	ROCHE	11	2.600	0.063	2.43	2.200	3.000	
2025-001	8 XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	2.510	0.122	4.86	2.100	2.900	
2025-001	8 XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	2.500	0.141	5.66	2.100	2.900	
2025-002	5 COLOR./K E	165	VITROS	63	KODAK	28	4.800	0.136	2.84	4.100	5.500	
2025-002	8 XYLIDYL B.	203	ROCHE	93	ROCHE	11	4.436	0.098	2.21	3.800	5.100	
2025-002	8 XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	4.300	0.245	5.70	3.700	4.900	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-002	8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	4.310	0.251	5.82	3.700	5.000
021 MAGNESIUM		CLIA TEST ID #: 455				EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-003	5	COLOR./K E	165	VITROS	63	KODAK	28	5.918	0.179	3.03	5.000	6.800
2025-003	8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	5.520	0.125	2.26	4.700	6.300
2025-003	8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	5.680	0.462	8.14	4.800	6.500
2025-003	8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	5.167	0.499	9.66	4.400	5.900
2025-004	5	COLOR./K E	165	VITROS	63	KODAK	28	2.068	0.080	3.89	1.800	2.400
2025-004	8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	1.900	0.060	3.17	1.600	2.200
2025-004	8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	1.833	0.094	5.14	1.600	2.100
2025-004	8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	1.870	0.100	5.37	1.600	2.200
2025-005	5	COLOR./K E	165	VITROS	63	KODAK	28	1.354	0.078	5.75	1.200	1.600
2025-005	8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	1.318	0.057	4.36	1.100	1.500
2025-005	8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	1.260	0.080	6.35	1.100	1.400
2025-005	8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	10	1.267	0.047	3.72	1.100	1.500
022 POTASSIUM		CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 0.30						
2025-001	3	ISE DILUT.	184	INTEGRA	93	ROCHE	28	3.129	0.075	2.39	2.800	3.400
2025-001	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	34	3.121	0.068	2.17	2.800	3.400
2025-001	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	3.140	0.061	1.95	2.800	3.400
2025-001	3	ISE DILUT.	203	ROCHE	93	ROCHE	61	3.166	0.077	2.42	2.900	3.500
2025-001	4	ISE UNDIL.	165	VITROS	63	KODAK	63	3.119	0.069	2.20	2.800	3.400
2025-001	4	ISE UNDIL.	165	VITROS	156	Kit 32	93	3.112	0.051	1.64	2.800	3.400
2025-001	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	29	3.155	0.119	3.78	2.900	3.500
2025-001	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	29	3.157	0.129	4.10	2.900	3.500
2025-001	4	ISE UNDIL.	220	Medica E.	130	MEDICA	14	2.986	0.052	1.73	2.700	3.300
2025-001	5	IMT	219	ATELLICA	143	SIEMENS	21	3.167	0.309	9.76	2.900	3.500
2025-001	5	IMT	219	ATELLICA	143	SIEMENS	21	3.060	0.058	1.91	2.800	3.400
2025-001	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	84	3.049	0.065	2.13	2.700	3.300

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
022 POTASSIUM		CLIA TEST ID #: 465	EVALUATION CRITERIA: TARGET VALUE			0.30					
2025-002	3 ISE DILUT.	184 INTEGRA	93 ROCHE		28	4.743	0.082	1.73	4.400	5.000	
2025-002	3 ISE DILUT.	186 BECK. COUL	76 AU-BECKMAN		34	4.691	0.083	1.77	4.400	5.000	
2025-002	3 ISE DILUT.	197 ARCHITECT	1 ABBOTT		15	4.757	0.073	1.53	4.500	5.100	
2025-002	3 ISE DILUT.	203 ROCHE	93 ROCHE		61	4.773	0.068	1.43	4.500	5.100	
2025-002	4 ISE UNDIL.	165 VITROS	63 KODAK		63	4.773	0.095	1.98	4.500	5.100	
2025-002	4 ISE UNDIL.	165 VITROS	156 Kit 32		93	4.782	0.090	1.88	4.500	5.100	
2025-002	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	4.400	0.169	3.84	4.100	4.700	
2025-002	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	4.655	0.171	3.68	4.400	5.000	
2025-002	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	4.650	0.098	2.11	4.400	5.000	
2025-002	5 IMT	219 ATELLICA	143 SIEMENS		21	4.695	0.102	2.18	4.400	5.000	
2025-002	5 IMT	219 ATELLICA	143 SIEMENS		21	5.000	0.356	7.12	4.700	5.300	
2025-002	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS		84	4.701	0.082	1.75	4.400	5.000	
2025-003	3 ISE DILUT.	184 INTEGRA	93 ROCHE		28	5.664	0.097	1.72	5.400	6.000	
2025-003	3 ISE DILUT.	186 BECK. COUL	76 AU-BECKMAN		34	5.570	0.124	2.23	5.300	5.900	
2025-003	3 ISE DILUT.	197 ARCHITECT	1 ABBOTT		15	5.613	0.273	4.86	5.300	5.900	
2025-003	3 ISE DILUT.	203 ROCHE	93 ROCHE		61	5.715	0.086	1.50	5.400	6.000	
2025-003	4 ISE UNDIL.	165 VITROS	63 KODAK		63	5.739	0.104	1.81	5.400	6.000	
2025-003	4 ISE UNDIL.	165 VITROS	156 Kit 32		93	5.746	0.095	1.65	5.400	6.000	
2025-003	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	5.604	0.184	3.29	5.300	5.900	
2025-003	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	5.186	0.125	2.40	4.900	5.500	
2025-003	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	5.586	0.106	1.90	5.300	5.900	
2025-003	5 IMT	219 ATELLICA	143 SIEMENS		21	5.767	0.249	4.33	5.500	6.100	
2025-003	5 IMT	219 ATELLICA	143 SIEMENS		21	5.581	0.073	1.31	5.300	5.900	
2025-003	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS		84	5.636	0.094	1.67	5.300	5.900	
2025-004	3 ISE DILUT.	184 INTEGRA	93 ROCHE		28	2.536	0.067	2.63	2.200	2.800	
2025-004	3 ISE DILUT.	186 BECK. COUL	76 AU-BECKMAN		34	2.559	0.049	1.92	2.300	2.900	
2025-004	3 ISE DILUT.	197 ARCHITECT	1 ABBOTT		15	2.540	0.061	2.41	2.200	2.800	

**Participant Summary**  
**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2025-004	3 ISE DILUT.	203 ROCHE	93 ROCHE		61	2.593	0.070	2.69	2.300	2.900	
2025-004	4 ISE UNDIL.	165 VITROS	63 KODAK		63	2.529	0.055	2.16	2.200	2.800	
2025-004	4 ISE UNDIL.	165 VITROS	156 Kit 32		93	2.530	0.054	2.15	2.200	2.800	
2025-004	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	2.657	0.150	5.64	2.400	3.000	
2025-004	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	2.597	0.110	4.23	2.300	2.900	
2025-004	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	2.454	0.063	2.59	2.200	2.800	
2025-004	5 IMT	219 ATELLICA	143 SIEMENS		21	2.500	0.000	0.00	2.200	2.800	
2025-004	5 IMT	219 ATELLICA	143 SIEMENS		21	2.633	0.125	4.74	2.300	2.900	
2025-004	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS		84	2.470	0.058	2.33	2.200	2.800	
022 POTASSIUM		CLIA TEST ID #: 465	EVALUATION CRITERIA: TARGET VALUE			0.30					
2025-005	3 ISE DILUT.	184 INTEGRA	93 ROCHE		28	2.032	0.047	2.30	1.700	2.300	
2025-005	3 ISE DILUT.	186 BECK. COUL	76 AU-BECKMAN		34	2.082	0.046	2.20	1.800	2.400	
2025-005	3 ISE DILUT.	197 ARCHITECT	1 ABBOTT		15	2.040	0.061	3.00	1.700	2.300	
2025-005	3 ISE DILUT.	203 ROCHE	93 ROCHE		61	2.085	0.065	3.14	1.800	2.400	
2025-005	4 ISE UNDIL.	165 VITROS	63 KODAK		63	2.010	0.039	1.93	1.700	2.300	
2025-005	4 ISE UNDIL.	165 VITROS	156 Kit 32		93	2.008	0.037	1.82	1.700	2.300	
2025-005	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	2.145	0.133	6.19	1.800	2.400	
2025-005	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	2.214	0.136	6.12	1.900	2.500	
2025-005	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	1.971	0.070	3.55	1.700	2.300	
2025-005	5 IMT	219 ATELLICA	143 SIEMENS		21	2.100	0.082	3.89	1.800	2.400	
2025-005	5 IMT	219 ATELLICA	143 SIEMENS		21	1.985	0.036	1.80	1.700	2.300	
2025-005	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS		84	1.945	0.057	2.91	1.600	2.200	
023 SODIUM		CLIA TEST ID #: 475	EVALUATION CRITERIA: TARGET VALUE			4.00					
2025-001	3 ISE DILUTE	184 INTEGRA	93 ROCHE		28	137.143	3.008	2.19	133.000	141.000	
2025-001	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		34	137.647	1.969	1.43	134.000	142.000	
2025-001	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		34	136.000	2.121	1.56	132.000	140.000	
2025-001	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT		12	138.167	1.675	1.21	134.000	142.000	
2025-001	3 ISE DILUTE	203 ROCHE	93 ROCHE		54	137.944	2.399	1.74	134.000	142.000	
2025-001	4 ISE UNDIL.	165 VITROS	63 KODAK		59	137.695	1.994	1.45	134.000	142.000	
2025-001	4 ISE UNDIL.	165 VITROS	156 Kit 32		97	137.250	1.860	1.35	133.000	141.000	

## Participant Summary

### MONTH 2 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2025-001	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	136.000	2.121	1.56	132.000	140.000	
2025-001	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	136.931	3.051	2.23	133.000	141.000	
2025-001	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	136.429	1.050	0.77	132.000	140.000	
2025-001	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	139.667	4.110	2.94	136.000	144.000	
2025-001	5 IMT	197 ARCHITECT	1 ABBOTT		11	138.636	2.012	1.45	135.000	143.000	
2025-001	5 IMT	219 ATELLICA	143 SIEMENS		21	137.450	1.830	1.33	133.000	141.000	
2025-001	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS		85	139.190	2.084	1.50	135.000	143.000	
023 SODIUM		CLIA TEST ID #: 475	EVALUATION CRITERIA: TARGET VALUE 4.00								
2025-002	3 ISE DILUTE	184 INTEGRA	93 ROCHE		28	153.571	2.993	1.95	150.000	158.000	
2025-002	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		34	151.250	4.603	3.04	147.000	155.000	
2025-002	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		34	154.529	2.291	1.48	151.000	159.000	
2025-002	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT		12	154.833	1.863	1.20	151.000	159.000	
2025-002	3 ISE DILUTE	203 ROCHE	93 ROCHE		54	154.981	1.995	1.29	151.000	159.000	
2025-002	4 ISE UNDIL.	165 VITROS	63 KODAK		59	157.508	2.452	1.56	154.000	162.000	
2025-002	4 ISE UNDIL.	165 VITROS	156 Kit 32		97	156.802	2.124	1.35	153.000	161.000	
2025-002	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	153.828	2.949	1.92	150.000	158.000	
2025-002	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	151.250	4.603	3.04	147.000	155.000	
2025-002	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	153.333	4.028	2.63	149.000	157.000	
2025-002	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	154.615	1.982	1.28	151.000	159.000	
2025-002	5 IMT	197 ARCHITECT	1 ABBOTT		11	156.182	3.099	1.98	152.000	160.000	
2025-002	5 IMT	219 ATELLICA	143 SIEMENS		21	154.000	2.933	1.90	150.000	158.000	
2025-002	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS		85	154.524	2.442	1.58	151.000	159.000	
2025-003	3 ISE DILUTE	184 INTEGRA	93 ROCHE		28	162.571	3.017	1.86	159.000	167.000	
2025-003	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		34	163.545	3.661	2.24	160.000	168.000	
2025-003	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		34	157.500	2.062	1.31	154.000	162.000	
2025-003	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT		12	163.167	5.014	3.07	159.000	167.000	
2025-003	3 ISE DILUTE	203 ROCHE	93 ROCHE		54	165.038	2.645	1.60	161.000	169.000	
2025-003	4 ISE UNDIL.	165 VITROS	63 KODAK		59	169.655	2.597	1.53	166.000	174.000	
2025-003	4 ISE UNDIL.	165 VITROS	156 Kit 32		97	168.670	2.332	1.38	165.000	173.000	



## Participant Summary

MONTH 2 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2025-003	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	157.500	2.062	1.31	154.000	162.000	
2025-003	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	165.172	3.108	1.88	161.000	169.000	
2025-003	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	165.500	3.311	2.00	162.000	170.000	
2025-003	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	165.667	3.091	1.87	162.000	170.000	
2025-003	5 IMT	197 ARCHITECT	1 ABBOTT		11	165.000	4.134	2.51	161.000	169.000	
2025-003	5 IMT	219 ATELLICA	143 SIEMENS		21	162.524	2.322	1.43	159.000	167.000	
2025-003	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS		85	163.553	2.720	1.66	160.000	168.000	
023 SODIUM		CLIA TEST ID #: 475	EVALUATION CRITERIA: TARGET VALUE 4.00								
2025-004	3 ISE DILUTE	184 INTEGRA	93 ROCHE		28	130.679	2.300	1.76	127.000	135.000	
2025-004	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		34	131.000	1.000	0.76	127.000	135.000	
2025-004	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		34	131.000	1.970	1.50	127.000	135.000	
2025-004	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT		12	131.500	1.500	1.14	128.000	136.000	
2025-004	3 ISE DILUTE	203 ROCHE	93 ROCHE		54	131.943	1.785	1.35	128.000	136.000	
2025-004	4 ISE UNDIL.	165 VITROS	63 KODAK		59	130.627	2.224	1.70	127.000	135.000	
2025-004	4 ISE UNDIL.	165 VITROS	156 Kit 32		97	130.516	1.595	1.22	127.000	135.000	
2025-004	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	130.793	2.427	1.86	127.000	135.000	
2025-004	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX		29	131.000	1.000	0.76	127.000	135.000	
2025-004	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	132.667	0.471	0.36	129.000	137.000	
2025-004	4 ISE UNDIL.	220 Medica E.	130 MEDICA		14	131.000	2.449	1.87	127.000	135.000	
2025-004	5 IMT	197 ARCHITECT	1 ABBOTT		11	131.818	1.585	1.20	128.000	136.000	
2025-004	5 IMT	219 ATELLICA	143 SIEMENS		21	131.333	2.146	1.63	127.000	135.000	
2025-004	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS		85	133.541	1.901	1.42	130.000	138.000	
2025-005	3 ISE DILUTE	184 INTEGRA	93 ROCHE		28	126.963	1.990	1.57	123.000	131.000	
2025-005	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		34	127.235	2.073	1.63	123.000	131.000	
2025-005	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN		34	127.250	0.829	0.65	123.000	131.000	
2025-005	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT		12	127.583	0.954	0.75	124.000	132.000	
2025-005	3 ISE DILUTE	203 ROCHE	93 ROCHE		54	127.736	2.011	1.57	124.000	132.000	
2025-005	4 ISE UNDIL.	165 VITROS	63 KODAK		59	125.797	1.792	1.42	122.000	130.000	
2025-005	4 ISE UNDIL.	165 VITROS	156 Kit 32		97	125.411	1.599	1.28	121.000	129.000	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-005	4	ISE UNLIL.	191	RX-SERIES	126	RANLDOX	29	127.250	0.829	0.65	123.000	131.000
2025-005	4	ISE UNLIL.	191	RX-SERIES	126	RANLDOX	29	126.897	2.746	2.16	123.000	131.000
2025-005	4	ISE UNLIL.	220	Medica E.	130	MEDICA	14	127.000	3.185	2.51	123.000	131.000
2025-005	4	ISE UNLIL.	220	Medica E.	130	MEDICA	14	129.333	2.055	1.59	125.000	133.000
2025-005	5	IMT	197	ARCHITECT	1	ABBOTT	11	128.364	1.823	1.42	124.000	132.000
2025-005	5	IMT	219	ATELLICA	143	SIEMENS	21	127.650	2.080	1.63	124.000	132.000
2025-005	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	85	129.647	1.926	1.49	126.000	134.000
024 TOTAL PROTEIN		CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 8 %						
2025-001	1	BIURET	38	SIEMENS DI	143	SIEMENS	84	4.477	0.122	2.73	4.100	4.800
2025-001	1	BIURET	165	VITROS	63	KODAK	140	4.461	0.096	2.15	4.100	4.800
2025-001	1	BIURET	184	INTEGRA	93	ROCHE	17	4.200	0.178	4.24	3.900	4.500
2025-001	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	31	4.381	0.115	2.62	4.000	4.700
2025-001	1	BIURET	191	RX-SERIES	126	RANLDOX	29	4.359	0.183	4.20	4.000	4.700
2025-001	1	BIURET	194	BIOLIS-24S	154	( IDG)	10	4.740	0.102	2.15	4.400	5.100
2025-001	1	BIURET	197	ARCHITECT	1	ABBOTT	20	4.355	0.147	3.36	4.000	4.700
2025-001	1	BIURET	203	ROCHE	93	ROCHE	49	4.360	0.099	2.28	4.000	4.700
2025-001	1	BIURET	219	ATELLICA	143	SIEMENS	21	4.400	0.100	2.27	4.000	4.800
2025-001	1	BIURET	220	Medica E.	130	MEDICA	11	4.227	0.154	3.65	3.900	4.600
2025-001	3	BIURET COL	203	ROCHE	93	ROCHE	14	4.371	0.096	2.19	4.000	4.700
2025-002	1	BIURET	38	SIEMENS DI	143	SIEMENS	84	6.659	0.186	2.80	6.100	7.200
2025-002	1	BIURET	165	VITROS	63	KODAK	140	6.353	0.156	2.45	5.800	6.900
2025-002	1	BIURET	184	INTEGRA	93	ROCHE	17	6.153	0.223	3.62	5.700	6.600
2025-002	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	31	6.474	0.148	2.29	6.000	7.000
2025-002	1	BIURET	191	RX-SERIES	126	RANLDOX	29	6.410	0.307	4.78	5.900	6.900
2025-002	1	BIURET	194	BIOLIS-24S	154	( IDG)	10	7.050	0.206	2.92	6.500	7.600
2025-002	1	BIURET	197	ARCHITECT	1	ABBOTT	20	6.550	0.209	3.18	6.000	7.100
2025-002	1	BIURET	203	ROCHE	93	ROCHE	49	6.431	0.199	3.10	5.900	6.900
2025-002	1	BIURET	219	ATELLICA	143	SIEMENS	21	6.525	0.164	2.51	6.000	7.000
2025-002	1	BIURET	220	Medica E.	130	MEDICA	11	6.364	0.187	2.94	5.900	6.900

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-002	3	BIURET COL	203	ROCHE	93	ROCHE	14	6.457	0.105	1.63	5.900	7.000	
024 TOTAL PROTEIN		CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 8 %							
2025-003	1	BIURET	38	SIEMENS DI	143	SIEMENS	84	7.883	0.212	2.68	7.300	8.500	
2025-003	1	BIURET	165	VITROS	63	KODAK	140	7.422	0.194	2.61	6.800	8.000	
2025-003	1	BIURET	184	INTEGRA	93	ROCHE	17	7.229	0.254	3.51	6.700	7.800	
2025-003	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	31	7.655	0.212	2.77	7.000	8.300	
2025-003	1	BIURET	191	RX-SERIES	126	RANDOX	29	7.648	0.296	3.86	7.000	8.300	
2025-003	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	8.490	0.239	2.81	7.800	9.200	
2025-003	1	BIURET	197	ARCHITECT	1	ABBOTT	20	7.826	0.286	3.66	7.200	8.500	
2025-003	1	BIURET	203	ROCHE	93	ROCHE	49	7.564	0.219	2.89	7.000	8.200	
2025-003	1	BIURET	219	ATELLICA	143	SIEMENS	21	7.657	0.252	3.29	7.000	8.300	
2025-003	1	BIURET	220	Medica E.	130	MEDICA	11	7.455	0.167	2.24	6.900	8.100	
2025-003	3	BIURET COL	203	ROCHE	93	ROCHE	14	7.571	0.122	1.61	7.000	8.200	
2025-004	1	BIURET	38	SIEMENS DI	143	SIEMENS	84	3.701	0.101	2.73	3.400	4.000	
2025-004	1	BIURET	165	VITROS	63	KODAK	140	3.723	0.093	2.49	3.400	4.000	
2025-004	1	BIURET	184	INTEGRA	93	ROCHE	17	3.482	0.162	4.64	3.200	3.800	
2025-004	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	31	3.581	0.078	2.18	3.300	3.900	
2025-004	1	BIURET	191	RX-SERIES	126	RANDOX	29	3.629	0.136	3.75	3.300	3.900	
2025-004	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	3.940	0.080	2.03	3.600	4.300	
2025-004	1	BIURET	197	ARCHITECT	1	ABBOTT	20	3.540	0.132	3.73	3.300	3.800	
2025-004	1	BIURET	203	ROCHE	93	ROCHE	49	3.606	0.103	2.85	3.300	3.900	
2025-004	1	BIURET	219	ATELLICA	143	SIEMENS	21	3.619	0.091	2.50	3.300	3.900	
2025-004	1	BIURET	220	Medica E.	130	MEDICA	11	3.409	0.375	11.01	3.100	3.700	
2025-004	3	BIURET COL	203	ROCHE	93	ROCHE	14	3.607	0.080	2.21	3.300	3.900	
2025-005	1	BIURET	38	SIEMENS DI	143	SIEMENS	84	2.982	0.100	3.36	2.700	3.200	
2025-005	1	BIURET	165	VITROS	63	KODAK	140	3.030	0.089	2.95	2.800	3.300	
2025-005	1	BIURET	184	INTEGRA	93	ROCHE	17	2.829	0.145	5.11	2.600	3.100	
2025-005	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	31	2.923	0.088	3.02	2.700	3.200	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-005	1	BIURET	191	RX-SERIES	126	RANDOX	29	2.934	0.115	3.93	2.700	3.200
2025-005	1	BIURET	194	BIOLIS-24S	154	(IDG)	10	3.180	0.087	2.74	2.900	3.400
2025-005	1	BIURET	197	ARCHITECT	1	ABBOTT	20	2.855	0.102	3.58	2.600	3.100
2025-005	1	BIURET	203	ROCHE	93	ROCHE	49	2.939	0.078	2.65	2.700	3.200
2025-005	1	BIURET	219	ATELLICA	143	SIEMENS	21	2.910	0.089	3.05	2.700	3.100
2025-005	1	BIURET	220	Medica E.	130	MEDICA	11	2.873	0.129	4.48	2.600	3.100
2025-005	3	BIURET COL	203	ROCHE	93	ROCHE	14	2.893	0.133	4.61	2.700	3.100
025 TRIGLYCERIDES			CLIA TEST ID #: 495				EVALUATION CRITERIA: TARGET VALUE 15 %					
2025-001	2	ENZ. COLO.	165	VITROS	63	KODAK	142	139.134	5.120	3.68	118.000	160.000
2025-001	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	13	121.538	3.028	2.49	103.000	140.000
2025-001	2	ENZ. COLO.	203	ROCHE	93	ROCHE	33	121.394	3.190	2.63	103.000	140.000
2025-001	2	ENZ. COLO.	220	Medica E.	130	MEDICA	12	111.500	4.856	4.36	95.000	128.000
2025-001	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	83	112.549	3.081	2.74	96.000	129.000
2025-001	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	116.250	2.126	1.83	99.000	134.000
2025-001	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	32	123.500	4.576	3.71	105.000	142.000
2025-001	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	30	119.767	6.883	5.75	102.000	138.000
2025-001	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	14	121.714	3.936	3.23	103.000	140.000
2025-001	10	ENZYM. GPO	203	ROCHE	93	ROCHE	25	121.640	2.278	1.87	103.000	140.000
2025-001	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	21	127.050	5.113	4.02	108.000	146.000
2025-001	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	10	118.500	9.287	7.84	101.000	136.000
2025-002	2	ENZ. COLO.	165	VITROS	63	KODAK	142	212.218	7.958	3.75	180.000	244.000
2025-002	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	13	173.000	4.540	2.62	147.000	199.000
2025-002	2	ENZ. COLO.	203	ROCHE	93	ROCHE	33	174.485	4.626	2.65	148.000	201.000
2025-002	2	ENZ. COLO.	220	Medica E.	130	MEDICA	12	158.333	9.384	5.93	135.000	182.000
2025-002	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	83	173.476	4.478	2.58	147.000	199.000
2025-002	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	172.455	3.750	2.17	147.000	198.000
2025-002	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	32	182.548	5.204	2.85	155.000	210.000
2025-002	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	30	173.667	10.064	5.80	148.000	200.000
2025-002	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	14	172.714	6.076	3.52	147.000	199.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-002	10 ENZYM. GPO	203	ROCHE	93	ROCHE	25	173.000	3.111	1.80	147.000	199.000	
2025-002	10 ENZYM. GPO	219	ATELLICA	143	SIEMENS	21	186.250	6.464	3.47	158.000	214.000	
2025-002	11 GLY PO4 OX	197	ARCHITECT	1	ABBOTT	10	171.400	3.774	2.20	146.000	197.000	
025 TRIGLYCERIDES		CLIA TEST ID #: 495				EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-003	2 ENZ. COLO.	165	VITROS	63	KODAK	142	253.585	9.091	3.59	216.000	292.000	
2025-003	2 ENZ. COLO.	184	INTEGRA	93	ROCHE	13	200.769	5.323	2.65	171.000	231.000	
2025-003	2 ENZ. COLO.	203	ROCHE	93	ROCHE	33	202.452	3.934	1.94	172.000	233.000	
2025-003	2 ENZ. COLO.	220	Medica E.	130	MEDICA	12	181.833	8.707	4.79	155.000	209.000	
2025-003	4 ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	83	205.113	4.342	2.12	174.000	236.000	
2025-003	5 HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	201.250	9.302	4.62	171.000	231.000	
2025-003	9 GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	32	216.806	7.411	3.42	184.000	249.000	
2025-003	9 GPO TRIND.	191	RX-SERIES	126	RANDOX	30	205.655	11.807	5.74	175.000	237.000	
2025-003	10 ENZYM. GPO	184	INTEGRA	93	ROCHE	14	199.857	7.140	3.57	170.000	230.000	
2025-003	10 ENZYM. GPO	203	ROCHE	93	ROCHE	25	201.542	3.253	1.61	171.000	232.000	
2025-003	10 ENZYM. GPO	219	ATELLICA	143	SIEMENS	21	217.524	6.602	3.03	185.000	250.000	
2025-003	11 GLY PO4 OX	197	ARCHITECT	1	ABBOTT	10	199.000	8.866	4.46	169.000	229.000	
2025-004	2 ENZ. COLO.	165	VITROS	63	KODAK	142	112.816	4.452	3.95	96.000	130.000	
2025-004	2 ENZ. COLO.	184	INTEGRA	93	ROCHE	13	102.000	2.386	2.34	87.000	117.000	
2025-004	2 ENZ. COLO.	203	ROCHE	93	ROCHE	33	101.303	2.668	2.63	86.000	116.000	
2025-004	2 ENZ. COLO.	220	Medica E.	130	MEDICA	12	92.333	9.428	10.21	78.000	106.000	
2025-004	4 ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	83	91.537	3.265	3.57	78.000	105.000	
2025-004	5 HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	94.917	1.754	1.85	81.000	109.000	
2025-004	9 GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	32	101.063	3.391	3.35	86.000	116.000	
2025-004	9 GPO TRIND.	191	RX-SERIES	126	RANDOX	30	99.900	6.074	6.08	85.000	115.000	
2025-004	10 ENZYM. GPO	184	INTEGRA	93	ROCHE	14	101.357	2.715	2.68	86.000	117.000	
2025-004	10 ENZYM. GPO	203	ROCHE	93	ROCHE	25	100.760	1.450	1.44	86.000	116.000	
2025-004	10 ENZYM. GPO	219	ATELLICA	143	SIEMENS	21	104.619	4.904	4.69	89.000	120.000	
2025-004	11 GLY PO4 OX	197	ARCHITECT	1	ABBOTT	10	94.700	2.052	2.17	80.000	109.000	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY      SUB: 10 ROUTINE      GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
025	TRIGLYCERIDES	CLIA TEST ID #: 495		EVALUATION CRITERIA: TARGET VALUE 15 %							
2025-005	2 ENZ. COLO.	165 VITROS	63 KODAK	142	89.796	3.424	3.81	76.000	103.000		
2025-005	2 ENZ. COLO.	184 INTEGRA	93 ROCHE	13	83.615	2.058	2.46	71.000	96.000		
2025-005	2 ENZ. COLO.	203 ROCHE	93 ROCHE	33	82.303	2.139	2.60	70.000	95.000		
2025-005	2 ENZ. COLO.	220 Medica E.	130 MEDICA	12	79.000	4.509	5.71	67.000	91.000		
2025-005	4 ENZ. (GPD)	38 SIEMENS DI	143 SIEMENS	83	71.146	2.960	4.16	60.000	82.000		
2025-005	5 HANTZCH-C)	197 ARCHITECT	1 ABBOTT	12	75.917	1.441	1.90	65.000	87.000		
2025-005	9 GPO TRIND.	186 BECK. COUL	76 AU-BECKMAN	32	81.677	2.620	3.21	69.000	94.000		
2025-005	9 GPO TRIND.	191 RX-SERIES	126 RANDOX	30	83.233	6.130	7.37	71.000	96.000		
2025-005	10 ENZYM. GPO	184 INTEGRA	93 ROCHE	14	83.500	3.246	3.89	71.000	96.000		
2025-005	10 ENZYM. GPO	203 ROCHE	93 ROCHE	25	82.240	1.242	1.51	70.000	95.000		
2025-005	10 ENZYM. GPO	219 ATELLICA	143 SIEMENS	21	85.250	4.969	5.83	72.000	98.000		
2025-005	11 GLY PO4 OX	197 ARCHITECT	1 ABBOTT	10	76.300	1.552	2.03	65.000	88.000		
026	UREA NITROGEN (BUN)	CLIA TEST ID #: 505		EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}							
2025-001	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS	86	19.488	0.880	4.51	17.000	21.000		
2025-001	2 UREAS.GLDH	184 INTEGRA	93 ROCHE	31	18.968	0.933	4.92	17.000	21.000		
2025-001	2 UREAS.GLDH	186 BECK. COUL	76 AU-BECKMAN	34	19.588	0.647	3.30	18.000	22.000		
2025-001	2 UREAS.GLDH	191 RX-SERIES	126 RANDOX	30	18.933	0.964	5.09	17.000	21.000		
2025-001	2 UREAS.GLDH	194 BIOLIS-24S	154 (IDG)	10	20.000	1.000	5.00	18.000	22.000		
2025-001	2 UREAS.GLDH	203 ROCHE	93 ROCHE	61	19.633	0.730	3.72	18.000	22.000		
2025-001	2 UREAS.GLDH	219 ATELLICA	143 SIEMENS	21	20.000	0.775	3.87	18.000	22.000		
2025-001	2 UREAS.GLDH	219 ATELLICA	143 SIEMENS	21	20.750	0.829	4.00	19.000	23.000		
2025-001	5 CHROMATOG.	197 ARCHITECT	1 ABBOTT	13	19.769	0.576	2.91	18.000	22.000		
2025-001	8 UREASE QUI	165 VITROS	63 KODAK	157	17.465	0.592	3.39	15.000	19.000		
2025-001	10 UREASE 37	220 Medica E.	130 MEDICA	14	19.214	0.674	3.51	17.000	21.000		
2025-002	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS	86	32.129	1.327	4.13	29.000	35.000		
2025-002	2 UREAS.GLDH	184 INTEGRA	93 ROCHE	31	31.516	1.267	4.02	29.000	34.000		
2025-002	2 UREAS.GLDH	186 BECK. COUL	76 AU-BECKMAN	34	31.912	1.095	3.43	29.000	35.000		
2025-002	2 UREAS.GLDH	191 RX-SERIES	126 RANDOX	30	29.767	1.802	6.05	27.000	32.000		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-002	2	UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	31.800	0.980	3.08	29.000	35.000
2025-002	2	UREAS.GLDH	203	ROCHE	93	ROCHE	61	31.917	0.936	2.93	29.000	35.000
2025-002	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	21	34.000	0.707	2.08	31.000	37.000
2025-002	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	21	31.857	1.521	4.77	29.000	35.000
2025-002	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	32.583	0.862	2.65	30.000	36.000
2025-002	8	UREASE QUI	165	VITROS	63	KODAK	157	29.859	0.796	2.67	27.000	33.000
2025-002	10	UREASE 37	220	Medica E.	130	MEDICA	14	31.214	1.081	3.46	28.000	34.000
026 UREA NITROGEN (BUN)		CLIA TEST ID #: 505				EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2025-003	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	86	39.118	1.604	4.10	36.000	43.000
2025-003	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	31	38.419	1.519	3.95	35.000	42.000
2025-003	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	34	38.853	1.263	3.25	35.000	42.000
2025-003	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	30	35.867	1.962	5.47	33.000	39.000
2025-003	2	UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	39.300	1.487	3.78	36.000	43.000
2025-003	2	UREAS.GLDH	203	ROCHE	93	ROCHE	61	38.817	1.310	3.38	35.000	42.000
2025-003	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	21	37.857	1.125	2.97	34.000	41.000
2025-003	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	21	40.000	0.707	1.77	36.000	44.000
2025-003	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	39.917	0.954	2.39	36.000	44.000
2025-003	8	UREASE QUI	165	VITROS	63	KODAK	157	37.064	0.915	2.47	34.000	40.000
2025-003	10	UREASE 37	220	Medica E.	130	MEDICA	14	37.714	1.097	2.91	34.000	41.000
2025-004	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	86	14.859	0.870	5.85	13.000	17.000
2025-004	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	31	14.742	0.761	5.16	13.000	17.000
2025-004	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	34	15.273	0.565	3.70	13.000	17.000
2025-004	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	30	14.833	0.778	5.25	13.000	17.000
2025-004	2	UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	15.900	0.700	4.40	14.000	18.000
2025-004	2	UREAS.GLDH	203	ROCHE	93	ROCHE	61	15.133	0.562	3.71	13.000	17.000
2025-004	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	21	15.750	0.433	2.75	14.000	18.000
2025-004	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	21	15.429	0.849	5.50	13.000	17.000
2025-004	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	15.538	0.634	4.08	14.000	18.000
2025-004	8	UREASE QUI	165	VITROS	63	KODAK	157	13.312	0.574	4.31	11.000	15.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-004	10 UREASE 37	220	Medica E.	130	MEDICA	14	15.000	0.392	2.61	13.000	17.000	
026	UREA NITROGEN (BUN)	CLIA TEST ID #: 505		EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}								
2025-005	2 UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	86	10.881	0.837	7.69	9.000	13.000	
2025-005	2 UREAS.GLDH	184	INTEGRA	93	ROCHE	31	10.839	0.677	6.24	9.000	13.000	
2025-005	2 UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	34	11.235	0.489	4.35	9.000	13.000	
2025-005	2 UREAS.GLDH	191	RX-SERIES	126	RANDEX	30	11.033	0.875	7.93	9.000	13.000	
2025-005	2 UREAS.GLDH	194	BIOLIS-24S	154	(IDG)	10	12.100	0.539	4.45	10.000	14.000	
2025-005	2 UREAS.GLDH	203	ROCHE	93	ROCHE	61	11.183	0.465	4.16	9.000	13.000	
2025-005	2 UREAS.GLDH	219	ATELLICA	143	SIEMENS	21	11.350	0.572	5.04	9.000	13.000	
2025-005	2 UREAS.GLDH	219	ATELLICA	143	SIEMENS	21	11.750	0.829	7.06	10.000	14.000	
2025-005	5 CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	11.231	0.576	5.13	9.000	13.000	
2025-005	8 UREASE QUI	165	VITROS	63	KODAK	157	9.452	0.510	5.40	7.000	11.000	
2025-005	10 UREASE 37	220	Medica E.	130	MEDICA	14	11.357	0.610	5.37	9.000	13.000	
027	URIC ACID	CLIA TEST ID #: 515		EVALUATION CRITERIA: TARGET VALUE 10 %								
2025-001	2 URICASE	38	SIEMENS DI	143	SIEMENS	47	4.278	0.149	3.48	3.900	4.700	
2025-001	2 URICASE	165	VITROS	63	KODAK	97	4.200	0.108	2.57	3.800	4.600	
2025-001	2 URICASE	184	INTEGRA	93	ROCHE	10	4.310	0.094	2.19	3.900	4.700	
2025-001	2 URICASE	203	ROCHE	93	ROCHE	36	4.156	0.126	3.03	3.700	4.600	
2025-001	2 URICASE	219	ATELLICA	143	SIEMENS	17	4.435	0.153	3.45	4.000	4.900	
2025-001	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	4.337	0.122	2.82	3.900	4.800	
2025-001	6 ENZY. COL	203	ROCHE	93	ROCHE	16	4.138	0.111	2.69	3.700	4.600	
2025-002	2 URICASE	38	SIEMENS DI	143	SIEMENS	47	8.043	0.248	3.09	7.200	8.800	
2025-002	2 URICASE	165	VITROS	63	KODAK	97	8.048	0.213	2.65	7.200	8.900	
2025-002	2 URICASE	184	INTEGRA	93	ROCHE	10	7.950	0.344	4.33	7.200	8.700	
2025-002	2 URICASE	203	ROCHE	93	ROCHE	36	7.837	0.194	2.48	7.100	8.600	
2025-002	2 URICASE	219	ATELLICA	143	SIEMENS	17	8.259	0.287	3.48	7.400	9.100	
2025-002	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	7.953	0.221	2.78	7.200	8.700	
2025-002	6 ENZY. COL	203	ROCHE	93	ROCHE	16	7.788	0.187	2.40	7.000	8.600	



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
027	URIC ACID	CLIA TEST ID #: 515				EVALUATION CRITERIA: TARGET VALUE 10 %						
2025-003	2 URICASE	38	SIEMENS DI	143	SIEMENS	47	10.168	0.334	3.28	9.200	11.200	
2025-003	2 URICASE	165	VITROS	63	KODAK	97	10.196	0.284	2.78	9.200	11.200	
2025-003	2 URICASE	184	INTEGRA	93	ROCHE	10	10.030	0.210	2.09	9.000	11.000	
2025-003	2 URICASE	203	ROCHE	93	ROCHE	36	9.811	0.339	3.45	8.800	10.800	
2025-003	2 URICASE	219	ATELLICA	143	SIEMENS	17	10.329	0.344	3.33	9.300	11.400	
2025-003	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	9.932	0.371	3.74	8.900	10.900	
2025-003	6 ENZY. COL	203	ROCHE	93	ROCHE	16	9.763	0.283	2.89	8.800	10.700	
2025-004	2 URICASE	38	SIEMENS DI	143	SIEMENS	47	2.909	0.093	3.19	2.600	3.200	
2025-004	2 URICASE	165	VITROS	63	KODAK	97	2.853	0.076	2.67	2.600	3.100	
2025-004	2 URICASE	184	INTEGRA	93	ROCHE	10	2.930	0.064	2.19	2.600	3.200	
2025-004	2 URICASE	203	ROCHE	93	ROCHE	36	2.829	0.081	2.87	2.500	3.100	
2025-004	2 URICASE	219	ATELLICA	143	SIEMENS	17	3.053	0.104	3.39	2.700	3.400	
2025-004	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	2.995	0.069	2.29	2.700	3.300	
2025-004	6 ENZY. COL	203	ROCHE	93	ROCHE	16	2.788	0.086	3.07	2.500	3.100	
2025-005	2 URICASE	38	SIEMENS DI	143	SIEMENS	47	1.726	0.109	6.33	1.600	1.900	
2025-005	2 URICASE	165	VITROS	63	KODAK	97	1.681	0.058	3.47	1.500	1.800	
2025-005	2 URICASE	184	INTEGRA	93	ROCHE	10	1.650	0.092	5.59	1.500	1.800	
2025-005	2 URICASE	203	ROCHE	93	ROCHE	36	1.609	0.055	3.44	1.400	1.800	
2025-005	2 URICASE	219	ATELLICA	143	SIEMENS	17	1.759	0.077	4.39	1.600	1.900	
2025-005	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	1.805	0.100	5.53	1.600	2.000	
2025-005	6 ENZY. COL	203	ROCHE	93	ROCHE	16	1.575	0.056	3.55	1.400	1.700	
135	GGT (GAMMA GLU. TRA)	CLIA TEST ID #: 411				EVALUATION CRITERIA: TARGET VALUE 15 % OR 5.00 {GREATER}						
2025-001	5 KINETIC 37	165	VITROS	63	KODAK	26	231.808	5.955	2.57	197.000	267.000	
2025-001	5 KINETIC 37	219	ATELLICA	143	SIEMENS	10	156.400	4.944	3.16	133.000	180.000	
2025-002	5 KINETIC 37	165	VITROS	63	KODAK	26	466.615	13.437	2.88	397.000	537.000	
2025-002	5 KINETIC 37	219	ATELLICA	143	SIEMENS	10	357.300	8.638	2.42	304.000	411.000	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
135	GGT (GAMMA GLU. TRA)	CLIA TEST ID #: 411		EVALUATION CRITERIA: TARGET VALUE 15 % OR 5.00 {GREATER}								
2025-003	5 KINETIC 37	165 VITROS	63 KODAK	26	576.846	17.096	2.96	490.000	663.000			
2025-003	5 KINETIC 37	219 ATELLICA	143 SIEMENS	10	466.300	11.892	2.55	396.000	536.000			
2025-004	5 KINETIC 37	165 VITROS	63 KODAK	26	127.692	3.439	2.69	109.000	147.000			
2025-004	5 KINETIC 37	219 ATELLICA	143 SIEMENS	10	83.700	2.410	2.88	71.000	96.000			
2025-005	5 KINETIC 37	165 VITROS	63 KODAK	26	22.000	1.074	4.88	17.000	27.000			
2025-005	5 KINETIC 37	219 ATELLICA	143 SIEMENS	10	16.200	1.077	6.65	11.000	21.000			
136	LACTIC ACID	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %								
2025-001	1 LACTATE-P.	165 VITROS	63 KODAK	26	2.450	0.080	3.25	2.000	2.900			
2025-002	1 LACTATE-P.	165 VITROS	63 KODAK	26	5.112	0.109	2.12	4.100	6.100			
2025-003	1 LACTATE-P.	165 VITROS	63 KODAK	26	6.465	0.157	2.42	5.200	7.800			
2025-004	1 LACTATE-P.	165 VITROS	63 KODAK	26	1.450	0.057	3.94	1.200	1.700			
2025-005	1 LACTATE-P.	165 VITROS	63 KODAK	26	0.600	0.000	0.00	0.500	0.700			
137	LIPASE											
2025-001	1 COLORIMET.	203 ROCHE	93 ROCHE	19	36.263	1.681	4.64	29.000	44.000			
2025-001	1 COLORIMET.	219 ATELLICA	143 SIEMENS	13	43.846	2.315	5.28	35.000	53.000			
2025-001	2 ENZIMATIC	165 VITROS	63 KODAK	85	316.235	13.216	4.18	253.000	379.000			
2025-001	4 ENZ/COLOR	184 INTEGRA	93 ROCHE	10	34.400	2.871	8.34	28.000	41.000			
2025-001	4 ENZ/COLOR	186 BECK. COUL	76 AU-BECKMAN	14	39.538	2.818	7.13	32.000	47.000			
2025-001	4 ENZ/COLOR	186 BECK. COUL	76 AU-BECKMAN	14	34.250	3.767	11.00	27.000	41.000			
2025-001	4 ENZ/COLOR	203 ROCHE	93 ROCHE	14	35.857	1.407	3.92	29.000	43.000			
2025-001	5 SIEMENS 37	38 SIEMENS DI	143 SIEMENS	14	38.000	2.646	6.96	30.000	46.000			

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
137	LIPASE	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %								
2025-002	1	COLORIMET.	203	ROCHE	93	ROCHE	19	66.211	2.745	4.15	53.000	79.000
2025-002	1	COLORIMET.	219	ATELLICA	143	SIEMENS	13	80.154	3.676	4.59	64.000	96.000
2025-002	2	ENZIMATIC	165	VITROS	63	KODAK	85	606.212	25.014	4.13	485.000	727.000
2025-002	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	61.600	5.064	8.22	49.000	74.000
2025-002	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	14	74.214	3.629	4.89	59.000	89.000
2025-002	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	14	65.750	3.269	4.97	53.000	79.000
2025-002	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	66.286	2.152	3.25	53.000	80.000
2025-002	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	14	69.071	4.697	6.80	55.000	83.000
2025-003	1	COLORIMET.	203	ROCHE	93	ROCHE	19	82.737	3.369	4.07	66.000	99.000
2025-003	1	COLORIMET.	219	ATELLICA	143	SIEMENS	13	100.923	2.759	2.73	81.000	121.000
2025-003	2	ENZIMATIC	165	VITROS	63	KODAK	85	747.529	46.292	6.19	598.000	897.000
2025-003	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	75.800	6.161	8.13	61.000	91.000
2025-003	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	14	92.000	3.595	3.91	74.000	110.000
2025-003	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	14	80.250	4.493	5.60	64.000	96.000
2025-003	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	82.571	2.382	2.88	66.000	99.000
2025-003	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	14	85.357	5.472	6.41	68.000	102.000
2025-004	1	COLORIMET.	203	ROCHE	93	ROCHE	19	24.895	1.293	5.20	20.000	30.000
2025-004	1	COLORIMET.	219	ATELLICA	143	SIEMENS	13	30.692	1.682	5.48	25.000	37.000
2025-004	2	ENZIMATIC	165	VITROS	63	KODAK	85	196.155	7.917	4.04	157.000	235.000
2025-004	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	24.300	1.616	6.65	19.000	29.000
2025-004	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	14	25.923	1.439	5.55	21.000	31.000
2025-004	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	14	26.000	1.414	5.44	21.000	31.000
2025-004	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	25.286	0.958	3.79	20.000	30.000
2025-004	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	14	27.429	1.917	6.99	22.000	33.000
2025-005	1	COLORIMET.	203	ROCHE	93	ROCHE	19	15.105	1.071	7.09	12.000	18.000
2025-005	1	COLORIMET.	219	ATELLICA	143	SIEMENS	13	18.077	0.997	5.52	14.000	22.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-005	2	ENZIMATIC	165	VITROS	63	KODAK	85	76.881	3.908	5.08	62.000	92.000
2025-005	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	15.300	1.005	6.57	12.000	18.000
2025-005	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	14	14.429	2.352	16.30	12.000	17.000
2025-005	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	14	16.000	0.707	4.42	13.000	19.000
2025-005	4	ENZ/COLOR	203	ROCHE	93	ROCHE	14	14.714	0.795	5.41	12.000	18.000
2025-005	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	14	17.214	1.423	8.27	14.000	21.000
138	PHOSPHORUS	CLIA TEST ID #: 460		EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}								
2025-001	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	45	3.038	0.095	3.13	2.700	3.300
2025-001	1	PHOSPHOMO.	165	VITROS	63	KODAK	94	3.094	0.117	3.80	2.800	3.400
2025-001	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	2.885	0.117	4.04	2.600	3.200
2025-001	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	2.916	0.142	4.88	2.600	3.200
2025-001	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	3.538	0.180	5.08	3.200	3.900
2025-001	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	48	2.848	0.098	3.44	2.500	3.100
2025-001	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	18	2.935	0.097	3.29	2.600	3.200
2025-002	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	45	4.978	0.105	2.11	4.500	5.500
2025-002	1	PHOSPHOMO.	165	VITROS	63	KODAK	94	4.746	0.166	3.50	4.300	5.200
2025-002	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	4.708	0.149	3.17	4.200	5.200
2025-002	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	5.613	0.190	3.39	5.100	6.200
2025-002	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	4.870	0.210	4.31	4.400	5.400
2025-002	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	48	4.772	0.132	2.76	4.300	5.200
2025-002	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	18	4.906	0.173	3.53	4.400	5.400
2025-003	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	45	6.047	0.128	2.11	5.400	6.700
2025-003	1	PHOSPHOMO.	165	VITROS	63	KODAK	94	5.718	0.187	3.26	5.100	6.300
2025-003	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	13	5.731	0.190	3.31	5.200	6.300
2025-003	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	5.911	0.189	3.20	5.300	6.500
2025-003	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	6.838	0.212	3.10	6.200	7.500
2025-003	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	48	5.840	0.164	2.81	5.300	6.400
2025-003	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	18	5.961	0.216	3.63	5.400	6.600

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
138	PHOSPHORUS	CLIA TEST ID #: 460		EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}								
2025-004	1	PHOSPHOMO.	38 SIEMENS DI	143	SIEMENS	45	2.304	0.082	3.54	2.000	2.600	
2025-004	1	PHOSPHOMO.	165 VITROS	63	KODAK	94	2.444	0.098	4.00	2.100	2.700	
2025-004	1	PHOSPHOMO.	184 INTEGRA	93	ROCHE	13	2.185	0.077	3.52	1.900	2.500	
2025-004	1	PHOSPHOMO.	186 BECK. COUL	76	AU-BECKMAN	20	2.800	0.100	3.57	2.500	3.100	
2025-004	1	PHOSPHOMO.	186 BECK. COUL	76	AU-BECKMAN	20	2.185	0.124	5.66	1.900	2.500	
2025-004	1	PHOSPHOMO.	203 ROCHE	93	ROCHE	48	2.156	0.079	3.65	1.900	2.500	
2025-004	1	PHOSPHOMO.	219 ATELLICA	143	SIEMENS	18	2.172	0.073	3.36	1.900	2.500	
2025-005	1	PHOSPHOMO.	38 SIEMENS DI	143	SIEMENS	45	1.618	0.074	4.57	1.300	1.900	
2025-005	1	PHOSPHOMO.	165 VITROS	63	KODAK	94	1.766	0.078	4.43	1.500	2.100	
2025-005	1	PHOSPHOMO.	184 INTEGRA	93	ROCHE	13	1.508	0.092	6.08	1.200	1.800	
2025-005	1	PHOSPHOMO.	186 BECK. COUL	76	AU-BECKMAN	20	1.516	0.104	6.86	1.200	1.800	
2025-005	1	PHOSPHOMO.	186 BECK. COUL	76	AU-BECKMAN	20	2.050	0.112	5.45	1.800	2.400	
2025-005	1	PHOSPHOMO.	203 ROCHE	93	ROCHE	48	1.475	0.063	4.27	1.200	1.800	
2025-005	1	PHOSPHOMO.	219 ATELLICA	143	SIEMENS	18	1.488	0.068	4.54	1.200	1.800	
169	CO2	CLIA TEST ID #: 351		EVALUATION CRITERIA: TARGET VALUE 20 %								
2025-001	1	Generic Me	184 INTEGRA	93	ROCHE	10	17.600	3.955	22.47	14.000	21.000	
2025-001	1	Generic Me	186 BECK. COUL	76	AU-BECKMAN	29	16.286	1.687	10.36	13.000	20.000	
2025-001	1	Generic Me	186 BECK. COUL	76	AU-BECKMAN	29	15.333	0.943	6.15	12.000	18.000	
2025-001	1	Generic Me	186 BECK. COUL	76	AU-BECKMAN	29	14.750	1.479	10.03	12.000	18.000	
2025-001	1	Generic Me	203 ROCHE	93	ROCHE	25	15.417	1.552	10.07	12.000	19.000	
2025-001	1	Generic Me	203 ROCHE	93	ROCHE	25	15.333	0.943	6.15	12.000	18.000	
2025-001	1	Generic Me	203 ROCHE	93	ROCHE	25	14.750	1.479	10.03	12.000	18.000	
2025-001	2	ENZYMATIC	38 SIEMENS DI	143	SIEMENS	68	18.373	1.744	9.49	15.000	22.000	
2025-001	2	ENZYMATIC	165 VITROS	63	KODAK	58	14.431	1.555	10.77	12.000	17.000	
2025-001	2	ENZYMATIC	165 VITROS	63	KODAK	58	14.600	0.800	5.48	12.000	18.000	
2025-001	2	ENZYMATIC	165 VITROS	156	Kit 32	82	13.927	1.702	12.22	11.000	17.000	
2025-001	2	ENZYMATIC	165 VITROS	156	Kit 32	82	13.778	2.200	15.97	11.000	17.000	
2025-001	2	ENZYMATIC	203 ROCHE	93	ROCHE	11	15.273	1.656	10.85	12.000	18.000	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-001	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	13.778	2.200	15.97	11.000	17.000
2025-001	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	19	17.316	2.001	11.56	14.000	21.000
169	CO2	CLIA TEST ID #: 351		EVALUATION CRITERIA: TARGET VALUE 20 %								
2025-002	1	Generic Me	184	INTEGRA	93	ROCHE	10	24.900	4.061	16.31	20.000	30.000
2025-002	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	22.000	0.816	3.71	18.000	26.000
2025-002	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	21.625	1.798	8.32	17.000	26.000
2025-002	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	23.821	2.122	8.91	19.000	29.000
2025-002	1	Generic Me	203	ROCHE	93	ROCHE	25	22.000	0.816	3.71	18.000	26.000
2025-002	1	Generic Me	203	ROCHE	93	ROCHE	25	21.625	1.798	8.32	17.000	26.000
2025-002	1	Generic Me	203	ROCHE	93	ROCHE	25	22.125	2.185	9.88	18.000	27.000
2025-002	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	68	25.838	2.266	8.77	21.000	31.000
2025-002	2	ENZYMATIC	165	VITROS	63	KODAK	58	20.600	1.020	4.95	16.000	25.000
2025-002	2	ENZYMATIC	165	VITROS	63	KODAK	58	21.596	1.909	8.84	17.000	26.000
2025-002	2	ENZYMATIC	165	VITROS	156	Kit 32	82	21.000	2.749	13.09	17.000	25.000
2025-002	2	ENZYMATIC	165	VITROS	156	Kit 32	82	21.707	1.596	7.35	17.000	26.000
2025-002	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	21.000	2.749	13.09	17.000	25.000
2025-002	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	22.364	1.872	8.37	18.000	27.000
2025-002	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	19	25.263	2.197	8.70	20.000	30.000
2025-003	1	Generic Me	184	INTEGRA	93	ROCHE	10	27.700	4.220	15.24	22.000	33.000
2025-003	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	29.429	2.583	8.78	24.000	35.000
2025-003	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	24.333	0.943	3.87	19.000	29.000
2025-003	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	26.125	2.713	10.38	21.000	31.000
2025-003	1	Generic Me	203	ROCHE	93	ROCHE	25	26.333	2.248	8.54	21.000	32.000
2025-003	1	Generic Me	203	ROCHE	93	ROCHE	25	24.333	0.943	3.87	19.000	29.000
2025-003	1	Generic Me	203	ROCHE	93	ROCHE	25	26.125	2.713	10.38	21.000	31.000
2025-003	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	68	30.074	2.608	8.67	24.000	36.000
2025-003	2	ENZYMATIC	165	VITROS	63	KODAK	58	26.052	2.452	9.41	21.000	31.000
2025-003	2	ENZYMATIC	165	VITROS	63	KODAK	58	26.400	1.200	4.55	21.000	32.000
2025-003	2	ENZYMATIC	165	VITROS	156	Kit 32	82	26.500	2.193	8.28	21.000	32.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-003	2	ENZYMATIC	165	VITROS	156	Kit 32	82	25.889	2.233	8.63	21.000	31.000
2025-003	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	27.636	2.186	7.91	22.000	33.000
2025-003	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	25.889	2.233	8.63	21.000	31.000
2025-003	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	19	29.579	1.955	6.61	24.000	35.000
169	CO2	CLIA TEST ID #: 351				EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-004	1	Generic Me	184	INTEGRA	93	ROCHE	10	14.600	4.779	32.73	12.000	18.000
2025-004	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	12.667	0.471	3.72	10.000	15.000
2025-004	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	12.625	1.317	10.43	10.000	15.000
2025-004	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	13.357	1.777	13.30	11.000	16.000
2025-004	1	Generic Me	203	ROCHE	93	ROCHE	25	12.667	0.471	3.72	10.000	15.000
2025-004	1	Generic Me	203	ROCHE	93	ROCHE	25	12.625	1.317	10.43	10.000	15.000
2025-004	1	Generic Me	203	ROCHE	93	ROCHE	25	12.625	2.058	16.30	10.000	15.000
2025-004	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	68	15.284	1.953	12.78	12.000	18.000
2025-004	2	ENZYMATIC	165	VITROS	63	KODAK	58	11.200	0.748	6.68	9.000	13.000
2025-004	2	ENZYMATIC	165	VITROS	63	KODAK	58	11.207	1.679	14.98	9.000	13.000
2025-004	2	ENZYMATIC	165	VITROS	156	Kit 32	82	10.000	1.764	17.64	8.000	12.000
2025-004	2	ENZYMATIC	165	VITROS	156	Kit 32	82	11.321	1.464	12.93	9.000	14.000
2025-004	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	10.000	1.764	17.64	8.000	12.000
2025-004	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	12.818	2.208	17.23	10.000	15.000
2025-004	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	19	14.778	1.436	9.72	12.000	18.000
2025-005	1	Generic Me	184	INTEGRA	93	ROCHE	10	12.500	4.566	36.53	10.000	15.000
2025-005	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	11.357	1.445	12.72	9.000	14.000
2025-005	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	10.333	0.471	4.56	8.000	12.000
2025-005	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	29	11.250	1.199	10.66	9.000	14.000
2025-005	1	Generic Me	203	ROCHE	93	ROCHE	25	10.667	1.886	17.68	9.000	13.000
2025-005	1	Generic Me	203	ROCHE	93	ROCHE	25	10.333	0.471	4.56	8.000	12.000
2025-005	1	Generic Me	203	ROCHE	93	ROCHE	25	11.250	1.199	10.66	9.000	14.000
2025-005	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	68	13.851	2.024	14.61	11.000	17.000
2025-005	2	ENZYMATIC	165	VITROS	63	KODAK	58	9.638	1.658	17.20	8.000	12.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2025-005	2 ENZYMATIC	165 VITROS	63 KODAK	58	8.000	1.789	22.36	6.000	10.000			
2025-005	2 ENZYMATIC	165 VITROS	156 Kit 32	82	9.593	1.585	16.53	8.000	12.000			
2025-005	2 ENZYMATIC	165 VITROS	156 Kit 32	82	9.333	1.247	13.36	7.000	11.000			
2025-005	2 ENZYMATIC	203 ROCHE	93 ROCHE	11	11.091	1.928	17.39	9.000	13.000			
2025-005	2 ENZYMATIC	203 ROCHE	93 ROCHE	11	9.333	1.247	13.36	7.000	11.000			
2025-005	2 ENZYMATIC	219 ATELLICA	143 SIEMENS	19	13.526	1.758	13.00	11.000	16.000			
170 DIRECT BILIRUBIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}									
2025-001	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	44	0.598	0.034	5.69	0.500	0.700			
2025-001	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	12	0.883	0.055	6.26	0.700	1.100			
2025-001	11 SPECT. WIT	165 VITROS	63 KODAK	70	0.241	0.246	101.87	0	1.000			
2025-001	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	22	0.600	0.062	10.29	0.400	0.800			
2025-001	14 VANADATE O	219 ATELLICA	143 SIEMENS	17	1.000	0.114	11.38	0.700	1.300			
2025-002	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	44	1.323	0.071	5.37	1.100	1.600			
2025-002	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	12	1.892	0.111	5.89	1.500	2.300			
2025-002	11 SPECT. WIT	165 VITROS	63 KODAK	70	0.880	0.195	22.12	0.300	1.500			
2025-002	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	22	1.248	0.085	6.83	1.000	1.500			
2025-002	14 VANADATE O	219 ATELLICA	143 SIEMENS	17	2.194	0.198	9.04	1.600	2.800			
2025-003	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	44	1.627	0.084	5.14	1.300	2.000			
2025-003	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	12	2.258	0.095	4.22	1.800	2.700			
2025-003	11 SPECT. WIT	165 VITROS	63 KODAK	70	1.206	0.307	25.50	0.300	2.100			
2025-003	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	22	1.476	0.106	7.21	1.200	1.800			
2025-003	14 VANADATE O	219 ATELLICA	143 SIEMENS	17	2.569	0.149	5.79	2.100	3.100			
2025-004	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	44	0.300	0.000	0.00	0.200	0.400			
2025-004	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	12	0.442	0.049	11.16	0.300	0.600			
2025-004	11 SPECT. WIT	165 VITROS	63 KODAK	70	0.071	0.151	213.22	0	0.500			
2025-004	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	22	0.305	0.037	12.03	0.200	0.400			
2025-004	14 VANADATE O	219 ATELLICA	143 SIEMENS	17	0.506	0.042	8.22	0.400	0.600			



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 10 ROUTINE

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
170	DIRECT BILIRUBIN		CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}						
2025-005	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	44	0.073	0.045	61.24	0	0.200	
2025-005	5	JEND.-GROG	197	ARCHITECT	1	ABBOTT	12	0.100	0.000	0.00	0.100	0.100	
2025-005	11	SPECT. WIT	165	VITROS	63	KODAK	70	0.000	0.000	0.00	0.000	0.000	
2025-005	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	22	0.205	0.021	10.40	0.100	0.300	
2025-005	14	VANADATE O	219	ATELLICA	143	SIEMENS	17	0.100	0.000	0.00	0.100	0.100	

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 15 WHOLE BLOOD GLUCOSE

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
157	WHOLE BLOOD GLUCOSE						EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2025-101	23	ABBOTT PRE					24	397.250	27.525	6.93	358.000	437.000	
2025-101	27	STAT SRIP.					88	280.000	10.425	3.72	252.000	308.000	
2025-101	27	STAT SRIP.					88	296.306	15.000	5.06	267.000	326.000	
2025-101	33	AC.CHEK II					36	389.750	10.425	2.67	351.000	429.000	
2025-101	33	AC.CHEK II					36	385.029	14.998	3.90	347.000	424.000	
2025-101	34	FREE STYL					40	433.667	38.777	8.94	390.000	477.000	
2025-102	23	ABBOTT PRE					24	111.125	6.790	6.11	100.000	122.000	
2025-102	27	STAT SRIP.					88	89.705	4.528	5.05	81.000	99.000	
2025-102	27	STAT SRIP.					88	74.000	2.915	3.94	67.000	81.000	
2025-102	33	AC.CHEK II					36	95.083	4.412	4.64	86.000	105.000	
2025-102	33	AC.CHEK II					36	98.000	2.915	2.97	88.000	108.000	
2025-102	34	FREE STYL					40	115.675	9.422	8.15	104.000	127.000	
2025-103	23	ABBOTT PRE					24	222.565	11.787	5.30	200.000	245.000	
2025-103	27	STAT SRIP.					88	148.000	4.062	2.74	133.000	163.000	
2025-103	27	STAT SRIP.					88	160.570	12.198	7.60	145.000	177.000	
2025-103	33	AC.CHEK II					36	205.000	4.062	1.98	185.000	226.000	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 15 WHOLE BLOOD GLUCOSE

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-103	33	AC.CHEK II		36	195.794	31.205	15.94	176.000	215.000
2025-103	34	FREE STYL		40	233.350	21.190	9.08	210.000	257.000
157 WHOLE BLOOD GLUCOSE				CLIA TEST ID #: 0                      EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}					
2025-104	23	ABBOTT PRE		24	220.696	13.521	6.13	199.000	243.000
2025-104	27	STAT SRIP.		88	146.322	27.014	18.46	132.000	161.000
2025-104	27	STAT SRIP.		88	148.000	5.745	3.88	133.000	163.000
2025-104	33	AC.CHEK II		36	204.912	7.338	3.58	184.000	225.000
2025-104	33	AC.CHEK II		36	205.000	5.745	2.80	185.000	226.000
2025-104	34	FREE STYL		40	234.750	18.478	7.87	211.000	258.000
2025-105	23	ABBOTT PRE		24	394.958	28.198	7.14	355.000	434.000
2025-105	27	STAT SRIP.		88	280.000	9.934	3.55	252.000	308.000
2025-105	27	STAT SRIP.		88	298.341	18.286	6.13	269.000	328.000
2025-105	33	AC.CHEK II		36	385.750	9.934	2.58	347.000	424.000
2025-105	33	AC.CHEK II		36	387.556	16.315	4.21	349.000	426.000
2025-105	34	FREE STYL		40	415.250	65.588	15.79	374.000	457.000

SPEC: 10 CHEMISTRY                      SUB: 20 BLOOD GASES                      GRP: 30 BLOOD GASES

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
007 BLOOD GASES-pCO2				CLIA TEST ID #: 335                      EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}					
2025-051	256	GEM PREMI.		10	66.500	1.500	2.26	61.200	71.800
2025-051	265	ROCHE COBA		33	66.073	1.224	1.85	60.800	71.400
2025-052	256	GEM PREMI.		10	40.700	1.187	2.92	35.700	45.700
2025-052	265	ROCHE COBA		33	42.761	0.811	1.90	37.800	47.800

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 20 BLOOD GASES		GRP: 30 BLOOD GASES						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
007	BLOOD GASES-pCO2	CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE	8	% OR 5.00	{GREATER}				
2025-053	256 GEM PREMI.			10	21.500	0.500	2.33	16.500	26.500	
2025-053	265 ROCHE COBA			33	23.470	0.658	2.80	18.500	28.500	
2025-054	256 GEM PREMI.			10	53.700	2.052	3.82	48.700	58.700	
2025-054	265 ROCHE COBA			33	54.234	2.193	4.04	49.200	59.200	
2025-055	256 GEM PREMI.			10	64.200	3.995	6.22	59.100	69.300	
2025-055	265 ROCHE COBA			33	66.842	1.384	2.07	61.500	72.200	
008	BLOOD GASES-pH	CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE	0.04						
2025-051	256 GEM PREMI.			10	7.156	0.007	0.09	7.116	7.196	
2025-051	265 ROCHE COBA			33	7.178	0.007	0.09	7.138	7.218	
2025-052	256 GEM PREMI.			10	7.441	0.009	0.13	7.401	7.481	
2025-052	265 ROCHE COBA			33	7.414	0.006	0.08	7.374	7.454	
2025-053	256 GEM PREMI.			10	7.633	0.010	0.13	7.593	7.673	
2025-053	265 ROCHE COBA			33	7.566	0.009	0.12	7.526	7.606	
2025-054	256 GEM PREMI.			10	7.231	0.009	0.13	7.191	7.271	
2025-054	265 ROCHE COBA			33	7.229	0.008	0.11	7.189	7.269	
2025-055	256 GEM PREMI.			10	7.162	0.018	0.25	7.122	7.202	
2025-055	265 ROCHE COBA			33	7.175	0.007	0.10	7.135	7.215	
009	BLOOD GASES-pO2	CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE	15	% OR 15.00	{GREATER}				
2025-051	256 GEM PREMI.			10	70.000	2.864	4.09	55.000	85.000	
2025-051	265 ROCHE COBA			33	55.821	16.981	30.42	40.800	70.800	
2025-051	265 ROCHE COBA			33	62.650	9.282	14.82	47.700	77.700	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
009	BLOOD GASES-pO2	CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE	15	%	OR 15.00	{GREATER}			
2025-052	256	GEM PREMI.		10	112.000	4.858	4.34	95.200	128.800	
2025-052	265	ROCHE COBA		33	115.267	13.399	11.62	98.000	132.600	
2025-052	265	ROCHE COBA		33	108.642	8.440	7.77	92.300	124.900	
2025-053	256	GEM PREMI.		10	181.200	7.935	4.38	154.000	208.400	
2025-053	265	ROCHE COBA		33	184.613	6.586	3.57	156.900	212.300	
2025-053	265	ROCHE COBA		33	210.300	53.459	25.42	178.800	241.800	
2025-054	256	GEM PREMI.		10	257.500	28.675	11.14	218.900	296.100	
2025-054	265	ROCHE COBA		33	308.300	43.412	14.08	262.100	354.500	
2025-054	265	ROCHE COBA		33	274.742	29.136	10.60	233.500	316.000	
2025-055	256	GEM PREMI.		10	78.600	31.926	40.62	63.600	93.600	
2025-055	265	ROCHE COBA		33	55.000	18.177	33.05	40.000	70.000	
2025-055	265	ROCHE COBA		33	60.483	6.456	10.67	45.500	75.500	

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
029	FOLL. STIM. HOR.-FSH	CLIA TEST ID #: 542	EVALUATION CRITERIA: TARGET VALUE	18	%	OR 2.00	{GREATER}			
2025-031	116	ROCHE COBA		16	16.188	0.923	5.70	13.300	19.100	
2025-031	149	ARC i2000s		11	15.327	0.983	6.41	12.600	18.100	
2025-031	169	ATELLICA		10	17.340	0.789	4.55	14.200	20.500	
2025-032	116	ROCHE COBA		16	28.950	1.450	5.01	23.700	34.200	
2025-032	149	ARC i2000s		11	27.718	1.797	6.48	22.700	32.700	
2025-032	169	ATELLICA		10	31.680	1.969	6.22	26.000	37.400	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
029	FOLL. STIM. HOR.-FSH	CLIA TEST ID #: 542	EVALUATION CRITERIA: TARGET VALUE	18	% OR 2.00	{GREATER}			
2025-033	116 ROCHE COBA			16	35.731	2.109	5.90	29.300	42.200
2025-033	149 ARC i2000s			11	35.382	1.392	3.93	29.000	41.800
2025-033	169 ATELLICA			10	38.610	1.979	5.12	31.700	45.600
2025-034	116 ROCHE COBA			16	11.519	0.639	5.54	9.400	13.600
2025-034	149 ARC i2000s			11	10.600	0.517	4.88	8.600	12.600
2025-034	169 ATELLICA			10	11.990	0.740	6.17	9.800	14.100
2025-035	116 ROCHE COBA			16	7.038	0.398	5.66	5.000	9.000
2025-035	149 ARC i2000s			11	6.382	0.467	7.31	4.400	8.400
2025-035	169 ATELLICA			10	6.860	0.367	5.34	4.900	8.900
030	FREE THYROXINE	CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE	15	% OR 0.30	{GREATER}			
2025-031	115 VITROS ECI			47	4.071	0.142	3.50	3.500	4.700
2025-031	116 ROCHE COBA			49	1.763	0.078	4.43	1.500	2.100
2025-031	125 B.C.ACCESS			39	1.546	0.103	6.69	1.200	1.800
2025-031	149 ARC i2000s			22	1.509	0.095	6.29	1.200	1.800
2025-031	160 SIEMENS EX			47	1.757	0.089	5.08	1.500	2.100
2025-031	169 ATELLICA			17	1.453	0.050	3.44	1.200	1.800
2025-032	115 VITROS ECI			47	6.287	0.144	2.29	5.300	7.200
2025-032	116 ROCHE COBA			49	2.681	0.101	3.78	2.300	3.100
2025-032	125 B.C.ACCESS			39	2.246	0.134	5.95	1.900	2.600
2025-032	149 ARC i2000s			22	2.177	0.168	7.70	1.900	2.500
2025-032	160 SIEMENS EX			47	2.733	0.110	4.04	2.300	3.100
2025-032	169 ATELLICA			17	2.194	0.080	3.66	1.900	2.500
2025-033	115 VITROS ECI			47	6.938	0.084	1.21	5.900	8.000
2025-033	116 ROCHE COBA			49	3.116	0.135	4.32	2.600	3.600
2025-033	125 B.C.ACCESS			39	2.528	0.145	5.73	2.100	2.900

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-033	149	ARC i2000s		22	2.371	0.167	7.03	2.000	2.700	
2025-033	160	SIEMENS EX		47	3.200	0.134	4.17	2.700	3.700	
2025-033	169	APELLICA		17	2.547	0.085	3.33	2.200	2.900	
030	FREE THYROXINE		CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.30 {GREATER}						
2025-034	115	VITROS ECI		47	2.843	0.110	3.86	2.400	3.300	
2025-034	116	ROCHE COBA		49	1.375	0.066	4.81	1.100	1.700	
2025-034	125	B.C.ACCESS		39	1.244	0.110	8.88	0.900	1.500	
2025-034	149	ARC i2000s		22	1.159	0.058	4.98	0.900	1.500	
2025-034	160	SIEMENS EX		47	1.352	0.074	5.50	1.100	1.700	
2025-034	169	APELLICA		17	1.153	0.061	5.25	0.900	1.500	
2025-035	115	VITROS ECI		47	1.678	0.059	3.50	1.400	2.000	
2025-035	116	ROCHE COBA		49	0.929	0.058	6.20	0.600	1.200	
2025-035	125	B.C.ACCESS		39	0.900	0.078	8.72	0.600	1.200	
2025-035	149	ARC i2000s		22	0.850	0.058	6.87	0.600	1.200	
2025-035	160	SIEMENS EX		47	0.957	0.058	6.03	0.700	1.300	
2025-035	169	APELLICA		17	0.812	0.047	5.80	0.500	1.100	
032	hCG-QUANTITATIVE		CLIA TEST ID #: 555	EVALUATION CRITERIA: TARGET VALUE 18 % OR 3.00 {GREATER}						
2025-031	115	VITROS ECI		22	379.486	17.168	4.52	311.200	447.800	
2025-031	116	ROCHE COBA		17	275.782	18.236	6.61	226.100	325.400	
2025-032	115	VITROS ECI		22	900.314	32.668	3.63	738.300	1062.400	
2025-032	116	ROCHE COBA		17	675.553	41.604	6.16	554.000	797.200	
2025-033	115	VITROS ECI		22	1204.641	46.285	3.84	987.800	1421.500	
2025-033	116	ROCHE COBA		17	898.676	59.846	6.66	736.900	1060.400	
2025-034	115	VITROS ECI		22	183.705	7.023	3.82	150.600	216.800	
2025-034	116	ROCHE COBA		17	134.371	15.673	11.66	110.200	158.600	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
032	hCG-QUANTITATIVE		CLIA TEST ID #: 555	EVALUATION CRITERIA: TARGET VALUE		18 %	OR 3.00	{GREATER}	
2025-035	115	VITROS ECI		22	3.995	0.444	11.10	1.000	7.000
2025-035	116	ROCHE COBA		17	2.965	0.293	9.88	0.000	6.000
035	PROLACTIN		CLIA TEST ID #: 563	EVALUATION CRITERIA: TARGET VALUE		20 %			
2025-031	116	ROCHE COBA		16	9.900	0.350	3.54	7.900	11.900
2025-031	169	APELLICA		10	8.430	0.276	3.27	6.700	10.100
2025-032	116	ROCHE COBA		16	22.650	0.906	4.00	18.100	27.200
2025-032	169	APELLICA		10	18.440	0.434	2.35	14.800	22.100
2025-033	116	ROCHE COBA		16	29.994	1.283	4.28	24.000	36.000
2025-033	169	APELLICA		10	23.870	0.866	3.63	19.100	28.600
2025-034	116	ROCHE COBA		16	5.619	0.243	4.32	4.500	6.700
2025-034	169	APELLICA		10	4.980	0.154	3.08	4.000	6.000
2025-035	116	ROCHE COBA		16	1.775	0.075	4.23	1.400	2.100
2025-035	169	APELLICA		10	1.670	0.100	6.02	1.300	2.000
037	TESTOSTERONE		CLIA TEST ID #: 570	EVALUATION CRITERIA: TARGET VALUE		30 %	OR 0.20	{GREATER}	
2025-031	116	ROCHE COBA		10	5.013	0.215	4.28	3.500	6.500
2025-031	149	ARC i2000s		10	4.590	0.491	10.69	3.200	6.000
2025-032	116	ROCHE COBA		10	10.050	0.357	3.55	7.000	13.100
2025-032	149	ARC i2000s		10	10.650	1.110	10.42	7.500	13.800
2025-033	116	ROCHE COBA		10	12.663	0.628	4.96	8.900	16.500
2025-033	149	ARC i2000s		10	13.540	1.572	11.61	9.500	17.600
2025-034	116	ROCHE COBA		10	2.875	0.109	3.79	2.000	3.700

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-034	149	ARC i2000s		10	2.560	0.196	7.65	1.800	3.300	
037	TESTOSTERONE		CLIA TEST ID #: 570		EVALUATION CRITERIA: TARGET VALUE 30 % OR 0.20 {GREATER}					
2025-035	116	ROCHE COBA		10	0.800	0.071	8.84	0.600	1.000	
2025-035	149	ARC i2000s		10	0.740	0.066	8.96	0.500	1.000	
039	THYRO. STI. HOR.-TSH		CLIA TEST ID #: 585		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}					
2025-031	115	VITROS ECI		53	3.451	0.119	3.45	2.800	4.100	
2025-031	116	ROCHE COBA		55	3.048	0.165	5.42	2.400	3.700	
2025-031	116	ROCHE COBA		55	3.725	0.238	6.40	3.000	4.500	
2025-031	125	B.C.ACCESS		49	2.575	0.131	5.11	2.100	3.100	
2025-031	149	ARC i2000s		24	2.483	0.114	4.60	2.000	3.000	
2025-031	160	SIEMENS EX		73	2.436	0.169	6.94	1.900	2.900	
2025-031	169	ATELLICA		19	2.874	0.152	5.28	2.300	3.400	
2025-032	115	VITROS ECI		53	7.113	0.195	2.75	5.700	8.500	
2025-032	116	ROCHE COBA		55	7.963	0.485	6.09	6.400	9.600	
2025-032	116	ROCHE COBA		55	6.072	0.359	5.91	4.900	7.300	
2025-032	125	B.C.ACCESS		49	5.517	0.310	5.63	4.400	6.600	
2025-032	149	ARC i2000s		24	5.250	0.202	3.85	4.200	6.300	
2025-032	160	SIEMENS EX		73	5.045	0.360	7.14	4.000	6.100	
2025-032	169	ATELLICA		19	5.921	0.322	5.44	4.700	7.100	
2025-033	115	VITROS ECI		53	9.006	0.227	2.52	7.200	10.800	
2025-033	116	ROCHE COBA		55	7.587	0.352	4.64	6.100	9.100	
2025-033	116	ROCHE COBA		55	10.088	0.525	5.21	8.100	12.100	
2025-033	125	B.C.ACCESS		49	7.065	0.421	5.96	5.700	8.500	
2025-033	149	ARC i2000s		24	6.733	0.314	4.67	5.400	8.100	
2025-033	160	SIEMENS EX		73	6.441	0.447	6.93	5.200	7.700	
2025-033	169	ATELLICA		19	7.537	0.426	5.65	6.000	9.000	
2025-034	115	VITROS ECI		53	1.962	0.059	3.01	1.600	2.400	



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY      SUB: 30 ENDOCRINOLOGY      GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-034	116	ROCHE COBA		55	2.100	0.122	5.83	1.700	2.500
2025-034	116	ROCHE COBA		55	1.919	0.249	12.97	1.500	2.300
2025-034	125	B.C.ACCESS		49	1.525	0.088	5.76	1.200	1.800
2025-034	149	ARC i2000s		24	1.457	0.071	4.89	1.200	1.700
2025-034	160	SIEMENS EX		73	1.458	0.111	7.61	1.200	1.700
2025-034	169	APELLICA		19	1.679	0.095	5.66	1.300	2.000
039	THYRO. STI. HOR.-TSH	CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}						
2025-035	115	VITROS ECI		53	0.500	0.000	0.00	0.300	0.700
2025-035	116	ROCHE COBA		55	0.720	0.049	6.75	0.500	0.900
2025-035	116	ROCHE COBA		55	0.650	0.050	7.69	0.500	0.900
2025-035	125	B.C.ACCESS		49	0.546	0.050	9.13	0.300	0.700
2025-035	149	ARC i2000s		24	0.488	0.033	6.78	0.300	0.700
2025-035	160	SIEMENS EX		73	0.529	0.051	9.68	0.300	0.700
2025-035	169	APELLICA		19	0.574	0.044	7.68	0.400	0.800
040	THYROXINE (T4)	CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}						
2025-031	32	SIEM DIME.		43	7.500	0.451	6.01	6.000	9.000
2025-031	32	SIEM DIME.		43	8.000	0.424	5.30	6.400	9.600
2025-031	115	VITROS ECI		42	6.112	0.252	4.12	4.900	7.300
2025-031	116	ROCHE COBA		47	7.148	0.507	7.09	5.700	8.600
2025-031	125	B.C.ACCESS		38	6.997	0.545	7.78	5.600	8.400
2025-031	149	ARC i2000s		22	6.427	0.336	5.23	5.100	7.700
2025-031	169	APELLICA		18	7.600	0.496	6.52	6.100	9.100
2025-032	32	SIEM DIME.		43	14.233	0.613	4.31	11.400	17.100
2025-032	32	SIEM DIME.		43	12.900	0.621	4.82	10.300	15.500
2025-032	115	VITROS ECI		42	10.193	0.397	3.90	8.200	12.200
2025-032	116	ROCHE COBA		47	11.909	0.890	7.47	9.500	14.300
2025-032	125	B.C.ACCESS		38	11.368	0.914	8.04	9.100	13.600
2025-032	149	ARC i2000s		22	11.523	0.578	5.02	9.200	13.800
2025-032	169	APELLICA		18	11.776	0.673	5.72	9.400	14.100

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
040	THYROXINE (T4)	CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE	20	% OR 1.00	{GREATER}			
2025-033	32	SIEM DIME.		43	15.939	0.720	4.52	12.800	19.100
2025-033	32	SIEM DIME.		43	17.100	0.510	2.98	13.700	20.500
2025-033	115	VITROS ECI		42	12.319	0.543	4.41	9.900	14.800
2025-033	116	ROCHE COBA		47	14.493	1.062	7.33	11.600	17.400
2025-033	125	B.C.ACCESS		38	13.366	0.921	6.89	10.700	16.000
2025-033	149	ARC i2000s		22	14.209	0.915	6.44	11.400	17.100
2025-033	169	ATELLICA		18	13.482	0.658	4.88	10.800	16.200
2025-034	32	SIEM DIME.		43	5.733	0.713	12.44	4.600	6.900
2025-034	32	SIEM DIME.		43	5.350	0.398	7.43	4.300	6.400
2025-034	115	VITROS ECI		42	4.610	0.182	3.96	3.600	5.600
2025-034	116	ROCHE COBA		47	5.417	0.567	10.47	4.300	6.500
2025-034	125	B.C.ACCESS		38	5.387	0.514	9.53	4.300	6.500
2025-034	149	ARC i2000s		22	4.576	0.239	5.22	3.600	5.600
2025-034	169	ATELLICA		18	5.639	0.501	8.89	4.500	6.800
2025-035	32	SIEM DIME.		43	3.572	0.436	12.20	2.600	4.600
2025-035	32	SIEM DIME.		43	3.433	0.685	19.94	2.400	4.400
2025-035	115	VITROS ECI		42	3.129	0.133	4.26	2.100	4.100
2025-035	116	ROCHE COBA		47	3.741	0.333	8.91	2.700	4.700
2025-035	125	B.C.ACCESS		38	3.295	0.342	10.37	2.300	4.300
2025-035	149	ARC i2000s		22	2.859	0.204	7.13	1.900	3.900
2025-035	169	ATELLICA		18	3.841	0.225	5.86	2.800	4.800
141	FOLATE	CLIA TEST ID #: 541	EVALUATION CRITERIA: TARGET VALUE	30	% OR 1.00	{GREATER}			
2025-031	115	VITROS ECI		15	3.393	0.546	16.09	2.400	4.400
2025-031	116	ROCHE COBA		24	2.522	0.424	16.82	1.500	3.500
2025-031	125	B.C.ACCESS		10	4.430	0.272	6.14	3.100	5.800
2025-031	149	ARC i2000s		13	4.131	0.434	10.50	2.900	5.400

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
141 FOLATE		CLIA TEST ID #: 541	EVALUATION CRITERIA: TARGET VALUE	30	% OR 1.00	{GREATER}			
2025-032	115 VITROS ECI			15	9.353	1.266	13.53	6.500	12.200
2025-032	116 ROCHE COBA			24	7.271	0.935	12.86	5.100	9.500
2025-032	125 B.C.ACCESS			10	9.970	0.533	5.35	7.000	13.000
2025-032	149 ARC i2000s			13	10.138	1.124	11.08	7.100	13.200
2025-033	115 VITROS ECI			15	12.607	1.611	12.78	8.800	16.400
2025-033	116 ROCHE COBA			24	9.921	1.082	10.91	6.900	12.900
2025-033	125 B.C.ACCESS			10	12.540	1.469	11.72	8.800	16.300
2025-033	149 ARC i2000s			13	13.308	1.617	12.15	9.300	17.300
2025-034	115 VITROS ECI			15	1.980	0.286	14.43	1.000	3.000
2025-034	116 ROCHE COBA			24	2.013	0.061	3.04	1.000	3.000
2025-034	125 B.C.ACCESS			10	2.500	0.379	15.18	1.500	3.500
2025-034	149 ARC i2000s			13	2.223	0.364	16.38	1.200	3.200
2025-035	115 VITROS ECI			15	0.947	0.182	19.23	0	1.900
2025-035	116 ROCHE COBA			24	2.000	0.000	0.00	1.000	3.000
2025-035	125 B.C.ACCESS			10	0.880	0.172	19.55	0	1.900
2025-035	149 ARC i2000s			13	1.077	0.817	75.89	0.100	2.100
142 hLH (HUMAN LUT. HOR)		CLIA TEST ID #: 560	EVALUATION CRITERIA: TARGET VALUE	20	%				
2025-031	116 ROCHE COBA			14	13.371	0.663	4.96	10.700	16.000
2025-031	149 ARC i2000s			10	7.910	0.423	5.35	6.300	9.500
2025-031	169 ATELLICA			10	10.480	0.496	4.73	8.400	12.600
2025-032	116 ROCHE COBA			14	24.900	1.255	5.04	19.900	29.900
2025-032	149 ARC i2000s			10	15.690	0.771	4.92	12.600	18.800
2025-032	169 ATELLICA			10	19.400	0.825	4.25	15.500	23.300
2025-033	116 ROCHE COBA			14	31.307	1.982	6.33	25.000	37.600

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2025-033	149	ARC i2000s		10	19.450	1.386	7.13	15.600	23.300	
2025-033	169	APELLICA		10	23.330	1.173	5.03	18.700	28.000	
142 hLH (HUMAN LUT. HOR)			CLIA TEST ID #: 560	EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-034	116	ROCHE COBA		14	8.929	0.534	5.98	7.100	10.700	
2025-034	149	ARC i2000s		10	5.090	0.288	5.66	4.100	6.100	
2025-034	169	APELLICA		10	6.710	0.321	4.78	5.400	8.100	
2025-035	116	ROCHE COBA		14	4.564	0.331	7.25	3.700	5.500	
2025-035	149	ARC i2000s		10	2.460	0.092	3.73	2.000	3.000	
2025-035	169	APELLICA		10	3.250	0.120	3.71	2.600	3.900	

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)					
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART	# LABS	# "SF"	Score	
SAMPLE	RESULT CODE	RESULT CODE	RESULT CODE	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS		
031 hCG-QUALITATIVE												
2025-031	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	22	22	22	100
2025-031	142	INSTANT VI		002	002	002	002	002 - POSITIVE	26	26	26	100
2025-031	150	AIM STEP		002	002	002	002	002 - POSITIVE	108	108	108	100
2025-031	164	HCG Alere		002	002	002	002	002 - POSITIVE	72	72	72	100
2025-031	165	Osom HCG C		002	002	002	002	002 - POSITIVE	14	14	14	100
2025-031	166	FaStep		002	002	002	002	002 - POSITIVE	15	15	15	100
2025-031	167	Tanner Sci		002	002	002	002	002 - POSITIVE	10	10	10	100
2025-031	168	STANBIO 20		002	002	002	002	002 - POSITIVE	15	15	15	100
2025-032	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	22	22	22	100
2025-032	142	INSTANT VI		002	002	002	002	002 - POSITIVE	26	26	26	100
2025-032	150	AIM STEP		002	002	002	002	002 - POSITIVE	108	108	108	100
2025-032	164	HCG Alere		002	002	002	002	002 - POSITIVE	72	72	72	100
2025-032	165	Osom HCG C		002	002	002	002	002 - POSITIVE	14	14	14	100

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-032	166	FaStep		002 002	002 002		002 - POSITIVE	15	15	15	100	
2025-032	167	Tanner Sci		002 002	002 002		002 - POSITIVE	10	10	10	100	
2025-032	168	STANBIO 20		002 002	002 002		002 - POSITIVE	15	15	15	100	
		031 hCG-QUALITATIVE										
2025-033	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	22	22	22	100	
2025-033	142	INSTANT VI		002 002	002 002		002 - POSITIVE	26	26	26	100	
2025-033	150	AIM STEP		002 002	002 002		002 - POSITIVE	108	108	108	100	
2025-033	164	HCG Alere		002 002	002 002		002 - POSITIVE	72	72	72	100	
2025-033	165	Osom HCG C		002 002	002 002		002 - POSITIVE	14	14	14	100	
2025-033	166	FaStep		002 002	002 002		002 - POSITIVE	15	15	15	100	
2025-033	167	Tanner Sci		002 002	002 002		002 - POSITIVE	10	10	10	100	
2025-033	168	STANBIO 20		002 002	002 002		002 - POSITIVE	15	15	15	100	
2025-034	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	22	22	22	100	
2025-034	142	INSTANT VI		002 002	002 002		002 - POSITIVE	26	26	26	100	
2025-034	150	AIM STEP		002 002	002 002		002 - POSITIVE	108	108	108	100	
2025-034	164	HCG Alere		002 002	002 002		002 - POSITIVE	72	72	72	100	
2025-034	165	Osom HCG C		002 002	002 002		002 - POSITIVE	14	14	14	100	
2025-034	166	FaStep		002 002	002 002		002 - POSITIVE	15	15	15	100	
2025-034	167	Tanner Sci		002 002	002 002		002 - POSITIVE	10	10	10	100	
2025-034	168	STANBIO 20		002 002	002 002		002 - POSITIVE	15	15	15	100	
2025-035	113	BIO-SIGN		001 001	001 001		001 - NEGATIVE	22	21	21	100	
2025-035	113	BIO-SIGN		001 001	001 001		002 - POSITIVE	22	1	21	0	
2025-035	142	INSTANT VI			001 001		001 - NEGATIVE	26	16	16	100	
2025-035	142	INSTANT VI			001 001		002 - POSITIVE	26	10	16	0	
2025-035	150	AIM STEP		001 001	001 001		001 - NEGATIVE	108	98	98	100	
2025-035	150	AIM STEP		001 001	001 001		002 - POSITIVE	108	10	98	0	
2025-035	164	HCG Alere		001 001	001 001		001 - NEGATIVE	72	64	64	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-035	164	HCG Alere		001 001	001 001		002 - POSITIVE	72	8	64	0	
2025-035	165	Osom HCG C		001 001	001 001		001 - NEGATIVE	14	14	14	100	
2025-035	166	FaStep		001 001	001 001		001 - NEGATIVE	15	13	13	100	
2025-035	166	FaStep		001 001	001 001		002 - POSITIVE	15	2	13	0	
2025-035	167	Tanner Sci		001 001	001 001		001 - NEGATIVE	10	9	9	100	
2025-035	167	Tanner Sci		001 001	001 001		002 - POSITIVE	10	1	9	0	
2025-035	168	STANBIO 20		001 001	001 001		001 - NEGATIVE	15	14	14	100	
2025-035	168	STANBIO 20		001 001	001 001		002 - POSITIVE	15	1	14	0	

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
151 hCG ONLY QUALITATIVE												
2025-021	018	BIO SIGN		002 002	002 002		002 - POSITIVE	25	25	25	100	
2025-021	114	INSTANT VI		002 002	002 002		002 - POSITIVE	62	62	62	100	
2025-021	118	AIM STEP		002 002	002 002		002 - POSITIVE	234	234	234	100	
2025-021	130	ALERE HCG		002 002	002 002		002 - POSITIVE	99	99	99	100	
2025-021	131	OSOM HCG		002 002	002 002		002 - POSITIVE	24	24	24	100	
2025-021	133	FaStep		002 002	002 002		002 - POSITIVE	28	28	28	100	
2025-021	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	57	57	57	100	
2025-021	136	CLARITY		002 002	002 002		002 - POSITIVE	20	20	20	100	
2025-021	137	CARDINAL		002 002	002 002		002 - POSITIVE	10	10	10	100	
2025-022	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	25	25	25	100	
2025-022	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	62	62	62	100	
2025-022	118	AIM STEP		001 001	001 001		001 - NEGATIVE	234	234	234	100	
2025-022	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	99	99	99	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-022	131 OSOM HCG			001 001	001 001		001 - NEGATIVE	24	24	24	100	
2025-022	133 FaStep			001 001	001 001		001 - NEGATIVE	28	28	28	100	
2025-022	134 Tanner Sc.			001 001	001 001		001 - NEGATIVE	57	57	57	100	
2025-022	136 CLARITY			001 001	001 001		001 - NEGATIVE	20	20	20	100	
2025-022	137 CARDINAL			001 001	001 001		001 - NEGATIVE	10	10	10	100	
151 hCG ONLY QUALITATIVE												
2025-023	018 BIO SIGN			001 001	001 001		001 - NEGATIVE	25	25	25	100	
2025-023	114 INSTANT VI			001 001	001 001		001 - NEGATIVE	62	61	61	100	
2025-023	114 INSTANT VI			001 001	001 001		002 - POSITIVE	62	1	61	0	
2025-023	118 AIM STEP			001 001	001 001		001 - NEGATIVE	234	234	234	100	
2025-023	130 ALERE HCG			001 001	001 001		001 - NEGATIVE	99	99	99	100	
2025-023	131 OSOM HCG			001 001	001 001		001 - NEGATIVE	24	24	24	100	
2025-023	133 FaStep			001 001	001 001		001 - NEGATIVE	28	28	28	100	
2025-023	134 Tanner Sc.			001 001	001 001		001 - NEGATIVE	57	57	57	100	
2025-023	136 CLARITY			001 001	001 001		001 - NEGATIVE	20	20	20	100	
2025-023	137 CARDINAL			001 001	001 001		001 - NEGATIVE	10	10	10	100	
2025-024	018 BIO SIGN			002 002	002 002		002 - POSITIVE	25	25	25	100	
2025-024	114 INSTANT VI			002 002	002 002		002 - POSITIVE	62	62	62	100	
2025-024	118 AIM STEP			002 002	002 002		002 - POSITIVE	234	234	234	100	
2025-024	130 ALERE HCG			002 002	002 002		002 - POSITIVE	99	99	99	100	
2025-024	131 OSOM HCG			002 002	002 002		002 - POSITIVE	24	24	24	100	
2025-024	133 FaStep			002 002	002 002		002 - POSITIVE	28	28	28	100	
2025-024	134 Tanner Sc.			002 002	002 002		002 - POSITIVE	57	57	57	100	
2025-024	136 CLARITY			002 002	002 002		002 - POSITIVE	20	20	20	100	
2025-024	137 CARDINAL			002 002	002 002		002 - POSITIVE	10	10	10	100	
2025-025	018 BIO SIGN			002 002	002 002		002 - POSITIVE	25	25	25	100	
2025-025	114 INSTANT VI			002 002	002 002		001 - NEGATIVE	62	1	61	0	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-025	114	INSTANT VI		002 002	002 002		002 - POSITIVE	62	61	61	100	
2025-025	118	AIM STEP		002 002	002 002		001 - NEGATIVE	234	1	233	0	
2025-025	118	AIM STEP		002 002	002 002		002 - POSITIVE	234	233	233	100	
2025-025	130	ALERE HCG		002 002	002 002		002 - POSITIVE	99	99	99	100	
2025-025	131	OSOM HCG		002 002	002 002		002 - POSITIVE	24	24	24	100	
2025-025	133	FaStep		002 002	002 002		002 - POSITIVE	28	28	28	100	
2025-025	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	57	57	57	100	
2025-025	136	CLARITY		002 002	002 002		002 - POSITIVE	20	20	20	100	
2025-025	137	CARDINAL		002 002	002 002		002 - POSITIVE	10	10	10	100	

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
173 T3 UPTAKE												
CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 18 %								
2025-031	1 %U	84 VITROS ECI	1 25-35	41	55.632	2.346	4.22	45.620	65.650			
2025-031	1 %U	91 B.C.ACCESS	2 35-45	24	48.917	2.829	5.78	40.110	57.720			
2025-031	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	0.833	0.040	4.83	0.680	0.980			
2025-031	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	0.832	0.069	8.33	0.680	0.980			
2025-031	4 %	32 DIMENSION	2 35-45	45	39.162	1.497	3.82	32.110	46.210			
2025-031	4 %	91 B.C.ACCESS	2 35-45	10	51.040	2.273	4.45	41.850	60.230			
2025-031	4 %	106 ATELLICA	1 25-35	17	45.561	3.061	6.72	37.360	53.760			
2025-031	5 TBI	98 ROCHE COBA	4 0.8-1.3	42	0.743	0.046	6.25	0.610	0.880			
2025-031	5 TBI	98 ROCHE COBA	4 0.8-1.3	42	0.749	0.060	8.01	0.610	0.880			
2025-032	1 %U	84 VITROS ECI	1 25-35	41	50.078	2.736	5.46	41.060	59.090			
2025-032	1 %U	91 B.C.ACCESS	2 35-45	24	46.548	1.860	4.00	38.170	54.930			
2025-032	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	1.039	0.072	6.91	0.850	1.230			
2025-032	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	1.027	0.021	2.00	0.840	1.210			



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-032	4 %	32	DIMENSION	2	35-45	45	39.611	1.208	3.05	32.480	46.740	
2025-032	4 %	91	B.C.ACCESS	2	35-45	10	47.880	1.594	3.33	39.260	56.500	
2025-032	4 %	106	ATELLICA	1	25-35	17	38.991	2.865	7.35	31.970	46.010	
2025-032	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.631	0.069	10.98	0.520	0.740	
2025-032	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.643	0.042	6.51	0.530	0.760	
173 T3 UPTAKE		CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 18 %						
2025-033	1 %U	84	VITROS ECI	1	25-35	41	47.632	2.851	5.99	39.060	56.210	
2025-033	1 %U	91	B.C.ACCESS	2	35-45	24	45.929	3.666	7.98	37.660	54.200	
2025-033	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	1.125	0.078	6.90	0.920	1.330	
2025-033	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	1.103	0.009	0.85	0.900	1.300	
2025-033	4 %	32	DIMENSION	2	35-45	45	40.126	1.639	4.09	32.900	47.350	
2025-033	4 %	91	B.C.ACCESS	2	35-45	10	46.240	2.886	6.24	37.920	54.560	
2025-033	4 %	106	ATELLICA	1	25-35	17	36.133	2.516	6.96	29.630	42.640	
2025-033	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.617	0.033	5.35	0.510	0.730	
2025-033	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.565	0.071	12.50	0.460	0.670	
2025-034	1 %U	84	VITROS ECI	1	25-35	41	57.732	1.927	3.34	47.340	68.120	
2025-034	1 %U	91	B.C.ACCESS	2	35-45	24	51.650	2.609	5.05	42.350	60.950	
2025-034	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	0.734	0.050	6.86	0.600	0.870	
2025-034	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	0.743	0.021	2.76	0.610	0.880	
2025-034	4 %	32	DIMENSION	2	35-45	45	39.108	1.145	2.93	32.070	46.150	
2025-034	4 %	91	B.C.ACCESS	2	35-45	10	53.740	3.558	6.62	44.070	63.410	
2025-034	4 %	106	ATELLICA	1	25-35	17	48.794	3.191	6.54	40.010	57.580	
2025-034	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.794	0.071	8.99	0.650	0.940	
2025-034	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.780	0.057	7.33	0.640	0.920	
2025-035	1 %U	84	VITROS ECI	1	25-35	41	59.073	1.935	3.27	48.440	69.710	
2025-035	1 %U	91	B.C.ACCESS	2	35-45	24	52.775	3.408	6.46	43.280	62.270	
2025-035	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	0.627	0.017	2.71	0.510	0.740	
2025-035	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	0.651	0.061	9.36	0.530	0.770	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY                      SUB: 30 ENDOCRINOLOGY                      GRP: 55 ENDO.(T3 UPTAKE)

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-035	4 %	32	DIMENSION	2	35-45	45	38.708	1.238	3.20	31.740	45.680		
2025-035	4 %	91	B.C.ACCESS	2	35-45	10	53.970	3.066	5.68	44.260	63.680		
2025-035	4 %	106	ATELLICA	1	25-35	17	53.125	3.326	6.26	43.560	62.690		
2025-035	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.830	0.062	7.43	0.680	0.980		
2025-035	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.840	0.068	8.04	0.690	0.990		

SPEC: 10 CHEMISTRY                      SUB: 40 TOXICOLOGY                      GRP: 60 TOXICOLOGY

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
043 DIGOXIN		CLIA TEST ID #: 645		EVALUATION CRITERIA: TARGET VALUE						15 % OR 0.20 {GREATER}			
2025-031	50 VITROS					16	0.744	0.117	15.74	0.500	0.900		
2025-031	50 VITROS					16	0.920	0.117	12.68	0.700	1.100		
2025-032	50 VITROS					16	1.800	0.089	4.97	1.500	2.100		
2025-032	50 VITROS					16	1.306	0.156	11.94	1.100	1.500		
2025-033	50 VITROS					16	1.650	0.170	10.28	1.400	1.900		
2025-033	50 VITROS					16	2.240	0.080	3.57	1.900	2.600		
2025-034	50 VITROS					16	0.620	0.117	18.81	0.400	0.800		
2025-034	50 VITROS					16	0.544	0.117	21.53	0.300	0.700		

## Participant Summary

### MONTH 2 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
043	DIGOXIN	CLIA TEST ID #: 645	EVALUATION CRITERIA: TARGET VALUE	15	% OR 0.20	{GREATER}				
2025-035	50 VITROS			16	0.413	0.033	8.02	0.200	0.600	
2025-035	50 VITROS			16	0.360	0.185	51.52	0.200	0.600	
045	FERRITIN	CLIA TEST ID #: 410	EVALUATION CRITERIA: TARGET VALUE	20	%					
2025-031	50 VITROS			21	53.519	2.278	4.26	42.800	64.200	
2025-031	90 ROCHE COBA			17	98.059	6.577	6.71	78.400	117.700	
2025-031	105 ATELLICA			11	63.573	2.965	4.66	50.900	76.300	
2025-032	50 VITROS			21	114.910	4.688	4.08	91.900	137.900	
2025-032	90 ROCHE COBA			17	202.629	9.694	4.78	162.100	243.200	
2025-032	105 ATELLICA			11	138.645	4.588	3.31	110.900	166.400	
2025-033	50 VITROS			21	151.257	4.784	3.16	121.000	181.500	
2025-033	90 ROCHE COBA			17	263.782	14.034	5.32	211.000	316.500	
2025-033	105 ATELLICA			11	179.364	6.238	3.48	143.500	215.200	
2025-034	50 VITROS			21	34.000	1.514	4.45	27.200	40.800	
2025-034	90 ROCHE COBA			17	61.459	4.316	7.02	49.200	73.800	
2025-034	105 ATELLICA			11	38.936	1.747	4.49	31.100	46.700	
2025-035	50 VITROS			21	16.100	0.801	4.97	12.900	19.300	
2025-035	90 ROCHE COBA			17	27.741	2.205	7.95	22.200	33.300	
2025-035	105 ATELLICA			11	16.873	0.697	4.13	13.500	20.200	
046	GENTAMICIN	CLIA TEST ID #: 665	EVALUATION CRITERIA: TARGET VALUE	25	%					
2025-031	50 VITROS			16	3.956	0.173	4.38	3.000	4.900	
2025-032	50 VITROS			16	9.863	0.607	6.16	7.400	12.300	
2025-033	50 VITROS			16	12.863	1.196	9.30	9.600	16.100	

## Participant Summary

MONTH 2 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY							
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
046	GENTAMICIN										
	2025-034	50	VITROS	CLIA TEST ID #: 665	EVALUATION CRITERIA: TARGET VALUE 25 %	16	2.013	0.086	4.26	1.500	2.500
	2025-035	50	VITROS			16	0.600	0.000	0.00	0.500	0.800
050	PHENYTOIN										
	2025-031	50	VITROS	CLIA TEST ID #: 695	EVALUATION CRITERIA: TARGET VALUE 15 % OR 2.00 {GREATER}	16	8.644	0.257	2.98	6.600	10.600
	2025-032	50	VITROS			16	20.331	0.918	4.51	17.300	23.400
	2025-033	50	VITROS			16	26.644	1.207	4.53	22.600	30.600
	2025-034	50	VITROS			16	4.438	0.180	4.05	2.400	6.400
	2025-035	50	VITROS			16	2.219	1.633	73.61	0.200	4.200
054	THEOPHYLLINE										
	2025-031	50	VITROS	CLIA TEST ID #: 735	EVALUATION CRITERIA: TARGET VALUE 20 %	13	23.815	0.993	4.17	19.100	28.600
	2025-032	50	VITROS			13	48.785	2.180	4.47	39.000	58.500
	2025-033	50	VITROS			13	62.783	3.163	5.04	50.200	75.300
	2025-034	50	VITROS			13	13.015	0.636	4.89	10.400	15.600
	2025-035	50	VITROS			13	2.923	0.396	13.56	2.300	3.500
127	VANCOMYCIN										
	2025-031	50	VITROS	CLIA TEST ID #: 756	EVALUATION CRITERIA: TARGET VALUE 15 % OR 2.00 {GREATER}	21	14.315	0.381	2.66	12.200	16.500
	2025-031	92	ROCHE COBA			10	15.150	0.824	5.44	12.900	17.400
	2025-032	50	VITROS			21	36.571	1.482	4.05	31.100	42.100

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-032	92	ROCHE COBA		10	36.570	1.191	3.26	31.100	42.100	
127	VANCOMYCIN		CLIA TEST ID #: 756	EVALUATION CRITERIA: TARGET VALUE 15 % OR 2.00 {GREATER}						
2025-033	50	VITROS		21	48.670	1.608	3.30	41.400	56.000	
2025-033	92	ROCHE COBA		10	48.480	2.246	4.63	41.200	55.800	
2025-034	50	VITROS		21	7.281	0.252	3.46	5.300	9.300	
2025-034	92	ROCHE COBA		10	7.570	0.626	8.27	5.600	9.600	
2025-035	50	VITROS		21	5.000	0.000	0.00	3.000	7.000	
2025-035	92	ROCHE COBA		10	4.000	0.000	0.00	2.000	6.000	

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
065	URINA-PROTEIN QUANT.		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
2025-061	58	VITROS		42	154.762	9.159	5.92	116.100	193.500	
2025-061	62	SIEM DIM.		45	112.582	2.585	2.30	84.400	140.700	
2025-061	79	BECK. COUL		19	94.663	3.680	3.89	71.000	118.300	
2025-061	93	ARCHITECT		17	95.141	2.419	2.54	71.400	118.900	
2025-061	113	ROCHE COBA		42	91.673	2.217	2.42	68.800	114.600	
2025-061	146	ATELLICA		14	110.471	3.688	3.34	82.900	138.100	
2025-062	58	VITROS		42	5.000	0.000	0.00	0.000	10.000	
2025-062	62	SIEM DIM.		45	15.227	1.512	9.93	10.200	20.200	
2025-062	79	BECK. COUL		19	4.911	0.535	10.89	0	9.900	
2025-062	93	ARCHITECT		17	6.806	0.056	0.82	1.800	11.800	
2025-062	113	ROCHE COBA		42	4.334	0.868	20.02	0	9.300	
2025-062	146	ATELLICA		14	15.850	2.563	16.17	10.900	20.900	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
065	URINA-PROTEIN QUANT.	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	25	% OR 5.00	{GREATER}			
2025-063	58 VITROS			42	127.732	6.786	5.31	95.800	159.700
2025-063	62 SIEM DIM.			45	105.684	2.318	2.19	79.300	132.100
2025-063	79 BECK. COUL			19	96.063	3.560	3.71	72.000	120.100
2025-063	93 ARCHITECT			17	94.035	2.389	2.54	70.500	117.500
2025-063	113 ROCHE COBA			42	88.326	1.931	2.19	66.200	110.400
2025-063	146 ATELLICA			14	104.271	2.981	2.86	78.200	130.300
2025-064	58 VITROS			42	5.073	0.260	5.13	0.100	10.100
2025-064	62 SIEM DIM.			45	22.298	1.378	6.18	16.700	27.900
2025-064	79 BECK. COUL			19	5.189	0.661	12.73	0.200	10.200
2025-064	93 ARCHITECT			17	6.813	0.060	0.88	1.800	11.800
2025-064	113 ROCHE COBA			42	4.176	0.946	22.64	0	9.200
2025-064	146 ATELLICA			14	23.986	2.730	11.38	18.000	30.000
2025-065	58 VITROS			42	148.293	7.296	4.92	111.200	185.400
2025-065	62 SIEM DIM.			45	112.107	1.966	1.75	84.100	140.100
2025-065	79 BECK. COUL			19	97.989	3.398	3.47	73.500	122.500
2025-065	93 ARCHITECT			17	95.653	4.435	4.64	71.700	119.600
2025-065	113 ROCHE COBA			42	88.821	2.196	2.47	66.600	111.000
2025-065	146 ATELLICA			14	110.257	3.264	2.96	82.700	137.800
067	URI-SPECIFIC GRAVITY		EVALUATION CRITERIA: TARGET VALUE	3	SD				
2025-061	11 AMES NM10S			33	1.019	0.003	0.31	1.010	1.029
2025-061	13 BAYER CLI			21	1.019	0.002	0.21	1.012	1.025
2025-061	67 URISCAN			56	1.015	0.002	0.23	1.008	1.022
2025-061	72 URS-9-TECO			56	1.017	0.004	0.37	1.006	1.029
2025-061	80 ROCHE (CHE			36	1.010	0.000	0.00	1.010	1.010
2025-061	89 AIMSTRIP			154	1.016	0.003	0.28	1.008	1.025
2025-061	94 CLINITEK			105	1.020	0.002	0.25	1.012	1.027
2025-061	102 ACON LAB			124	1.017	0.003	0.33	1.007	1.027

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-061	131	iCHEM VELO		33	1.028	0.001	0.09	1.025	1.031
2025-061	140	MISSION A		40	0.992	0.158	15.98	0.516	1.467
2025-061	145	CLINITEK		43	1.031	0.001	0.07	1.029	1.033
2025-061	147	Mission120		37	1.019	0.002	0.18	1.014	1.025
2025-061	148	Mission500		133	1.016	0.002	0.23	1.009	1.023
2025-061	151	Clari. Uro		22	1.015	0.002	0.21	1.009	1.021
067 URI-SPECIFIC GRAVITY		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD					
2025-062	11	AMES NM10S		33	1.021	0.003	0.30	1.012	1.030
2025-062	13	BAYER CLI		21	1.020	0.004	0.35	1.009	1.031
2025-062	67	URISCAN		56	1.020	0.003	0.32	1.011	1.030
2025-062	72	URS-9-TECO		56	1.019	0.006	0.58	1.001	1.037
2025-062	80	ROCHE (CHE		36	1.017	0.002	0.24	1.010	1.025
2025-062	89	AIMSTRIP		154	1.020	0.002	0.24	1.013	1.027
2025-062	94	CLINITEK		105	1.021	0.004	0.39	1.009	1.033
2025-062	102	ACON LAB		124	1.020	0.002	0.21	1.014	1.026
2025-062	131	iCHEM VELO		33	1.028	0.001	0.07	1.025	1.030
2025-062	140	MISSION A		40	1.020	0.002	0.24	1.013	1.027
2025-062	145	CLINITEK		43	1.034	0.001	0.09	1.031	1.037
2025-062	147	Mission120		37	1.020	0.000	0.00	1.020	1.020
2025-062	148	Mission500		133	1.020	0.002	0.18	1.014	1.025
2025-062	151	Clari. Uro		22	1.023	0.004	0.38	1.011	1.034
2025-063	11	AMES NM10S		33	1.024	0.002	0.20	1.018	1.031
2025-063	13	BAYER CLI		21	1.023	0.003	0.32	1.013	1.033
2025-063	67	URISCAN		56	1.022	0.004	0.39	1.010	1.034
2025-063	72	URS-9-TECO		56	1.021	0.005	0.48	1.007	1.036
2025-063	80	ROCHE (CHE		36	1.016	0.002	0.17	1.011	1.021
2025-063	89	AIMSTRIP		154	1.021	0.002	0.20	1.015	1.027
2025-063	94	CLINITEK		105	1.024	0.004	0.35	1.013	1.034
2025-063	102	ACON LAB		124	1.021	0.002	0.20	1.015	1.027

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-063	131	iCHEM VELO		33	1.025	0.001	0.06	1.023	1.027
2025-063	140	MISSION A		40	1.021	0.003	0.26	1.013	1.029
2025-063	145	CLINITEK		43	1.030	0.001	0.06	1.028	1.032
2025-063	147	Mission120		37	1.023	0.003	0.27	1.015	1.031
2025-063	148	Mission500		133	1.020	0.000	0.00	1.020	1.020
2025-063	151	Clari. Uro		22	1.023	0.003	0.28	1.014	1.032
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD					
2025-064	11	AMES NM10S		33	1.013	0.003	0.33	1.003	1.024
2025-064	13	BAYER CLI		21	1.014	0.003	0.29	1.005	1.023
2025-064	67	URISCAN		56	1.010	0.003	0.29	1.001	1.019
2025-064	72	URS-9-TECO		56	1.012	0.004	0.35	1.002	1.023
2025-064	80	ROCHE (CHE		36	1.009	0.003	0.28	1.001	1.018
2025-064	89	AIMSTRIP		154	1.013	0.004	0.36	1.002	1.024
2025-064	94	CLINITEK		105	1.014	0.003	0.29	1.005	1.023
2025-064	102	ACON LAB		124	1.012	0.003	0.26	1.005	1.021
2025-064	131	iCHEM VELO		33	1.026	0.001	0.07	1.023	1.028
2025-064	140	MISSION A		40	1.012	0.002	0.24	1.005	1.019
2025-064	145	CLINITEK		43	1.031	0.001	0.07	1.029	1.033
2025-064	147	Mission120		37	1.015	0.003	0.26	1.007	1.023
2025-064	148	Mission500		133	1.013	0.003	0.30	1.003	1.022
2025-064	151	Clari. Uro		22	1.012	0.003	0.32	1.002	1.022
2025-065	11	AMES NM10S		33	1.022	0.003	0.31	1.012	1.032
2025-065	13	BAYER CLI		21	1.021	0.002	0.21	1.015	1.028
2025-065	67	URISCAN		56	1.018	0.003	0.30	1.009	1.027
2025-065	72	URS-9-TECO		56	1.020	0.004	0.38	1.008	1.032
2025-065	80	ROCHE (CHE		36	1.013	0.002	0.24	1.006	1.020
2025-065	89	AIMSTRIP		154	1.018	0.002	0.25	1.011	1.026
2025-065	94	CLINITEK		105	1.022	0.003	0.26	1.014	1.030
2025-065	102	ACON LAB		124	1.018	0.003	0.25	1.011	1.026



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-065	131	icHEM VELO		33	1.025	0.001	0.12	1.022	1.029
2025-065	140	MISSION A		40	1.018	0.004	0.35	1.008	1.029
2025-065	145	CLINITEK		43	1.027	0.001	0.07	1.025	1.029
2025-065	147	Mission120		37	1.020	0.001	0.14	1.016	1.025
2025-065	148	Mission500		133	1.019	0.002	0.22	1.012	1.025
2025-065	151	Clari. Uro		22	1.017	0.002	0.24	1.010	1.024
166	MICROALBUMIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2025-061	58	VITROS		53	816.325	36.646	4.49	612.200	1020.400
2025-061	62	SIEM DIM.		73	816.064	102.948	12.62	612.000	1020.100
2025-061	79	BECK. COUL		20	754.665	91.387	12.11	566.000	943.300
2025-061	85	Rx DAYTONA		12	711.883	99.417	13.97	533.900	889.900
2025-061	93	ARCHITECT		21	806.470	22.568	2.80	604.900	1008.100
2025-061	95	INTEGRA		19	818.132	55.499	6.78	613.600	1022.700
2025-061	113	ROCHE COBA		48	780.272	36.056	4.62	585.200	975.300
2025-061	146	ATELLICA		19	670.750	18.905	2.82	503.100	838.400
2025-061	154	CS400DIRUI		11	690.400	168.809	24.45	517.800	863.000
2025-062	58	VITROS		53	5.980	0.140	2.34	1.000	11.000
2025-062	62	SIEM DIM.		73	3.493	1.535	43.95	0	8.500
2025-062	79	BECK. COUL		20	2.125	2.889	135.93	0	7.100
2025-062	85	Rx DAYTONA		12	2.567	2.177	84.83	0	7.600
2025-062	93	ARCHITECT		21	5.000	0.000	0.00	0.000	10.000
2025-062	95	INTEGRA		19	3.233	1.435	44.39	0	8.200
2025-062	113	ROCHE COBA		48	11.255	2.853	25.34	6.300	16.300
2025-062	146	ATELLICA		19	3.000	0.000	0.00	0	8.000
2025-062	154	CS400DIRUI		11	5.000	3.827	76.54	0.000	10.000
2025-063	58	VITROS		53	827.082	29.874	3.61	620.300	1033.900
2025-063	62	SIEM DIM.		73	832.872	61.393	7.37	624.700	1041.100
2025-063	79	BECK. COUL		20	762.260	83.569	10.96	571.700	952.800

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-063	85	Rx DAYTONA		12	736.708	83.657	11.36	552.500	920.900	
2025-063	93	ARCHITECT		21	833.257	36.629	4.40	624.900	1041.600	
2025-063	95	INTEGRA		19	823.437	57.516	6.98	617.600	1029.300	
2025-063	113	ROCHE COBA		48	792.387	36.028	4.55	594.300	990.500	
2025-063	146	ATELLICA		19	672.700	23.883	3.55	504.500	840.900	
2025-063	154	CS400DIRUI		11	683.844	173.396	25.36	512.900	854.800	
166	MICROALBUMIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
2025-064	58	VITROS		53	5.980	0.140	2.34	1.000	11.000	
2025-064	62	SIEM DIM.		73	2.301	1.256	54.60	0	7.300	
2025-064	79	BECK. COUL		20	2.045	2.900	141.79	0	7.000	
2025-064	85	Rx DAYTONA		12	2.517	1.887	74.99	0	7.500	
2025-064	93	ARCHITECT		21	5.000	0.000	0.00	0.000	10.000	
2025-064	95	INTEGRA		19	3.267	1.497	45.83	0	8.300	
2025-064	113	ROCHE COBA		48	12.000	0.000	0.00	7.000	17.000	
2025-064	146	ATELLICA		19	3.000	0.000	0.00	0	8.000	
2025-064	154	CS400DIRUI		11	3.422	3.365	98.32	0	8.400	
2025-065	58	VITROS		53	836.084	31.712	3.79	627.100	1045.100	
2025-065	62	SIEM DIM.		73	831.472	60.500	7.28	623.600	1039.300	
2025-065	79	BECK. COUL		20	769.050	86.127	11.20	576.800	961.300	
2025-065	85	Rx DAYTONA		12	741.117	91.148	12.30	555.800	926.400	
2025-065	93	ARCHITECT		21	834.025	19.317	2.32	625.500	1042.500	
2025-065	95	INTEGRA		19	834.668	46.534	5.58	626.000	1043.300	
2025-065	113	ROCHE COBA		48	798.902	40.592	5.08	599.200	998.600	
2025-065	146	ATELLICA		19	685.950	21.984	3.20	514.500	857.400	
2025-065	154	CS400DIRUI		11	726.689	202.182	27.82	545.000	908.400	
167	CREATININE									
2025-061	58	VITROS		59	235.838	6.759	2.87	176.900	294.800	
2025-061	62	SIEM DIM.		72	232.035	6.218	2.68	174.000	290.000	
2025-061	79	BECK. COUL		21	194.833	8.207	4.21	146.100	243.500	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS				
ANALYTE	SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2025-061	85	Rx DAYTONA		10	226.080	21.915	9.69	169.600	282.600
	2025-061	93	ARCHITECT		19	228.437	5.799	2.54	171.300	285.500
	2025-061	95	INTEGRA		20	235.405	8.617	3.66	176.600	294.300
	2025-061	113	ROCHE COBA		48	237.838	8.681	3.65	178.400	297.300
	2025-061	146	ATELLICA		19	216.863	8.658	3.99	162.600	271.100
	2025-061	154	CS400DIRUI		10	225.180	19.974	8.87	168.900	281.500
167 CREATININE			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
	2025-062	58	VITROS		59	3.214	0.105	3.27	0	8.200
	2025-062	62	SIEM DIM.		72	9.464	5.318	56.19	4.500	14.500
	2025-062	79	BECK. COUL		21	0.360	0.426	118.31	0	5.400
	2025-062	85	Rx DAYTONA		10	1.980	1.790	90.40	0	7.000
	2025-062	93	ARCHITECT		19	5.000	0.000	0.00	0.000	10.000
	2025-062	95	INTEGRA		20	0.237	0.418	176.61	0	5.200
	2025-062	113	ROCHE COBA		48	3.564	1.263	35.43	0	8.600
	2025-062	146	ATELLICA		19	3.000	0.000	0.00	0	8.000
	2025-062	154	CS400DIRUI		10	3.040	4.040	132.91	0	8.000
	2025-063	58	VITROS		59	3.193	0.191	5.98	0	8.200
	2025-063	62	SIEM DIM.		72	9.461	5.322	56.25	4.500	14.500
	2025-063	79	BECK. COUL		21	0.420	0.383	91.16	0	5.400
	2025-063	85	Rx DAYTONA		10	1.510	1.592	105.44	0	6.500
	2025-063	93	ARCHITECT		19	5.000	0.000	0.00	0.000	10.000
	2025-063	95	INTEGRA		20	0.411	0.380	92.47	0	5.400
	2025-063	113	ROCHE COBA		48	3.560	1.296	36.40	0	8.600
	2025-063	146	ATELLICA		19	3.000	0.000	0.00	0	8.000
	2025-063	154	CS400DIRUI		10	0.800	0.900	112.50	0	5.800
	2025-064	58	VITROS		59	245.562	10.623	4.33	184.200	307.000
	2025-064	62	SIEM DIM.		72	242.428	6.818	2.81	181.800	303.000
	2025-064	79	BECK. COUL		21	216.819	6.328	2.92	162.600	271.000

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-064	85	Rx DAYTONA		10	230.180	21.834	9.49	172.600	287.700	
2025-064	93	ARCHITECT		19	236.894	6.410	2.71	177.700	296.100	
2025-064	95	INTEGRA		20	244.880	10.193	4.16	183.700	306.100	
2025-064	113	ROCHE COBA		48	244.398	9.524	3.90	183.300	305.500	
2025-064	146	ATELLICA		19	225.942	9.612	4.25	169.500	282.400	
2025-064	154	CS400DIRUI		10	225.120	19.186	8.52	168.800	281.400	
167	CREATININE		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
2025-065	58	VITROS		59	238.721	6.514	2.73	179.000	298.400	
2025-065	62	SIEM DIM.		72	245.616	6.470	2.63	184.200	307.000	
2025-065	79	BECK. COUL		21	218.229	6.315	2.89	163.700	272.800	
2025-065	85	Rx DAYTONA		10	233.900	23.800	10.18	175.400	292.400	
2025-065	93	ARCHITECT		19	237.611	5.606	2.36	178.200	297.000	
2025-065	95	INTEGRA		20	246.705	10.917	4.43	185.000	308.400	
2025-065	113	ROCHE COBA		48	247.673	9.092	3.67	185.800	309.600	
2025-065	146	ATELLICA		19	226.379	7.779	3.44	169.800	283.000	
2025-065	154	CS400DIRUI		10	226.220	19.124	8.45	169.700	282.800	

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
057 URINALYSIS-BILIRUBIN											
2025-061	011	AMES NM10S		058 060	057 059		058 - TRACES,1+	33	5	33	100
2025-061	011	AMES NM10S		058 060	057 059		059 - 2+	33	26	33	100
2025-061	011	AMES NM10S		058 060	057 059		060 - 3+	33	2	33	100
2025-061	013	BAYER CLI		058 060	057 059		058 - TRACES,1+	21	6	21	100
2025-061	013	BAYER CLI		058 060	057 059		059 - 2+	21	14	21	100
2025-061	013	BAYER CLI		058 060	057 059		060 - 3+	21	1	21	100
2025-061	067	URISCAN		057 059	057 059		057 - NEGATIVE	56	11	55	100
2025-061	067	URISCAN		057 059	057 059		058 - TRACES,1+	56	36	55	100

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-061	067	URISCAN		057 059	057 059		059 - 2+	56	8	55	100	
2025-061	067	URISCAN		057 059	057 059		060 - 3+	56	1	55	0	
2025-061	072	URS-9-TECO		058 060	057 059		057 - NEGATIVE	56	4	56	100	
2025-061	072	URS-9-TECO		058 060	057 059		058 - TRACES, 1+	56	15	56	100	
2025-061	072	URS-9-TECO		058 060	057 059		059 - 2+	56	34	56	100	
2025-061	072	URS-9-TECO		058 060	057 059		060 - 3+	56	3	56	100	
2025-061	080	ROCHE (CHE		057 059	057 059		058 - TRACES, 1+	35	31	33	100	
2025-061	080	ROCHE (CHE		057 059	057 059		059 - 2+	35	2	33	100	
2025-061	080	ROCHE (CHE		057 059	057 059		060 - 3+	35	2	33	0	
2025-061	089	AIMSTRIP		057 059	057 059		057 - NEGATIVE	152	5	148	100	
2025-061	089	AIMSTRIP		057 059	057 059		058 - TRACES, 1+	152	106	148	100	
2025-061	089	AIMSTRIP		057 059	057 059		059 - 2+	152	37	148	100	
2025-061	089	AIMSTRIP		057 059	057 059		060 - 3+	152	4	148	0	
2025-061	094	CLINITEK		058 060	057 059		058 - TRACES, 1+	105	14	105	100	
2025-061	094	CLINITEK		058 060	057 059		059 - 2+	105	89	105	100	
2025-061	094	CLINITEK		058 060	057 059		060 - 3+	105	2	105	100	
2025-061	102	ACON LAB		057 059	057 059		058 - TRACES, 1+	119	88	117	100	
2025-061	102	ACON LAB		057 059	057 059		059 - 2+	119	29	117	100	
2025-061	102	ACON LAB		057 059	057 059		060 - 3+	119	2	117	0	
2025-061	131	iCHEM VELO		057 057	057 059		057 - NEGATIVE	34	34	34	100	
2025-061	138	URS-10T		057 059	057 059		057 - NEGATIVE	10	1	9	100	
2025-061	138	URS-10T		057 059	057 059		058 - TRACES, 1+	10	4	9	100	
2025-061	138	URS-10T		057 059	057 059		059 - 2+	10	4	9	100	
2025-061	138	URS-10T		057 059	057 059		060 - 3+	10	1	9	0	
2025-061	140	MISSION A		057 059	057 059		058 - TRACES, 1+	36	30	36	100	
2025-061	140	MISSION A		057 059	057 059		059 - 2+	36	6	36	100	
2025-061	145	CLINITEK		057 057	057 059		057 - NEGATIVE	43	41	43	100	
2025-061	145	CLINITEK		057 057	057 059		058 - TRACES, 1+	43	1	43	100	
2025-061	145	CLINITEK		057 057	057 059		059 - 2+	43	1	43	100	
2025-061	147	Mission120		057 059	057 059		057 - NEGATIVE	39	1	38	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-061	147	Mission120		057 059	057 059		058 - TRACES,1+	39	32	38	100	
2025-061	147	Mission120		057 059	057 059		059 - 2+	39	5	38	100	
2025-061	147	Mission120		057 059	057 059		060 - 3+	39	1	38	0	
2025-061	148	Mission500		057 059	057 059		058 - TRACES,1+	137	123	137	100	
2025-061	148	Mission500		057 059	057 059		059 - 2+	137	14	137	100	
2025-061	151	Clari. Uro		057 059	057 059		058 - TRACES,1+	24	22	24	100	
2025-061	151	Clari. Uro		057 059	057 059		059 - 2+	24	2	24	100	
057 URINALYSIS-BILIRUBIN												
2025-062	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	33	33	33	100	
2025-062	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	21	21	21	100	
2025-062	067	URISCAN		057 057	057 057		057 - NEGATIVE	56	56	56	100	
2025-062	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	56	56	56	100	
2025-062	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	35	35	35	100	
2025-062	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	152	151	151	100	
2025-062	089	AIMSTRIP		057 057	057 057		059 - 2+	152	1	151	0	
2025-062	094	CLINITEK		057 057	057 057		057 - NEGATIVE	105	105	105	100	
2025-062	102	ACON LAB		057 057	057 057		057 - NEGATIVE	119	119	119	100	
2025-062	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	34	34	34	100	
2025-062	138	URS-10T		057 057	057 057		057 - NEGATIVE	10	10	10	100	
2025-062	140	MISSION A		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2025-062	145	CLINITEK		057 057	057 057		057 - NEGATIVE	43	43	43	100	
2025-062	147	Mission120		057 057	057 057		057 - NEGATIVE	39	39	39	100	
2025-062	148	Mission500		057 057	057 057		057 - NEGATIVE	137	136	136	100	
2025-062	148	Mission500		057 057	057 057		058 - TRACES,1+	137	1	136	0	
2025-062	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	24	24	24	100	
2025-063	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	33	33	33	100	
2025-063	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	21	21	21	100	
2025-063	067	URISCAN		057 057	057 057		057 - NEGATIVE	56	55	55	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-063	067	URISCAN		057 057	057 057		060 - 3+	56	1	55	0	
2025-063	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	56	56	56	100	
2025-063	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	35	35	35	100	
2025-063	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	152	152	152	100	
2025-063	094	CLINITEK		057 057	057 057		057 - NEGATIVE	105	105	105	100	
2025-063	102	ACON LAB		057 057	057 057		057 - NEGATIVE	119	119	119	100	
2025-063	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	34	34	34	100	
2025-063	138	URS-10T		057 057	057 057		057 - NEGATIVE	10	10	10	100	
2025-063	140	MISSION A		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2025-063	145	CLINITEK		057 057	057 057		057 - NEGATIVE	43	43	43	100	
2025-063	147	Mission120		057 057	057 057		057 - NEGATIVE	39	39	39	100	
2025-063	148	Mission500		057 057	057 057		057 - NEGATIVE	137	137	137	100	
2025-063	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	24	24	24	100	
057 URINALYSIS-BILIRUBIN												
2025-064	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	33	33	33	100	
2025-064	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	21	21	21	100	
2025-064	067	URISCAN		057 057	057 057		057 - NEGATIVE	56	56	56	100	
2025-064	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	56	56	56	100	
2025-064	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	35	35	35	100	
2025-064	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	152	152	152	100	
2025-064	094	CLINITEK		057 057	057 057		057 - NEGATIVE	105	105	105	100	
2025-064	102	ACON LAB		057 057	057 057		057 - NEGATIVE	119	119	119	100	
2025-064	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	34	34	34	100	
2025-064	138	URS-10T		057 057	057 057		057 - NEGATIVE	10	10	10	100	
2025-064	140	MISSION A		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2025-064	145	CLINITEK		057 057	057 057		057 - NEGATIVE	43	43	43	100	
2025-064	147	Mission120		057 057	057 057		057 - NEGATIVE	39	39	39	100	
2025-064	148	Mission500		057 057	057 057		057 - NEGATIVE	137	137	137	100	
2025-064	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	24	24	24	100	

## Participant Summary

### MONTH 2 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
057 URINALYSIS-BILIRUBIN												
2025-065	011	AMES NM10S		057	057	057	057	057 - NEGATIVE	33	33	33	100
2025-065	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	21	21	21	100
2025-065	067	URISCAN		057	057	057	057	057 - NEGATIVE	56	55	55	100
2025-065	067	URISCAN		057	057	057	057	060 - 3+	56	1	55	0
2025-065	072	URS-9-TECO		057	057	057	057	057 - NEGATIVE	56	56	56	100
2025-065	080	ROCHE (CHE		057	057	057	057	057 - NEGATIVE	35	35	35	100
2025-065	089	AIMSTRIP		057	057	057	057	057 - NEGATIVE	152	152	152	100
2025-065	094	CLINITEK		057	057	057	057	057 - NEGATIVE	105	105	105	100
2025-065	102	ACON LAB		057	057	057	057	057 - NEGATIVE	119	119	119	100
2025-065	131	ICHEM VELO		057	057	057	057	057 - NEGATIVE	34	34	34	100
2025-065	138	URS-10T		057	057	057	057	057 - NEGATIVE	10	10	10	100
2025-065	140	MISSION A		057	057	057	057	057 - NEGATIVE	36	36	36	100
2025-065	145	CLINITEK		057	057	057	057	057 - NEGATIVE	43	43	43	100
2025-065	147	Mission120		057	057	057	057	057 - NEGATIVE	39	39	39	100
2025-065	148	Mission500		057	057	057	057	057 - NEGATIVE	137	137	137	100
2025-065	151	Clari. Uro		057	057	057	057	057 - NEGATIVE	24	24	24	100
058 URINALYSIS-GLUCOSE												
2025-061	011	AMES NM10S		073	073	073	073	073 - NEGATIVE	33	33	33	100
2025-061	013	BAYER CLI		073	073	073	073	073 - NEGATIVE	21	21	21	100
2025-061	067	URISCAN		073	073	073	073	073 - NEGATIVE	56	55	55	100
2025-061	067	URISCAN		073	073	073	073	074 - TRACES	56	1	55	0
2025-061	072	URS-9-TECO		073	073	073	073	073 - NEGATIVE	56	56	56	100
2025-061	080	ROCHE (CHE		073	073	073	073	073 - NEGATIVE	36	36	36	100
2025-061	089	AIMSTRIP		073	073	073	073	073 - NEGATIVE	153	153	153	100
2025-061	094	CLINITEK		073	073	073	073	073 - NEGATIVE	105	105	105	100
2025-061	102	ACON LAB		073	073	073	073	073 - NEGATIVE	122	122	122	100
2025-061	131	ICHEM VELO		073	073	073	073	073 - NEGATIVE	34	34	34	100
2025-061	138	URS-10T		073	073	073	073	073 - NEGATIVE	10	9	9	100



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-061	138	URS-10T		073 073	073 073		074 - TRACES	10	1	9	0	
2025-061	140	MISSION A		073 073	073 073		073 - NEGATIVE	39	39	39	100	
2025-061	145	CLINITEK		073 073	073 073		073 - NEGATIVE	43	43	43	100	
2025-061	147	Mission120		073 073	073 073		073 - NEGATIVE	37	37	37	100	
2025-061	148	Mission500		073 073	073 073		073 - NEGATIVE	135	135	135	100	
2025-061	151	Clari. Uro		073 073	073 073		073 - NEGATIVE	23	23	23	100	
058 URINALYSIS-GLUCOSE												
2025-062	011	AMES NM10S		073 075	074 076		073 - NEGATIVE	33	1	33	100	
2025-062	011	AMES NM10S		073 075	074 076		074 - TRACES	33	16	33	100	
2025-062	011	AMES NM10S		073 075	074 076		075 - 250mg/dl-+	33	15	33	100	
2025-062	011	AMES NM10S		073 075	074 076		076 - 500mg/dl2+	33	1	33	100	
2025-062	013	BAYER CLI		073 075	074 076		073 - NEGATIVE	21	1	21	100	
2025-062	013	BAYER CLI		073 075	074 076		074 - TRACES	21	11	21	100	
2025-062	013	BAYER CLI		073 075	074 076		075 - 250mg/dl-+	21	9	21	100	
2025-062	067	URISCAN			074 076		073 - NEGATIVE	56	7	41	0	
2025-062	067	URISCAN			074 076		074 - TRACES	56	3	41	100	
2025-062	067	URISCAN			074 076		075 - 250mg/dl-+	56	28	41	100	
2025-062	067	URISCAN			074 076		076 - 500mg/dl2+	56	10	41	100	
2025-062	067	URISCAN			074 076		077 - 1000mg/dl	56	8	41	0	
2025-062	072	URS-9-TECO		073 075	074 076		073 - NEGATIVE	56	13	55	100	
2025-062	072	URS-9-TECO		073 075	074 076		074 - TRACES	56	23	55	100	
2025-062	072	URS-9-TECO		073 075	074 076		075 - 250mg/dl-+	56	18	55	100	
2025-062	072	URS-9-TECO		073 075	074 076		076 - 500mg/dl2+	56	1	55	100	
2025-062	072	URS-9-TECO		073 075	074 076		077 - 1000mg/dl	56	1	55	0	
2025-062	080	ROCHE (CHE		076 078	074 076		075 - 250mg/dl-+	36	1	36	100	
2025-062	080	ROCHE (CHE		076 078	074 076		077 - 1000mg/dl	36	33	36	100	
2025-062	080	ROCHE (CHE		076 078	074 076		078 - 2000mg/dl	36	2	36	100	
2025-062	089	AIMSTRIP		074 076	074 076		073 - NEGATIVE	153	4	149	0	
2025-062	089	AIMSTRIP		074 076	074 076		074 - TRACES	153	31	149	100	
2025-062	089	AIMSTRIP		074 076	074 076		075 - 250mg/dl-+	153	118	149	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-062	094	CLINITEK		073 075	074 076		073 - NEGATIVE	105	1	105	100	
2025-062	094	CLINITEK		073 075	074 076		074 - TRACES	105	62	105	100	
2025-062	094	CLINITEK		073 075	074 076		075 - 250mg/dl-+	105	42	105	100	
2025-062	102	ACON LAB		074 076	074 076		073 - NEGATIVE	122	5	117	0	
2025-062	102	ACON LAB		074 076	074 076		074 - TRACES	122	17	117	100	
2025-062	102	ACON LAB		074 076	074 076		075 - 250mg/dl-+	122	100	117	100	
2025-062	131	iCHEM VELO		075 077	074 076		076 - 500mg/dl2+	34	30	34	100	
2025-062	131	iCHEM VELO		075 077	074 076		077 - 1000mg/dl	34	4	34	100	
2025-062	138	URS-10T			074 076		073 - NEGATIVE	10	3	7	0	
2025-062	138	URS-10T			074 076		074 - TRACES	10	2	7	100	
2025-062	138	URS-10T			074 076		075 - 250mg/dl-+	10	4	7	100	
2025-062	138	URS-10T			074 076		076 - 500mg/dl2+	10	1	7	100	
2025-062	140	MISSION A		074 076	074 076		073 - NEGATIVE	39	1	38	0	
2025-062	140	MISSION A		074 076	074 076		074 - TRACES	39	6	38	100	
2025-062	140	MISSION A		074 076	074 076		075 - 250mg/dl-+	39	32	38	100	
2025-062	145	CLINITEK		076 078	074 076		075 - 250mg/dl-+	43	1	43	100	
2025-062	145	CLINITEK		076 078	074 076		076 - 500mg/dl2+	43	7	43	100	
2025-062	145	CLINITEK		076 078	074 076		077 - 1000mg/dl	43	33	43	100	
2025-062	145	CLINITEK		076 078	074 076		078 - 2000mg/dl	43	2	43	100	
2025-062	147	Mission120		074 076	074 076		074 - TRACES	37	5	37	100	
2025-062	147	Mission120		074 076	074 076		075 - 250mg/dl-+	37	31	37	100	
2025-062	147	Mission120		074 076	074 076		076 - 500mg/dl2+	37	1	37	100	
2025-062	148	Mission500		074 076	074 076		073 - NEGATIVE	135	3	132	0	
2025-062	148	Mission500		074 076	074 076		074 - TRACES	135	12	132	100	
2025-062	148	Mission500		074 076	074 076		075 - 250mg/dl-+	135	119	132	100	
2025-062	148	Mission500		074 076	074 076		076 - 500mg/dl2+	135	1	132	100	
2025-062	151	Clari. Uro		074 076	074 076		073 - NEGATIVE	23	1	22	0	
2025-062	151	Clari. Uro		074 076	074 076		074 - TRACES	23	2	22	100	
2025-062	151	Clari. Uro		074 076	074 076		075 - 250mg/dl-+	23	20	22	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
058 URINALYSIS-GLUCOSE													
2025-063	011 AMES NM10S			076 078	076 078		074 - TRACES	33	1	32	0		
2025-063	011 AMES NM10S			076 078	076 078		076 - 500mg/dl2+	33	8	32	100		
2025-063	011 AMES NM10S			076 078	076 078		077 - 1000mg/dl	33	22	32	100		
2025-063	011 AMES NM10S			076 078	076 078		078 - 2000mg/dl	33	2	32	100		
2025-063	013 BAYER CLI			076 078	076 078		075 - 250mg/dl-+	21	1	20	0		
2025-063	013 BAYER CLI			076 078	076 078		076 - 500mg/dl2+	21	7	20	100		
2025-063	013 BAYER CLI			076 078	076 078		077 - 1000mg/dl	21	13	20	100		
2025-063	067 URISCAN			077 078	076 078		076 - 500mg/dl2+	56	6	56	100		
2025-063	067 URISCAN			077 078	076 078		077 - 1000mg/dl	56	17	56	100		
2025-063	067 URISCAN			077 078	076 078		078 - 2000mg/dl	56	33	56	100		
2025-063	072 URS-9-TECO			076 078	076 078		075 - 250mg/dl-+	56	1	55	0		
2025-063	072 URS-9-TECO			076 078	076 078		076 - 500mg/dl2+	56	16	55	100		
2025-063	072 URS-9-TECO			076 078	076 078		077 - 1000mg/dl	56	36	55	100		
2025-063	072 URS-9-TECO			076 078	076 078		078 - 2000mg/dl	56	3	55	100		
2025-063	080 ROCHE (CHE			076 078	076 078		075 - 250mg/dl-+	36	2	34	0		
2025-063	080 ROCHE (CHE			076 078	076 078		077 - 1000mg/dl	36	32	34	100		
2025-063	080 ROCHE (CHE			076 078	076 078		078 - 2000mg/dl	36	2	34	100		
2025-063	089 AIMSTRIP			076 078	076 078		073 - NEGATIVE	153	1	150	0		
2025-063	089 AIMSTRIP			076 078	076 078		075 - 250mg/dl-+	153	2	150	0		
2025-063	089 AIMSTRIP			076 078	076 078		076 - 500mg/dl2+	153	50	150	100		
2025-063	089 AIMSTRIP			076 078	076 078		077 - 1000mg/dl	153	96	150	100		
2025-063	089 AIMSTRIP			076 078	076 078		078 - 2000mg/dl	153	4	150	100		
2025-063	094 CLINITEK			076 078	076 078		073 - NEGATIVE	105	1	100	0		
2025-063	094 CLINITEK			076 078	076 078		074 - TRACES	105	1	100	0		
2025-063	094 CLINITEK			076 078	076 078		075 - 250mg/dl-+	105	3	100	0		
2025-063	094 CLINITEK			076 078	076 078		076 - 500mg/dl2+	105	27	100	100		
2025-063	094 CLINITEK			076 078	076 078		077 - 1000mg/dl	105	73	100	100		
2025-063	102 ACON LAB			076 078	076 078		075 - 250mg/dl-+	122	1	121	0		
2025-063	102 ACON LAB			076 078	076 078		076 - 500mg/dl2+	122	55	121	100		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-063	102	ACON LAB		076 078	076 078		077 - 1000mg/dl	122	58	121	100	
2025-063	102	ACON LAB		076 078	076 078		078 - 2000mg/dl	122	8	121	100	
2025-063	131	iCHEM VELO		075 077	076 078		076 - 500mg/dl2+	34	30	34	100	
2025-063	131	iCHEM VELO		075 077	076 078		077 - 1000mg/dl	34	4	34	100	
2025-063	138	URS-10T		076 078	076 078		076 - 500mg/dl2+	10	3	10	100	
2025-063	138	URS-10T		076 078	076 078		077 - 1000mg/dl	10	7	10	100	
2025-063	140	MISSION A		076 078	076 078		075 - 250mg/dl-+	39	2	37	0	
2025-063	140	MISSION A		076 078	076 078		076 - 500mg/dl2+	39	5	37	100	
2025-063	140	MISSION A		076 078	076 078		077 - 1000mg/dl	39	23	37	100	
2025-063	140	MISSION A		076 078	076 078		078 - 2000mg/dl	39	9	37	100	
2025-063	145	CLINITEK		076 078	076 078		076 - 500mg/dl2+	43	3	43	100	
2025-063	145	CLINITEK		076 078	076 078		077 - 1000mg/dl	43	37	43	100	
2025-063	145	CLINITEK		076 078	076 078		078 - 2000mg/dl	43	3	43	100	
2025-063	147	Mission120		077 078	076 078		076 - 500mg/dl2+	37	5	37	100	
2025-063	147	Mission120		077 078	076 078		077 - 1000mg/dl	37	13	37	100	
2025-063	147	Mission120		077 078	076 078		078 - 2000mg/dl	37	19	37	100	
2025-063	148	Mission500		076 078	076 078		073 - NEGATIVE	135	1	130	0	
2025-063	148	Mission500		076 078	076 078		074 - TRACES	135	2	130	0	
2025-063	148	Mission500		076 078	076 078		075 - 250mg/dl-+	135	2	130	0	
2025-063	148	Mission500		076 078	076 078		076 - 500mg/dl2+	135	37	130	100	
2025-063	148	Mission500		076 078	076 078		077 - 1000mg/dl	135	71	130	100	
2025-063	148	Mission500		076 078	076 078		078 - 2000mg/dl	135	22	130	100	
2025-063	151	Clari. Uro		076 078	076 078		076 - 500mg/dl2+	23	3	23	100	
2025-063	151	Clari. Uro		076 078	076 078		077 - 1000mg/dl	23	20	23	100	
058 URINALYSIS-GLUCOSE												
2025-064	011	AMES NM10S		076 078	076 078		076 - 500mg/dl2+	33	11	33	100	
2025-064	011	AMES NM10S		076 078	076 078		077 - 1000mg/dl	33	21	33	100	
2025-064	011	AMES NM10S		076 078	076 078		078 - 2000mg/dl	33	1	33	100	
2025-064	013	BAYER CLI		076 078	076 078		075 - 250mg/dl-+	21	2	19	0	
2025-064	013	BAYER CLI		076 078	076 078		076 - 500mg/dl2+	21	7	19	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-064	013	BAYER CLI		076 078	076 078		077 - 1000mg/dl	21	12	19	100	
2025-064	067	URISCAN		077 078	076 078		076 - 500mg/dl2+	56	3	56	100	
2025-064	067	URISCAN		077 078	076 078		077 - 1000mg/dl	56	23	56	100	
2025-064	067	URISCAN		077 078	076 078		078 - 2000mg/dl	56	30	56	100	
2025-064	072	URS-9-TECO		076 078	076 078		075 - 250mg/dl-+	56	3	53	0	
2025-064	072	URS-9-TECO		076 078	076 078		076 - 500mg/dl2+	56	20	53	100	
2025-064	072	URS-9-TECO		076 078	076 078		077 - 1000mg/dl	56	32	53	100	
2025-064	072	URS-9-TECO		076 078	076 078		078 - 2000mg/dl	56	1	53	100	
2025-064	080	ROCHE (CHE		076 078	076 078		075 - 250mg/dl-+	36	3	33	0	
2025-064	080	ROCHE (CHE		076 078	076 078		077 - 1000mg/dl	36	31	33	100	
2025-064	080	ROCHE (CHE		076 078	076 078		078 - 2000mg/dl	36	2	33	100	
2025-064	089	AIMSTRIP		076 078	076 078		073 - NEGATIVE	153	1	148	0	
2025-064	089	AIMSTRIP		076 078	076 078		075 - 250mg/dl-+	153	4	148	0	
2025-064	089	AIMSTRIP		076 078	076 078		076 - 500mg/dl2+	153	44	148	100	
2025-064	089	AIMSTRIP		076 078	076 078		077 - 1000mg/dl	153	103	148	100	
2025-064	089	AIMSTRIP		076 078	076 078		078 - 2000mg/dl	153	1	148	100	
2025-064	094	CLINITEK		076 078	076 078		075 - 250mg/dl-+	105	2	103	0	
2025-064	094	CLINITEK		076 078	076 078		076 - 500mg/dl2+	105	31	103	100	
2025-064	094	CLINITEK		076 078	076 078		077 - 1000mg/dl	105	72	103	100	
2025-064	102	ACON LAB		076 078	076 078		075 - 250mg/dl-+	122	3	119	0	
2025-064	102	ACON LAB		076 078	076 078		076 - 500mg/dl2+	122	47	119	100	
2025-064	102	ACON LAB		076 078	076 078		077 - 1000mg/dl	122	64	119	100	
2025-064	102	ACON LAB		076 078	076 078		078 - 2000mg/dl	122	8	119	100	
2025-064	131	iCHEM VELO		075 077	076 078		076 - 500mg/dl2+	34	30	34	100	
2025-064	131	iCHEM VELO		075 077	076 078		077 - 1000mg/dl	34	4	34	100	
2025-064	138	URS-10T		075 077	076 078		076 - 500mg/dl2+	10	6	10	100	
2025-064	138	URS-10T		075 077	076 078		077 - 1000mg/dl	10	4	10	100	
2025-064	140	MISSION A		076 078	076 078		075 - 250mg/dl-+	39	1	38	0	
2025-064	140	MISSION A		076 078	076 078		076 - 500mg/dl2+	39	11	38	100	
2025-064	140	MISSION A		076 078	076 078		077 - 1000mg/dl	39	19	38	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-064	140 MISSION A			076 078	076 078		078 - 2000mg/dl	39	8	38	100	
2025-064	145 CLINITEK			075 077	076 078		075 - 250mg/dl-+	43	1	43	100	
2025-064	145 CLINITEK			075 077	076 078		076 - 500mg/dl2+	43	24	43	100	
2025-064	145 CLINITEK			075 077	076 078		077 - 1000mg/dl	43	16	43	100	
2025-064	145 CLINITEK			075 077	076 078		078 - 2000mg/dl	43	2	43	100	
2025-064	147 Mission120			076 078	076 078		076 - 500mg/dl2+	37	3	37	100	
2025-064	147 Mission120			076 078	076 078		077 - 1000mg/dl	37	17	37	100	
2025-064	147 Mission120			076 078	076 078		078 - 2000mg/dl	37	17	37	100	
2025-064	148 Mission500			076 078	076 078		073 - NEGATIVE	135	2	131	0	
2025-064	148 Mission500			076 078	076 078		075 - 250mg/dl-+	135	2	131	0	
2025-064	148 Mission500			076 078	076 078		076 - 500mg/dl2+	135	32	131	100	
2025-064	148 Mission500			076 078	076 078		077 - 1000mg/dl	135	72	131	100	
2025-064	148 Mission500			076 078	076 078		078 - 2000mg/dl	135	27	131	100	
2025-064	151 Clari. Uro			076 078	076 078		076 - 500mg/dl2+	23	4	23	100	
2025-064	151 Clari. Uro			076 078	076 078		077 - 1000mg/dl	23	18	23	100	
2025-064	151 Clari. Uro			076 078	076 078		078 - 2000mg/dl	23	1	23	100	
058 URINALYSIS-GLUCOSE												
2025-065	011 AMES NM10S			073 073	073 073		073 - NEGATIVE	33	33	33	100	
2025-065	013 BAYER CLI			073 073	073 073		073 - NEGATIVE	21	21	21	100	
2025-065	067 URISCAN			073 073	073 073		073 - NEGATIVE	56	55	55	100	
2025-065	067 URISCAN			073 073	073 073		075 - 250mg/dl-+	56	1	55	0	
2025-065	072 URS-9-TECO			073 073	073 073		073 - NEGATIVE	56	56	56	100	
2025-065	080 ROCHE (CHE			073 073	073 073		073 - NEGATIVE	36	36	36	100	
2025-065	089 AIMSTRIP			073 073	073 073		073 - NEGATIVE	153	153	153	100	
2025-065	094 CLINITEK			073 073	073 073		073 - NEGATIVE	105	105	105	100	
2025-065	102 ACON LAB			073 073	073 073		073 - NEGATIVE	122	121	121	100	
2025-065	102 ACON LAB			073 073	073 073		077 - 1000mg/dl	122	1	121	0	
2025-065	131 iCHEM VELO			073 073	073 073		073 - NEGATIVE	34	34	34	100	
2025-065	138 URS-10T			073 073	073 073		073 - NEGATIVE	10	10	10	100	
2025-065	140 MISSION A			073 073	073 073		073 - NEGATIVE	39	39	39	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-065	145	CLINITEK		073 073	073 073		073 - NEGATIVE	43	43	43	100	
2025-065	147	Mission120		073 073	073 073		073 - NEGATIVE	37	37	37	100	
2025-065	148	Mission500		073 073	073 073		073 - NEGATIVE	135	134	134	100	
2025-065	148	Mission500		073 073	073 073		077 - 1000mg/dl	135	1	134	0	
2025-065	151	Clari. Uro		073 073	073 073		073 - NEGATIVE	23	23	23	100	
059 URINALYS.HG.OR BLOOD												
2025-061	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	33	8	33	100	
2025-061	011	AMES NM10S		068 069	068 069		069 - POS.(3+) )	33	25	33	100	
2025-061	013	BAYER CLI		068 069	068 069		068 - POS.(1-2+)	21	4	21	100	
2025-061	013	BAYER CLI		068 069	068 069		069 - POS.(3+) )	21	17	21	100	
2025-061	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	56	11	56	100	
2025-061	067	URISCAN		068 069	068 069		069 - POS.(3+) )	56	45	56	100	
2025-061	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	56	13	56	100	
2025-061	072	URS-9-TECO		068 069	068 069		069 - POS.(3+) )	56	43	56	100	
2025-061	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	36	2	36	100	
2025-061	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+) )	36	34	36	100	
2025-061	089	AIMSTRIP		068 069	068 069		068 - POS.(1-2+)	152	6	152	100	
2025-061	089	AIMSTRIP		068 069	068 069		069 - POS.(3+) )	152	146	152	100	
2025-061	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	105	15	105	100	
2025-061	094	CLINITEK		068 069	068 069		069 - POS.(3+) )	105	90	105	100	
2025-061	102	ACON LAB		068 069	068 069		066 - NEGATIVE	124	1	123	0	
2025-061	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	124	5	123	100	
2025-061	102	ACON LAB		068 069	068 069		069 - POS.(3+) )	124	118	123	100	
2025-061	131	iCHEM VELO		067 069	068 069		067 - TRACES	34	1	34	100	
2025-061	131	iCHEM VELO		067 069	068 069		068 - POS.(1-2+)	34	20	34	100	
2025-061	131	iCHEM VELO		067 069	068 069		069 - POS.(3+) )	34	13	34	100	
2025-061	138	URS-10T		068 069	068 069		068 - POS.(1-2+)	10	1	10	100	
2025-061	138	URS-10T		068 069	068 069		069 - POS.(3+) )	10	9	10	100	
2025-061	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	37	2	37	100	
2025-061	140	MISSION A		068 069	068 069		069 - POS.(3+) )	37	35	37	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-061	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	43	21	43	100	
2025-061	145	CLINITEK		068 069	068 069		069 - POS.(3+)	43	22	43	100	
2025-061	147	Mission120		068 069	068 069		068 - POS.(1-2+)	38	1	38	100	
2025-061	147	Mission120		068 069	068 069		069 - POS.(3+)	38	37	38	100	
2025-061	148	Mission500		068 069	068 069		068 - POS.(1-2+)	134	1	134	100	
2025-061	148	Mission500		068 069	068 069		069 - POS.(3+)	134	133	134	100	
2025-061	151	Clari. Uro		068 069	068 069		069 - POS.(3+)	23	23	23	100	
059 URINALYS.HG.OR BLOOD												
2025-062	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	33	33	33	100	
2025-062	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	21	21	21	100	
2025-062	067	URISCAN		066 066	066 066		066 - NEGATIVE	56	56	56	100	
2025-062	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	56	56	56	100	
2025-062	080	ROCHE (CHE		066 066	066 066		066 - NEGATIVE	36	36	36	100	
2025-062	089	AIMSTRIP		066 066	066 066		066 - NEGATIVE	152	152	152	100	
2025-062	094	CLINITEK		066 066	066 066		066 - NEGATIVE	105	104	104	100	
2025-062	094	CLINITEK		066 066	066 066		067 - TRACES	105	1	104	0	
2025-062	102	ACON LAB		066 066	066 066		066 - NEGATIVE	124	123	123	100	
2025-062	102	ACON LAB		066 066	066 066		068 - POS.(1-2+)	124	1	123	0	
2025-062	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	34	34	34	100	
2025-062	138	URS-10T		066 066	066 066		066 - NEGATIVE	10	10	10	100	
2025-062	140	MISSION A		066 066	066 066		066 - NEGATIVE	37	37	37	100	
2025-062	145	CLINITEK		066 066	066 066		066 - NEGATIVE	43	43	43	100	
2025-062	147	Mission120		066 066	066 066		066 - NEGATIVE	38	38	38	100	
2025-062	148	Mission500		066 066	066 066		066 - NEGATIVE	134	133	133	100	
2025-062	148	Mission500		066 066	066 066		069 - POS.(3+)	134	1	133	0	
2025-062	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	23	23	23	100	
2025-063	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	33	3	33	100	
2025-063	011	AMES NM10S		068 069	068 069		069 - POS.(3+)	33	30	33	100	



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-063	013	BAYER CLI		068 069	068 069		068 - POS.(1-2+)	21	1	21	100
2025-063	013	BAYER CLI		068 069	068 069		069 - POS.(3+)	21	20	21	100
2025-063	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	56	8	56	100
2025-063	067	URISCAN		068 069	068 069		069 - POS.(3+)	56	48	56	100
2025-063	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	56	4	56	100
2025-063	072	URS-9-TECO		068 069	068 069		069 - POS.(3+)	56	52	56	100
2025-063	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	36	3	36	100
2025-063	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+)	36	33	36	100
2025-063	089	AIMSTRIP		068 069	068 069		068 - POS.(1-2+)	152	7	152	100
2025-063	089	AIMSTRIP		068 069	068 069		069 - POS.(3+)	152	145	152	100
2025-063	094	CLINITEK		068 069	068 069		067 - TRACES	105	1	104	0
2025-063	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	105	1	104	100
2025-063	094	CLINITEK		068 069	068 069		069 - POS.(3+)	105	103	104	100
2025-063	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	124	2	124	100
2025-063	102	ACON LAB		068 069	068 069		069 - POS.(3+)	124	122	124	100
2025-063	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	34	2	34	100
2025-063	131	iCHEM VELO		068 069	068 069		069 - POS.(3+)	34	32	34	100
2025-063	138	URS-10T		068 069	068 069		069 - POS.(3+)	10	10	10	100
2025-063	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	37	1	37	100
2025-063	140	MISSION A		068 069	068 069		069 - POS.(3+)	37	36	37	100
2025-063	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	43	4	43	100
2025-063	145	CLINITEK		068 069	068 069		069 - POS.(3+)	43	39	43	100
2025-063	147	Mission120		068 069	068 069		069 - POS.(3+)	38	38	38	100
2025-063	148	Mission500		068 069	068 069		069 - POS.(3+)	134	134	134	100
2025-063	151	Clari. Uro		068 069	068 069		069 - POS.(3+)	23	23	23	100
059 URINALYS.HG.OR BLOOD											
2025-064	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	33	33	33	100
2025-064	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	21	21	21	100
2025-064	067	URISCAN		066 066	066 066		066 - NEGATIVE	56	55	55	100
2025-064	067	URISCAN		066 066	066 066		068 - POS.(1-2+)	56	1	55	0

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-064	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	56	56	56	100	
2025-064	080	ROCHE (CHE		066 066	066 066		066 - NEGATIVE	36	34	34	100	
2025-064	080	ROCHE (CHE		066 066	066 066		067 - TRACES	36	2	34	0	
2025-064	089	AIMSTRIP		066 066	066 066		066 - NEGATIVE	152	151	151	100	
2025-064	089	AIMSTRIP		066 066	066 066		067 - TRACES	152	1	151	0	
2025-064	094	CLINITEK		066 066	066 066		066 - NEGATIVE	105	105	105	100	
2025-064	102	ACON LAB		066 066	066 066		066 - NEGATIVE	124	122	122	100	
2025-064	102	ACON LAB		066 066	066 066		068 - POS. (1-2+)	124	2	122	0	
2025-064	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	34	34	34	100	
2025-064	138	URS-10T		066 066	066 066		066 - NEGATIVE	10	10	10	100	
2025-064	140	MISSION A		066 066	066 066		066 - NEGATIVE	37	37	37	100	
2025-064	145	CLINITEK		066 066	066 066		066 - NEGATIVE	43	43	43	100	
2025-064	147	Mission120		066 066	066 066		066 - NEGATIVE	38	38	38	100	
2025-064	148	Mission500		066 066	066 066		066 - NEGATIVE	134	134	134	100	
2025-064	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	23	23	23	100	
059 URINALYS.HG.OR BLOOD												
2025-065	011	AMES NM10S		068 069	068 069		066 - NEGATIVE	33	1	32	0	
2025-065	011	AMES NM10S		068 069	068 069		068 - POS. (1-2+)	33	3	32	100	
2025-065	011	AMES NM10S		068 069	068 069		069 - POS. (3+ )	33	29	32	100	
2025-065	013	BAYER CLI		068 069	068 069		068 - POS. (1-2+)	21	1	21	100	
2025-065	013	BAYER CLI		068 069	068 069		069 - POS. (3+ )	21	20	21	100	
2025-065	067	URISCAN		068 069	068 069		066 - NEGATIVE	56	1	55	0	
2025-065	067	URISCAN		068 069	068 069		068 - POS. (1-2+)	56	6	55	100	
2025-065	067	URISCAN		068 069	068 069		069 - POS. (3+ )	56	49	55	100	
2025-065	072	URS-9-TECO		068 069	068 069		068 - POS. (1-2+)	56	2	56	100	
2025-065	072	URS-9-TECO		068 069	068 069		069 - POS. (3+ )	56	54	56	100	
2025-065	080	ROCHE (CHE		068 069	068 069		068 - POS. (1-2+)	36	2	36	100	
2025-065	080	ROCHE (CHE		068 069	068 069		069 - POS. (3+ )	36	34	36	100	
2025-065	089	AIMSTRIP		068 069	068 069		066 - NEGATIVE	152	2	150	0	
2025-065	089	AIMSTRIP		068 069	068 069		068 - POS. (1-2+)	152	3	150	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-065	089 AIMSTRIP			068 069	068 069		069 - POS. (3+ )	152	147	150	100
2025-065	094 CLINITEK			068 069	068 069		069 - POS. (3+ )	105	105	105	100
2025-065	102 ACON LAB			068 069	068 069		066 - NEGATIVE	124	2	122	0
2025-065	102 ACON LAB			068 069	068 069		069 - POS. (3+ )	124	122	122	100
2025-065	131 iCHEM VELO			068 069	068 069		066 - NEGATIVE	34	1	33	0
2025-065	131 iCHEM VELO			068 069	068 069		068 - POS. (1-2+)	34	2	33	100
2025-065	131 iCHEM VELO			068 069	068 069		069 - POS. (3+ )	34	31	33	100
2025-065	138 URS-10T			068 069	068 069		069 - POS. (3+ )	10	10	10	100
2025-065	140 MISSION A			068 069	068 069		068 - POS. (1-2+)	37	1	37	100
2025-065	140 MISSION A			068 069	068 069		069 - POS. (3+ )	37	36	37	100
2025-065	145 CLINITEK			068 069	068 069		068 - POS. (1-2+)	43	1	43	100
2025-065	145 CLINITEK			068 069	068 069		069 - POS. (3+ )	43	42	43	100
2025-065	147 Mission120			068 069	068 069		069 - POS. (3+ )	38	38	38	100
2025-065	148 Mission500			068 069	068 069		066 - NEGATIVE	134	1	133	0
2025-065	148 Mission500			068 069	068 069		068 - POS. (1-2+)	134	1	133	100
2025-065	148 Mission500			068 069	068 069		069 - POS. (3+ )	134	132	133	100
2025-065	151 Clari. Uro			068 069	068 069		069 - POS. (3+ )	23	23	23	100
060 URINALYSIS-KETONES											
2025-061	011 AMES NM10S			093 094	093 094		093 - MOD. (2+)	33	2	33	100
2025-061	011 AMES NM10S			093 094	093 094		094 - LARGE-3-4+	33	31	33	100
2025-061	013 BAYER CLI			093 094	093 094		093 - MOD. (2+)	21	2	21	100
2025-061	013 BAYER CLI			093 094	093 094		094 - LARGE-3-4+	21	19	21	100
2025-061	067 URISCAN			093 094	093 094		092 - SMALL (1+)	56	1	55	0
2025-061	067 URISCAN			093 094	093 094		093 - MOD. (2+)	56	17	55	100
2025-061	067 URISCAN			093 094	093 094		094 - LARGE-3-4+	56	38	55	100
2025-061	072 URS-9-TECO			093 094	093 094		093 - MOD. (2+)	55	3	55	100
2025-061	072 URS-9-TECO			093 094	093 094		094 - LARGE-3-4+	55	52	55	100
2025-061	080 ROCHE (CHE			093 094	093 094		092 - SMALL (1+)	36	1	35	0
2025-061	080 ROCHE (CHE			093 094	093 094		093 - MOD. (2+)	36	3	35	100
2025-061	080 ROCHE (CHE			093 094	093 094		094 - LARGE-3-4+	36	32	35	100

## Participant Summary

### MONTH 2 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-061	089	AIMSTRIP		093 094	093 094		093 - MOD. (2+)	153	7	153	100
2025-061	089	AIMSTRIP		093 094	093 094		094 - LARGE-3-4+	153	146	153	100
2025-061	094	CLINITEK		093 094	093 094		093 - MOD. (2+)	105	9	105	100
2025-061	094	CLINITEK		093 094	093 094		094 - LARGE-3-4+	105	96	105	100
2025-061	102	ACON LAB		093 094	093 094		093 - MOD. (2+)	122	2	122	100
2025-061	102	ACON LAB		093 094	093 094		094 - LARGE-3-4+	122	120	122	100
2025-061	131	iCHEM VELO		092 094	093 094		092 - SMALL (1+)	34	1	34	100
2025-061	131	iCHEM VELO		092 094	093 094		093 - MOD. (2+)	34	19	34	100
2025-061	131	iCHEM VELO		092 094	093 094		094 - LARGE-3-4+	34	14	34	100
2025-061	138	URS-10T		093 094	093 094		093 - MOD. (2+)	10	1	10	100
2025-061	138	URS-10T		093 094	093 094		094 - LARGE-3-4+	10	9	10	100
2025-061	140	MISSION A		093 094	093 094		093 - MOD. (2+)	40	2	40	100
2025-061	140	MISSION A		093 094	093 094		094 - LARGE-3-4+	40	38	40	100
2025-061	145	CLINITEK		093 094	093 094		094 - LARGE-3-4+	43	43	43	100
2025-061	147	Mission120		093 094	093 094		094 - LARGE-3-4+	37	37	37	100
2025-061	148	Mission500		093 094	093 094		094 - LARGE-3-4+	134	134	134	100
2025-061	151	Clari. Uro		093 094	093 094		094 - LARGE-3-4+	23	23	23	100
060 URINALYSIS-KETONES											
2025-062	011	AMES NM10S		092 094	092 094		091 - TRACE	33	1	32	0
2025-062	011	AMES NM10S		092 094	092 094		092 - SMALL (1+)	33	6	32	100
2025-062	011	AMES NM10S		092 094	092 094		093 - MOD. (2+)	33	22	32	100
2025-062	011	AMES NM10S		092 094	092 094		094 - LARGE-3-4+	33	4	32	100
2025-062	013	BAYER CLI		092 094	092 094		092 - SMALL (1+)	21	8	21	100
2025-062	013	BAYER CLI		092 094	092 094		093 - MOD. (2+)	21	13	21	100
2025-062	067	URISCAN		092 094	092 094		092 - SMALL (1+)	56	9	56	100
2025-062	067	URISCAN		092 094	092 094		093 - MOD. (2+)	56	35	56	100
2025-062	067	URISCAN		092 094	092 094		094 - LARGE-3-4+	56	12	56	100
2025-062	072	URS-9-TECO		092 094	092 094		092 - SMALL (1+)	55	7	55	100
2025-062	072	URS-9-TECO		092 094	092 094		093 - MOD. (2+)	55	37	55	100
2025-062	072	URS-9-TECO		092 094	092 094		094 - LARGE-3-4+	55	11	55	100

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-062	080	ROCHE (CHE		092 094	092 094		092 - SMALL (1+)	36	9	36	100	
2025-062	080	ROCHE (CHE		092 094	092 094		093 - MOD. (2+)	36	23	36	100	
2025-062	080	ROCHE (CHE		092 094	092 094		094 - LARGE-3-4+	36	4	36	100	
2025-062	089	AIMSTRIP		092 094	092 094		090 - NEGATIVE	153	1	151	0	
2025-062	089	AIMSTRIP		092 094	092 094		091 - TRACE	153	1	151	0	
2025-062	089	AIMSTRIP		092 094	092 094		092 - SMALL (1+)	153	17	151	100	
2025-062	089	AIMSTRIP		092 094	092 094		093 - MOD. (2+)	153	91	151	100	
2025-062	089	AIMSTRIP		092 094	092 094		094 - LARGE-3-4+	153	43	151	100	
2025-062	094	CLINITEK		092 094	092 094		090 - NEGATIVE	105	1	102	0	
2025-062	094	CLINITEK		092 094	092 094		091 - TRACE	105	2	102	0	
2025-062	094	CLINITEK		092 094	092 094		092 - SMALL (1+)	105	30	102	100	
2025-062	094	CLINITEK		092 094	092 094		093 - MOD. (2+)	105	69	102	100	
2025-062	094	CLINITEK		092 094	092 094		094 - LARGE-3-4+	105	3	102	100	
2025-062	102	ACON LAB		092 094	092 094		091 - TRACE	122	1	121	0	
2025-062	102	ACON LAB		092 094	092 094		092 - SMALL (1+)	122	11	121	100	
2025-062	102	ACON LAB		092 094	092 094		093 - MOD. (2+)	122	82	121	100	
2025-062	102	ACON LAB		092 094	092 094		094 - LARGE-3-4+	122	28	121	100	
2025-062	131	iCHEM VELO		091 093	092 094		091 - TRACE	34	1	34	100	
2025-062	131	iCHEM VELO		091 093	092 094		092 - SMALL (1+)	34	17	34	100	
2025-062	131	iCHEM VELO		091 093	092 094		093 - MOD. (2+)	34	10	34	100	
2025-062	131	iCHEM VELO		091 093	092 094		094 - LARGE-3-4+	34	6	34	100	
2025-062	138	URS-10T			092 094		092 - SMALL (1+)	10	3	10	100	
2025-062	138	URS-10T			092 094		093 - MOD. (2+)	10	3	10	100	
2025-062	138	URS-10T			092 094		094 - LARGE-3-4+	10	4	10	100	
2025-062	140	MISSION A		093 094	092 094		092 - SMALL (1+)	40	3	40	100	
2025-062	140	MISSION A		093 094	092 094		093 - MOD. (2+)	40	14	40	100	
2025-062	140	MISSION A		093 094	092 094		094 - LARGE-3-4+	40	23	40	100	
2025-062	145	CLINITEK		092 094	092 094		092 - SMALL (1+)	43	3	43	100	
2025-062	145	CLINITEK		092 094	092 094		093 - MOD. (2+)	43	40	43	100	
2025-062	147	Mission120		093 094	092 094		093 - MOD. (2+)	37	8	37	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-062	147	Mission120		093 094	092 094		094 - LARGE-3-4+	37	29	37	100	
2025-062	148	Mission500		092 094	092 094		092 - SMALL (1+)	134	1	134	100	
2025-062	148	Mission500		092 094	092 094		093 - MOD. (2+)	134	111	134	100	
2025-062	148	Mission500		092 094	092 094		094 - LARGE-3-4+	134	22	134	100	
2025-062	151	Clari. Uro		092 094	092 094		093 - MOD. (2+)	23	16	23	100	
2025-062	151	Clari. Uro		092 094	092 094		094 - LARGE-3-4+	23	7	23	100	
060 URINALYSIS-KETONES												
2025-063	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	33	33	33	100	
2025-063	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	21	21	21	100	
2025-063	067	URISCAN		090 090	090 090		090 - NEGATIVE	56	56	56	100	
2025-063	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	55	55	55	100	
2025-063	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	36	36	36	100	
2025-063	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	153	153	153	100	
2025-063	094	CLINITEK		090 090	090 090		090 - NEGATIVE	105	105	105	100	
2025-063	102	ACON LAB		090 090	090 090		090 - NEGATIVE	122	122	122	100	
2025-063	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	34	34	34	100	
2025-063	138	URS-10T		090 090	090 090		090 - NEGATIVE	10	10	10	100	
2025-063	140	MISSION A		090 090	090 090		090 - NEGATIVE	40	40	40	100	
2025-063	145	CLINITEK		090 090	090 090		090 - NEGATIVE	43	43	43	100	
2025-063	147	Mission120		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2025-063	148	Mission500		090 090	090 090		090 - NEGATIVE	134	134	134	100	
2025-063	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	23	23	23	100	
2025-064	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	33	33	33	100	
2025-064	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	21	21	21	100	
2025-064	067	URISCAN		090 090	090 090		090 - NEGATIVE	56	56	56	100	
2025-064	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	55	55	55	100	
2025-064	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	36	36	36	100	
2025-064	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	153	153	153	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-064	094 CLINITEK			090 090	090 090		090 - NEGATIVE	105	105	105	100		
2025-064	102 ACON LAB			090 090	090 090		090 - NEGATIVE	122	122	122	100		
2025-064	131 iCHEM VELO			090 090	090 090		090 - NEGATIVE	34	34	34	100		
2025-064	138 URS-10T			090 090	090 090		090 - NEGATIVE	10	10	10	100		
2025-064	140 MISSION A			090 090	090 090		090 - NEGATIVE	40	40	40	100		
2025-064	145 CLINITEK			090 090	090 090		090 - NEGATIVE	43	43	43	100		
2025-064	147 Mission120			090 090	090 090		090 - NEGATIVE	37	37	37	100		
2025-064	148 Mission500			090 090	090 090		090 - NEGATIVE	134	134	134	100		
2025-064	151 Clari. Uro			090 090	090 090		090 - NEGATIVE	23	23	23	100		
060 URINALYSIS-KETONES													
2025-065	011 AMES NM10S			090 090	090 090		090 - NEGATIVE	33	33	33	100		
2025-065	013 BAYER CLI			090 090	090 090		090 - NEGATIVE	21	21	21	100		
2025-065	067 URISCAN			090 090	090 090		090 - NEGATIVE	56	56	56	100		
2025-065	072 URS-9-TECO			090 090	090 090		090 - NEGATIVE	55	55	55	100		
2025-065	080 ROCHE (CHE			090 090	090 090		090 - NEGATIVE	36	36	36	100		
2025-065	089 AIMSTRIP			090 090	090 090		090 - NEGATIVE	153	153	153	100		
2025-065	094 CLINITEK			090 090	090 090		090 - NEGATIVE	105	105	105	100		
2025-065	102 ACON LAB			090 090	090 090		090 - NEGATIVE	122	122	122	100		
2025-065	131 iCHEM VELO			090 090	090 090		090 - NEGATIVE	34	34	34	100		
2025-065	138 URS-10T			090 090	090 090		090 - NEGATIVE	10	10	10	100		
2025-065	140 MISSION A			090 090	090 090		090 - NEGATIVE	40	40	40	100		
2025-065	145 CLINITEK			090 090	090 090		090 - NEGATIVE	43	43	43	100		
2025-065	147 Mission120			090 090	090 090		090 - NEGATIVE	37	37	37	100		
2025-065	148 Mission500			090 090	090 090		090 - NEGATIVE	134	134	134	100		
2025-065	151 Clari. Uro			090 090	090 090		090 - NEGATIVE	23	23	23	100		
061 URINALYSIS-NITRATE													
2025-061	011 AMES NM10S			070 070	070 070		070 - NEGATIVE	33	33	33	100		
2025-061	013 BAYER CLI			070 070	070 070		070 - NEGATIVE	21	21	21	100		
2025-061	067 URISCAN			070 070	070 070		070 - NEGATIVE	56	56	56	100		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-061	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	56	56	56	100
2025-061	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	36	36	100
2025-061	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	153	153	153	100
2025-061	094	CLINITEK		070 070	070 070		070 - NEGATIVE	105	105	105	100
2025-061	102	ACON LAB		070 070	070 070		070 - NEGATIVE	122	122	122	100
2025-061	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	34	34	34	100
2025-061	138	URS-10T		070 070	070 070		070 - NEGATIVE	10	10	10	100
2025-061	140	MISSION A		070 070	070 070		070 - NEGATIVE	38	38	38	100
2025-061	145	CLINITEK		070 070	070 070		070 - NEGATIVE	42	42	42	100
2025-061	147	Mission120		070 070	070 070		070 - NEGATIVE	38	38	38	100
2025-061	148	Mission500		070 070	070 070		070 - NEGATIVE	134	134	134	100
2025-061	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	23	23	23	100
061 URINALYSIS-NITRATE											
2025-062	011	AMES NM10S		071 072	071 072		072 - POSITIVE	33	33	33	100
2025-062	013	BAYER CLI		071 072	071 072		072 - POSITIVE	21	21	21	100
2025-062	067	URISCAN		071 072	071 072		070 - NEGATIVE	56	1	55	0
2025-062	067	URISCAN		071 072	071 072		072 - POSITIVE	56	55	55	100
2025-062	072	URS-9-TECO		071 072	071 072		072 - POSITIVE	56	56	56	100
2025-062	080	ROCHE (CHE		071 072	071 072		072 - POSITIVE	36	36	36	100
2025-062	089	AIMSTRIP		071 072	071 072		070 - NEGATIVE	153	1	152	0
2025-062	089	AIMSTRIP		071 072	071 072		071 - WEAK POS.	153	2	152	100
2025-062	089	AIMSTRIP		071 072	071 072		072 - POSITIVE	153	150	152	100
2025-062	094	CLINITEK		071 072	071 072		072 - POSITIVE	105	105	105	100
2025-062	102	ACON LAB		071 072	071 072		072 - POSITIVE	122	122	122	100
2025-062	131	iCHEM VELO		071 072	071 072		072 - POSITIVE	34	34	34	100
2025-062	138	URS-10T		071 072	071 072		071 - WEAK POS.	10	1	10	100
2025-062	138	URS-10T		071 072	071 072		072 - POSITIVE	10	9	10	100
2025-062	140	MISSION A		071 072	071 072		070 - NEGATIVE	38	1	37	0
2025-062	140	MISSION A		071 072	071 072		072 - POSITIVE	38	37	37	100
2025-062	145	CLINITEK		071 072	071 072		072 - POSITIVE	42	42	42	100



## Participant Summary

### MONTH 2 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-062	147	Mission120		071 072	071 072		072 - POSITIVE	38	38	38	100		
2025-062	148	Mission500		071 072	071 072		071 - WEAK POS.	134	1	134	100		
2025-062	148	Mission500		071 072	071 072		072 - POSITIVE	134	133	134	100		
2025-062	151	Clari. Uro		071 072	071 072		072 - POSITIVE	23	23	23	100		
061 URINALYSIS-NITRATE													
2025-063	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	33	33	33	100		
2025-063	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	21	21	21	100		
2025-063	067	URISCAN		070 070	070 070		070 - NEGATIVE	56	56	56	100		
2025-063	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	56	56	56	100		
2025-063	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	35	35	100		
2025-063	080	ROCHE (CHE		070 070	070 070		072 - POSITIVE	36	1	35	0		
2025-063	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	153	153	153	100		
2025-063	094	CLINITEK		070 070	070 070		070 - NEGATIVE	105	104	104	100		
2025-063	094	CLINITEK		070 070	070 070		072 - POSITIVE	105	1	104	0		
2025-063	102	ACON LAB		070 070	070 070		070 - NEGATIVE	122	122	122	100		
2025-063	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	34	34	34	100		
2025-063	138	URS-10T		070 070	070 070		070 - NEGATIVE	10	10	10	100		
2025-063	140	MISSION A		070 070	070 070		070 - NEGATIVE	38	38	38	100		
2025-063	145	CLINITEK		070 070	070 070		070 - NEGATIVE	42	42	42	100		
2025-063	147	Mission120		070 070	070 070		070 - NEGATIVE	38	38	38	100		
2025-063	148	Mission500		070 070	070 070		070 - NEGATIVE	134	134	134	100		
2025-063	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	23	23	23	100		
2025-064	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	33	33	33	100		
2025-064	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	21	21	21	100		
2025-064	067	URISCAN		070 070	070 070		070 - NEGATIVE	56	56	56	100		
2025-064	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	56	56	56	100		
2025-064	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	34	34	100		
2025-064	080	ROCHE (CHE		070 070	070 070		072 - POSITIVE	36	2	34	0		

## Participant Summary

### MONTH 2 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-064	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	153	153	153	100		
2025-064	094	CLINITEK		070 070	070 070		070 - NEGATIVE	105	105	105	100		
2025-064	102	ACON LAB		070 070	070 070		070 - NEGATIVE	122	122	122	100		
2025-064	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	34	34	34	100		
2025-064	138	URS-10T		070 070	070 070		070 - NEGATIVE	10	10	10	100		
2025-064	140	MISSION A		070 070	070 070		070 - NEGATIVE	38	38	38	100		
2025-064	145	CLINITEK		070 070	070 070		070 - NEGATIVE	42	42	42	100		
2025-064	147	Mission120		070 070	070 070		070 - NEGATIVE	38	38	38	100		
2025-064	148	Mission500		070 070	070 070		070 - NEGATIVE	134	134	134	100		
2025-064	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	23	23	23	100		
061 URINALYSIS-NITRATE													
2025-065	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	33	33	33	100		
2025-065	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	21	21	21	100		
2025-065	067	URISCAN		070 070	070 070		070 - NEGATIVE	56	56	56	100		
2025-065	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	56	56	56	100		
2025-065	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	35	35	100		
2025-065	080	ROCHE (CHE		070 070	070 070		072 - POSITIVE	36	1	35	0		
2025-065	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	153	153	153	100		
2025-065	094	CLINITEK		070 070	070 070		070 - NEGATIVE	105	105	105	100		
2025-065	102	ACON LAB		070 070	070 070		070 - NEGATIVE	122	122	122	100		
2025-065	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	34	34	34	100		
2025-065	138	URS-10T		070 070	070 070		070 - NEGATIVE	10	10	10	100		
2025-065	140	MISSION A		070 070	070 070		070 - NEGATIVE	38	38	38	100		
2025-065	145	CLINITEK		070 070	070 070		070 - NEGATIVE	42	42	42	100		
2025-065	147	Mission120		070 070	070 070		070 - NEGATIVE	38	38	38	100		
2025-065	148	Mission500		070 070	070 070		070 - NEGATIVE	134	134	134	100		
2025-065	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	23	23	23	100		
062 URINALYSIS-pH													
2025-061	011	AMES NM10S		085 088	085 088		086 - 7.0	33	2	33	100		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-061	011	AMES NM10S		085 088	085 088		087 - 7.5	33	29	33	100	
2025-061	011	AMES NM10S		085 088	085 088		088 - 8.0OR MORE	33	2	33	100	
2025-061	013	BAYER CLI		085 088	085 088		087 - 7.5	21	21	21	100	
2025-061	067	URISCAN		084 088	085 088		086 - 7.0	56	36	56	100	
2025-061	067	URISCAN		084 088	085 088		087 - 7.5	56	20	56	100	
2025-061	072	URS-9-TECO		085 088	085 088		086 - 7.0	56	23	56	100	
2025-061	072	URS-9-TECO		085 088	085 088		087 - 7.5	56	33	56	100	
2025-061	080	ROCHE (CHE		084 088	085 088		086 - 7.0	36	36	36	100	
2025-061	089	AIMSTRIP		085 088	085 088		085 - 6.5	153	1	153	100	
2025-061	089	AIMSTRIP		085 088	085 088		086 - 7.0	153	42	153	100	
2025-061	089	AIMSTRIP		085 088	085 088		087 - 7.5	153	109	153	100	
2025-061	089	AIMSTRIP		085 088	085 088		088 - 8.0OR MORE	153	1	153	100	
2025-061	094	CLINITEK		085 088	085 088		086 - 7.0	105	5	105	100	
2025-061	094	CLINITEK		085 088	085 088		087 - 7.5	105	96	105	100	
2025-061	094	CLINITEK		085 088	085 088		088 - 8.0OR MORE	105	4	105	100	
2025-061	102	ACON LAB		085 088	085 088		084 - 6.0	123	1	122	0	
2025-061	102	ACON LAB		085 088	085 088		085 - 6.5	123	1	122	100	
2025-061	102	ACON LAB		085 088	085 088		086 - 7.0	123	30	122	100	
2025-061	102	ACON LAB		085 088	085 088		087 - 7.5	123	91	122	100	
2025-061	131	iCHEM VELO		084 088	085 088		086 - 7.0	34	34	34	100	
2025-061	138	URS-10T		085 088	085 088		086 - 7.0	10	5	10	100	
2025-061	138	URS-10T		085 088	085 088		087 - 7.5	10	5	10	100	
2025-061	140	MISSION A		085 088	085 088		086 - 7.0	40	11	40	100	
2025-061	140	MISSION A		085 088	085 088		087 - 7.5	40	28	40	100	
2025-061	140	MISSION A		085 088	085 088		088 - 8.0OR MORE	40	1	40	100	
2025-061	145	CLINITEK		085 088	085 088		087 - 7.5	43	43	43	100	
2025-061	147	Mission120		085 088	085 088		086 - 7.0	37	12	37	100	
2025-061	147	Mission120		085 088	085 088		087 - 7.5	37	25	37	100	
2025-061	148	Mission500		085 088	085 088		086 - 7.0	132	35	132	100	
2025-061	148	Mission500		085 088	085 088		087 - 7.5	132	96	132	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-061	148	Mission500		085 088	085 088		088 - 8.00R MORE	132	1	132	100		
2025-061	151	Clari. Uro		085 088	085 088		086 - 7.0	23	6	23	100		
2025-061	151	Clari. Uro		085 088	085 088		087 - 7.5	23	17	23	100		
062 URINALYSIS-pH													
2025-062	011	AMES NM10S		081 085	080 084		082 - 5.0	33	4	33	100		
2025-062	011	AMES NM10S		081 085	080 084		083 - 5.5	33	15	33	100		
2025-062	011	AMES NM10S		081 085	080 084		084 - 6.0	33	14	33	100		
2025-062	013	BAYER CLI		081 085	080 084		082 - 5.0	21	5	21	100		
2025-062	013	BAYER CLI		081 085	080 084		083 - 5.5	21	8	21	100		
2025-062	013	BAYER CLI		081 085	080 084		084 - 6.0	21	8	21	100		
2025-062	067	URISCAN		080 084	080 084		082 - 5.0	56	50	56	100		
2025-062	067	URISCAN		080 084	080 084		083 - 5.5	56	6	56	100		
2025-062	072	URS-9-TECO		082 086	080 084		082 - 5.0	56	13	56	100		
2025-062	072	URS-9-TECO		082 086	080 084		083 - 5.5	56	7	56	100		
2025-062	072	URS-9-TECO		082 086	080 084		084 - 6.0	56	32	56	100		
2025-062	072	URS-9-TECO		082 086	080 084		085 - 6.5	56	4	56	100		
2025-062	080	ROCHE (CHE		080 084	080 084		082 - 5.0	36	26	36	100		
2025-062	080	ROCHE (CHE		080 084	080 084		083 - 5.5	36	2	36	100		
2025-062	080	ROCHE (CHE		080 084	080 084		084 - 6.0	36	8	36	100		
2025-062	089	AIMSTRIP		082 086	080 084		082 - 5.0	153	34	153	100		
2025-062	089	AIMSTRIP		082 086	080 084		083 - 5.5	153	35	153	100		
2025-062	089	AIMSTRIP		082 086	080 084		084 - 6.0	153	83	153	100		
2025-062	089	AIMSTRIP		082 086	080 084		086 - 7.0	153	1	153	100		
2025-062	094	CLINITEK		082 086	080 084		082 - 5.0	105	15	105	100		
2025-062	094	CLINITEK		082 086	080 084		083 - 5.5	105	29	105	100		
2025-062	094	CLINITEK		082 086	080 084		084 - 6.0	105	61	105	100		
2025-062	102	ACON LAB		082 086	080 084		082 - 5.0	123	27	123	100		
2025-062	102	ACON LAB		082 086	080 084		083 - 5.5	123	27	123	100		
2025-062	102	ACON LAB		082 086	080 084		084 - 6.0	123	69	123	100		
2025-062	131	iCHEM VELO		080 084	080 084		082 - 5.0	34	34	34	100		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-062	138	URS-10T			080	084	082 - 5.0	10	4	6	100	
2025-062	138	URS-10T			080	084	083 - 5.5	10	1	6	100	
2025-062	138	URS-10T			080	084	084 - 6.0	10	1	6	100	
2025-062	138	URS-10T			080	084	085 - 6.5	10	4	6	0	
2025-062	140	MISSION A		081	085	080	084	082 - 5.0	40	6	40	100
2025-062	140	MISSION A		081	085	080	084	083 - 5.5	40	18	40	100
2025-062	140	MISSION A		081	085	080	084	084 - 6.0	40	16	40	100
2025-062	145	CLINITEK		081	085	080	084	082 - 5.0	43	18	43	100
2025-062	145	CLINITEK		081	085	080	084	083 - 5.5	43	24	43	100
2025-062	145	CLINITEK		081	085	080	084	084 - 6.0	43	1	43	100
2025-062	147	Mission120		081	085	080	084	082 - 5.0	37	15	37	100
2025-062	147	Mission120		081	085	080	084	083 - 5.5	37	19	37	100
2025-062	147	Mission120		081	085	080	084	084 - 6.0	37	3	37	100
2025-062	148	Mission500		082	086	080	084	082 - 5.0	132	1	132	100
2025-062	148	Mission500		082	086	080	084	083 - 5.5	132	14	132	100
2025-062	148	Mission500		082	086	080	084	084 - 6.0	132	117	132	100
2025-062	151	Clari. Uro		082	086	080	084	082 - 5.0	23	3	23	100
2025-062	151	Clari. Uro		082	086	080	084	083 - 5.5	23	7	23	100
2025-062	151	Clari. Uro		082	086	080	084	084 - 6.0	23	13	23	100
062 URINALYSIS-pH												
2025-063	011	AMES NM10S		082	086	082	086	082 - 5.0	33	1	33	100
2025-063	011	AMES NM10S		082	086	082	086	084 - 6.0	33	22	33	100
2025-063	011	AMES NM10S		082	086	082	086	085 - 6.5	33	10	33	100
2025-063	013	BAYER CLI		083	087	082	086	084 - 6.0	21	8	21	100
2025-063	013	BAYER CLI		083	087	082	086	085 - 6.5	21	13	21	100
2025-063	067	URISCAN		082	086	082	086	084 - 6.0	56	35	56	100
2025-063	067	URISCAN		082	086	082	086	085 - 6.5	56	4	56	100
2025-063	067	URISCAN		082	086	082	086	082 - 5.0	56	1	56	100
2025-063	067	URISCAN		082	086	082	086	083 - 5.5	56	16	56	100
2025-063	072	URS-9-TECO		083	087	082	086	084 - 6.0	56	27	56	100

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-063	072	URS-9-TECO		083 087	082 086		085 - 6.5	56	29	56	100	
2025-063	080	ROCHE (CHE		082 086	082 086		084 - 6.0	36	35	36	100	
2025-063	080	ROCHE (CHE		082 086	082 086		085 - 6.5	36	1	36	100	
2025-063	089	AIMSTRIP		082 086	082 086		083 - 5.5	153	1	153	100	
2025-063	089	AIMSTRIP		082 086	082 086		084 - 6.0	153	104	153	100	
2025-063	089	AIMSTRIP		082 086	082 086		085 - 6.5	153	48	153	100	
2025-063	094	CLINITEK		082 086	082 086		084 - 6.0	105	66	105	100	
2025-063	094	CLINITEK		082 086	082 086		085 - 6.5	105	37	105	100	
2025-063	094	CLINITEK		082 086	082 086		086 - 7.0	105	2	105	100	
2025-063	102	ACON LAB		082 086	082 086		083 - 5.5	123	5	123	100	
2025-063	102	ACON LAB		082 086	082 086		084 - 6.0	123	79	123	100	
2025-063	102	ACON LAB		082 086	082 086		085 - 6.5	123	39	123	100	
2025-063	131	iCHEM VELO		082 086	082 086		084 - 6.0	34	34	34	100	
2025-063	138	URS-10T		083 087	082 086		084 - 6.0	10	4	10	100	
2025-063	138	URS-10T		083 087	082 086		085 - 6.5	10	6	10	100	
2025-063	140	MISSION A		082 086	082 086		084 - 6.0	40	35	40	100	
2025-063	140	MISSION A		082 086	082 086		085 - 6.5	40	5	40	100	
2025-063	145	CLINITEK		082 086	082 086		084 - 6.0	43	35	43	100	
2025-063	145	CLINITEK		082 086	082 086		085 - 6.5	43	8	43	100	
2025-063	147	Mission120		082 086	082 086		084 - 6.0	37	36	37	100	
2025-063	147	Mission120		082 086	082 086		085 - 6.5	37	1	37	100	
2025-063	148	Mission500		082 086	082 086		084 - 6.0	132	78	132	100	
2025-063	148	Mission500		082 086	082 086		085 - 6.5	132	54	132	100	
2025-063	151	Clari. Uro		082 086	082 086		084 - 6.0	23	21	23	100	
2025-063	151	Clari. Uro		082 086	082 086		085 - 6.5	23	2	23	100	
062 URINALYSIS-pH												
2025-064	011	AMES NM10S		085 088	085 088		086 - 7.0	33	1	33	100	
2025-064	011	AMES NM10S		085 088	085 088		087 - 7.5	33	26	33	100	
2025-064	011	AMES NM10S		085 088	085 088		088 - 8.0OR MORE	33	6	33	100	
2025-064	013	BAYER CLI		085 088	085 088		086 - 7.0	21	1	21	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-064	013	BAYER CLI		085 088	085 088		087 - 7.5	21	17	21	100	
2025-064	013	BAYER CLI		085 088	085 088		088 - 8.0OR MORE	21	3	21	100	
2025-064	067	URISCAN		085 088	085 088		086 - 7.0	56	6	56	100	
2025-064	067	URISCAN		085 088	085 088		087 - 7.5	56	48	56	100	
2025-064	067	URISCAN		085 088	085 088		088 - 8.0OR MORE	56	2	56	100	
2025-064	072	URS-9-TECO		085 088	085 088		085 - 6.5	56	1	56	100	
2025-064	072	URS-9-TECO		085 088	085 088		086 - 7.0	56	10	56	100	
2025-064	072	URS-9-TECO		085 088	085 088		087 - 7.5	56	45	56	100	
2025-064	080	ROCHE (CHE		084 088	085 088		086 - 7.0	36	36	36	100	
2025-064	089	AIMSTRIP		085 088	085 088		084 - 6.0	153	1	152	0	
2025-064	089	AIMSTRIP		085 088	085 088		086 - 7.0	153	14	152	100	
2025-064	089	AIMSTRIP		085 088	085 088		087 - 7.5	153	129	152	100	
2025-064	089	AIMSTRIP		085 088	085 088		088 - 8.0OR MORE	153	9	152	100	
2025-064	094	CLINITEK		085 088	085 088		086 - 7.0	105	3	105	100	
2025-064	094	CLINITEK		085 088	085 088		087 - 7.5	105	74	105	100	
2025-064	094	CLINITEK		085 088	085 088		088 - 8.0OR MORE	105	28	105	100	
2025-064	102	ACON LAB		085 088	085 088		086 - 7.0	123	11	123	100	
2025-064	102	ACON LAB		085 088	085 088		087 - 7.5	123	103	123	100	
2025-064	102	ACON LAB		085 088	085 088		088 - 8.0OR MORE	123	9	123	100	
2025-064	131	iCHEM VELO		084 088	085 088		086 - 7.0	34	34	34	100	
2025-064	138	URS-10T		085 088	085 088		086 - 7.0	10	3	10	100	
2025-064	138	URS-10T		085 088	085 088		087 - 7.5	10	7	10	100	
2025-064	140	MISSION A		085 088	085 088		086 - 7.0	40	5	40	100	
2025-064	140	MISSION A		085 088	085 088		087 - 7.5	40	34	40	100	
2025-064	140	MISSION A		085 088	085 088		088 - 8.0OR MORE	40	1	40	100	
2025-064	145	CLINITEK		085 088	085 088		087 - 7.5	43	43	43	100	
2025-064	147	Mission120		085 088	085 088		085 - 6.5	37	1	37	100	
2025-064	147	Mission120		085 088	085 088		086 - 7.0	37	7	37	100	
2025-064	147	Mission120		085 088	085 088		087 - 7.5	37	28	37	100	
2025-064	147	Mission120		085 088	085 088		088 - 8.0OR MORE	37	1	37	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-064	148	Mission500		085 088	085 088		086 - 7.0	132	7	132	100	
2025-064	148	Mission500		085 088	085 088		087 - 7.5	132	117	132	100	
2025-064	148	Mission500		085 088	085 088		088 - 8.0OR MORE	132	8	132	100	
2025-064	151	Clari. Uro		085 088	085 088		087 - 7.5	23	23	23	100	
062 URINALYSIS-pH												
2025-065	011	AMES NM10S		084 088	084 088		086 - 7.0	33	30	33	100	
2025-065	011	AMES NM10S		084 088	084 088		087 - 7.5	33	3	33	100	
2025-065	013	BAYER CLI		084 088	084 088		086 - 7.0	21	19	21	100	
2025-065	013	BAYER CLI		084 088	084 088		087 - 7.5	21	2	21	100	
2025-065	067	URISCAN		084 088	084 088		085 - 6.5	56	19	56	100	
2025-065	067	URISCAN		084 088	084 088		086 - 7.0	56	37	56	100	
2025-065	072	URS-9-TECO		084 088	084 088		085 - 6.5	56	4	56	100	
2025-065	072	URS-9-TECO		084 088	084 088		086 - 7.0	56	51	56	100	
2025-065	072	URS-9-TECO		084 088	084 088		087 - 7.5	56	1	56	100	
2025-065	080	ROCHE (CHE		084 088	084 088		086 - 7.0	36	36	36	100	
2025-065	089	AIMSTRIP		084 088	084 088		085 - 6.5	153	5	153	100	
2025-065	089	AIMSTRIP		084 088	084 088		086 - 7.0	153	135	153	100	
2025-065	089	AIMSTRIP		084 088	084 088		087 - 7.5	153	13	153	100	
2025-065	094	CLINITEK		084 088	084 088		086 - 7.0	105	99	105	100	
2025-065	094	CLINITEK		084 088	084 088		087 - 7.5	105	6	105	100	
2025-065	102	ACON LAB		084 088	084 088		085 - 6.5	123	10	123	100	
2025-065	102	ACON LAB		084 088	084 088		086 - 7.0	123	107	123	100	
2025-065	102	ACON LAB		084 088	084 088		087 - 7.5	123	5	123	100	
2025-065	102	ACON LAB		084 088	084 088		088 - 8.0OR MORE	123	1	123	100	
2025-065	131	iCHEM VELO		084 088	084 088		082 - 5.0	34	1	33	0	
2025-065	131	iCHEM VELO		084 088	084 088		086 - 7.0	34	33	33	100	
2025-065	138	URS-10T		084 088	084 088		086 - 7.0	10	9	10	100	
2025-065	138	URS-10T		084 088	084 088		087 - 7.5	10	1	10	100	
2025-065	140	MISSION A		084 088	084 088		085 - 6.5	40	8	40	100	
2025-065	140	MISSION A		084 088	084 088		086 - 7.0	40	32	40	100	



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-065	145 CLINITEK			084 088	084 088		086 - 7.0	43	43	43	100	
2025-065	147 Mission120			083 087	084 088		085 - 6.5	37	19	37	100	
2025-065	147 Mission120			083 087	084 088		086 - 7.0	37	18	37	100	
2025-065	148 Mission500			084 088	084 088		086 - 7.0	132	131	132	100	
2025-065	148 Mission500			084 088	084 088		087 - 7.5	132	1	132	100	
2025-065	151 Clari. Uro			084 088	084 088		086 - 7.0	23	23	23	100	
064 URIN-PROTEIN QUALI.												
2025-061	011 AMES NM10S			053 055	053 055		054 - 2+	33	21	32	100	
2025-061	011 AMES NM10S			053 055	053 055		051 - NEGATIVE	33	1	32	0	
2025-061	011 AMES NM10S			053 055	053 055		055 - 3+	33	11	32	100	
2025-061	013 BAYER CLI			053 055	053 055		054 - 2+	21	12	21	100	
2025-061	013 BAYER CLI			053 055	053 055		055 - 3+	21	9	21	100	
2025-061	067 URISCAN			053 055	053 055		054 - 2+	57	44	56	100	
2025-061	067 URISCAN			053 055	053 055		052 - TRACES	57	1	56	0	
2025-061	067 URISCAN			053 055	053 055		053 - 1+	57	9	56	100	
2025-061	067 URISCAN			053 055	053 055		055 - 3+	57	3	56	100	
2025-061	072 URS-9-TECO			053 055	053 055		054 - 2+	56	30	55	100	
2025-061	072 URS-9-TECO			053 055	053 055		055 - 3+	56	25	55	100	
2025-061	072 URS-9-TECO			053 055	053 055		056 - 4+	56	1	55	0	
2025-061	080 ROCHE (CHE			053 055	053 055		054 - 2+	36	26	35	100	
2025-061	080 ROCHE (CHE			053 055	053 055		055 - 3+	36	9	35	100	
2025-061	080 ROCHE (CHE			053 055	053 055		056 - 4+	36	1	35	0	
2025-061	089 AIMSTRIP			053 055	053 055		054 - 2+	152	88	150	100	
2025-061	089 AIMSTRIP			053 055	053 055		051 - NEGATIVE	152	1	150	0	
2025-061	089 AIMSTRIP			053 055	053 055		053 - 1+	152	2	150	100	
2025-061	089 AIMSTRIP			053 055	053 055		055 - 3+	152	60	150	100	
2025-061	089 AIMSTRIP			053 055	053 055		056 - 4+	152	1	150	0	
2025-061	094 CLINITEK			053 055	053 055		054 - 2+	104	78	101	100	
2025-061	094 CLINITEK			053 055	053 055		051 - NEGATIVE	104	1	101	0	
2025-061	094 CLINITEK			053 055	053 055		053 - 1+	104	6	101	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-061	094	CLINITEK		053 055	053 055		055 - 3+	104	17	101	100	
2025-061	094	CLINITEK		053 055	053 055		056 - 4+	104	2	101	0	
2025-061	102	ACON LAB		053 055	053 055		054 - 2+	124	86	123	100	
2025-061	102	ACON LAB		053 055	053 055		053 - 1+	124	2	123	100	
2025-061	102	ACON LAB		053 055	053 055		055 - 3+	124	35	123	100	
2025-061	102	ACON LAB		053 055	053 055		056 - 4+	124	1	123	0	
2025-061	131	iCHEM VELO		053 055	053 055		053 - 1+	34	1	34	100	
2025-061	131	iCHEM VELO		053 055	053 055		055 - 3+	34	6	34	100	
2025-061	131	iCHEM VELO		053 055	053 055		054 - 2+	34	27	34	100	
2025-061	138	URS-10T		053 055	053 055		054 - 2+	10	8	10	100	
2025-061	138	URS-10T		053 055	053 055		055 - 3+	10	2	10	100	
2025-061	140	MISSION A		053 055	053 055		054 - 2+	38	33	38	100	
2025-061	140	MISSION A		053 055	053 055		053 - 1+	38	1	38	100	
2025-061	140	MISSION A		053 055	053 055		055 - 3+	38	4	38	100	
2025-061	145	CLINITEK		053 055	053 055		054 - 2+	43	32	43	100	
2025-061	145	CLINITEK		053 055	053 055		053 - 1+	43	1	43	100	
2025-061	145	CLINITEK		053 055	053 055		055 - 3+	43	10	43	100	
2025-061	147	Mission120		053 055	053 055		054 - 2+	38	33	38	100	
2025-061	147	Mission120		053 055	053 055		053 - 1+	38	4	38	100	
2025-061	147	Mission120		053 055	053 055		055 - 3+	38	1	38	100	
2025-061	148	Mission500		053 055	053 055		054 - 2+	133	97	133	100	
2025-061	148	Mission500		053 055	053 055		053 - 1+	133	9	133	100	
2025-061	148	Mission500		053 055	053 055		055 - 3+	133	27	133	100	
2025-061	151	Clari. Uro		053 055	053 055		054 - 2+	23	20	23	100	
2025-061	151	Clari. Uro		053 055	053 055		055 - 3+	23	3	23	100	
064 URIN-PROTEIN QUALI.												
2025-062	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	33	33	33	100	
2025-062	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	21	21	21	100	
2025-062	067	URISCAN		051 051	051 051		051 - NEGATIVE	57	57	57	100	
2025-062	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	56	56	56	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-062	080 ROCHE (CHE			051 051	051 051		051 - NEGATIVE	36	35	35	100
2025-062	080 ROCHE (CHE			051 051	051 051		053 - 1+	36	1	35	0
2025-062	089 AIMSTRIP			051 051	051 051		051 - NEGATIVE	152	152	152	100
2025-062	094 CLINITEK			051 051	051 051		051 - NEGATIVE	104	104	104	100
2025-062	102 ACON LAB			051 051	051 051		051 - NEGATIVE	124	124	124	100
2025-062	131 iCHEM VELO			051 051	051 051		051 - NEGATIVE	34	34	34	100
2025-062	138 URS-10T			051 051	051 051		051 - NEGATIVE	10	10	10	100
2025-062	140 MISSION A			051 051	051 051		051 - NEGATIVE	38	38	38	100
2025-062	145 CLINITEK			051 051	051 051		051 - NEGATIVE	43	43	43	100
2025-062	147 Mission120			051 051	051 051		051 - NEGATIVE	38	38	38	100
2025-062	148 Mission500			051 051	051 051		051 - NEGATIVE	133	133	133	100
2025-062	151 Clari. Uro			051 051	051 051		051 - NEGATIVE	23	23	23	100
064 URIN-PROTEIN QUALI.											
2025-063	011 AMES NM10S			053 055	053 055		054 - 2+	33	23	33	100
2025-063	011 AMES NM10S			053 055	053 055		053 - 1+	33	1	33	100
2025-063	011 AMES NM10S			053 055	053 055		055 - 3+	33	9	33	100
2025-063	013 BAYER CLI			053 055	053 055		054 - 2+	21	17	21	100
2025-063	013 BAYER CLI			053 055	053 055		055 - 3+	21	4	21	100
2025-063	067 URISCAN			053 055	053 055		054 - 2+	57	31	56	100
2025-063	067 URISCAN			053 055	053 055		052 - TRACES	57	1	56	0
2025-063	067 URISCAN			053 055	053 055		053 - 1+	57	24	56	100
2025-063	067 URISCAN			053 055	053 055		055 - 3+	57	1	56	100
2025-063	072 URS-9-TECO			053 055	053 055		054 - 2+	56	43	56	100
2025-063	072 URS-9-TECO			053 055	053 055		053 - 1+	56	4	56	100
2025-063	072 URS-9-TECO			053 055	053 055		055 - 3+	56	9	56	100
2025-063	080 ROCHE (CHE			053 055	053 055		054 - 2+	36	22	35	100
2025-063	080 ROCHE (CHE			053 055	053 055		051 - NEGATIVE	36	1	35	0
2025-063	080 ROCHE (CHE			053 055	053 055		053 - 1+	36	3	35	100
2025-063	080 ROCHE (CHE			053 055	053 055		055 - 3+	36	10	35	100
2025-063	089 AIMSTRIP			053 055	053 055		054 - 2+	152	126	151	100

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-063	089	AIMSTRIP		053 055	053 055		051 - NEGATIVE	152	1	151	0	
2025-063	089	AIMSTRIP		053 055	053 055		053 - 1+	152	6	151	100	
2025-063	089	AIMSTRIP		053 055	053 055		055 - 3+	152	19	151	100	
2025-063	094	CLINITEK		053 055	053 055		054 - 2+	104	87	103	100	
2025-063	094	CLINITEK		053 055	053 055		051 - NEGATIVE	104	1	103	0	
2025-063	094	CLINITEK		053 055	053 055		053 - 1+	104	6	103	100	
2025-063	094	CLINITEK		053 055	053 055		055 - 3+	104	10	103	100	
2025-063	102	ACON LAB		053 055	053 055		054 - 2+	124	109	123	100	
2025-063	102	ACON LAB		053 055	053 055		053 - 1+	124	5	123	100	
2025-063	102	ACON LAB		053 055	053 055		055 - 3+	124	9	123	100	
2025-063	102	ACON LAB		053 055	053 055		056 - 4+	124	1	123	0	
2025-063	131	iCHEM VELO		053 055	053 055		054 - 2+	34	32	33	100	
2025-063	131	iCHEM VELO		053 055	053 055		051 - NEGATIVE	34	1	33	0	
2025-063	131	iCHEM VELO		053 055	053 055		053 - 1+	34	1	33	100	
2025-063	138	URS-10T		053 055	053 055		054 - 2+	10	8	10	100	
2025-063	138	URS-10T		053 055	053 055		055 - 3+	10	2	10	100	
2025-063	140	MISSION A		053 055	053 055		054 - 2+	38	32	38	100	
2025-063	140	MISSION A		053 055	053 055		053 - 1+	38	4	38	100	
2025-063	140	MISSION A		053 055	053 055		055 - 3+	38	2	38	100	
2025-063	145	CLINITEK		053 055	053 055		054 - 2+	43	40	43	100	
2025-063	145	CLINITEK		053 055	053 055		053 - 1+	43	2	43	100	
2025-063	145	CLINITEK		053 055	053 055		055 - 3+	43	1	43	100	
2025-063	147	Mission120		053 055	053 055		054 - 2+	38	29	37	100	
2025-063	147	Mission120		053 055	053 055		052 - TRACES	38	1	37	0	
2025-063	147	Mission120		053 055	053 055		053 - 1+	38	7	37	100	
2025-063	147	Mission120		053 055	053 055		055 - 3+	38	1	37	100	
2025-063	148	Mission500		053 055	053 055		054 - 2+	133	117	131	100	
2025-063	148	Mission500		053 055	053 055		051 - NEGATIVE	133	2	131	0	
2025-063	148	Mission500		053 055	053 055		053 - 1+	133	9	131	100	
2025-063	148	Mission500		053 055	053 055		055 - 3+	133	5	131	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-063	151	Clari. Uro		053 055	053 055		054 - 2+	23	22	23	100	
2025-063	151	Clari. Uro		053 055	053 055		053 - 1+	23	1	23	100	
064 URIN-PROTEIN QUALI.												
2025-064	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	33	33	33	100	
2025-064	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	21	19	19	100	
2025-064	013	BAYER CLI		051 051	051 051		052 - TRACES	21	2	19	0	
2025-064	067	URISCAN		051 051	051 051		051 - NEGATIVE	57	57	57	100	
2025-064	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	56	55	55	100	
2025-064	072	URS-9-TECO		051 051	051 051		052 - TRACES	56	1	55	0	
2025-064	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	36	33	33	100	
2025-064	080	ROCHE (CHE		051 051	051 051		052 - TRACES	36	2	33	0	
2025-064	080	ROCHE (CHE		051 051	051 051		053 - 1+	36	1	33	0	
2025-064	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	152	141	141	100	
2025-064	089	AIMSTRIP		051 051	051 051		052 - TRACES	152	10	141	0	
2025-064	089	AIMSTRIP		051 051	051 051		053 - 1+	152	1	141	0	
2025-064	094	CLINITEK		051 051	051 051		051 - NEGATIVE	104	104	104	100	
2025-064	102	ACON LAB		051 051	051 051		051 - NEGATIVE	124	122	122	100	
2025-064	102	ACON LAB		051 051	051 051		052 - TRACES	124	2	122	0	
2025-064	131	ICHEM VELO		051 051	051 051		051 - NEGATIVE	34	34	34	100	
2025-064	138	URS-10T		051 051	051 051		051 - NEGATIVE	10	10	10	100	
2025-064	140	MISSION A		051 051	051 051		051 - NEGATIVE	38	36	36	100	
2025-064	140	MISSION A		051 051	051 051		052 - TRACES	38	2	36	0	
2025-064	145	CLINITEK		051 051	051 051		051 - NEGATIVE	43	43	43	100	
2025-064	147	Mission120		051 051	051 051		051 - NEGATIVE	38	38	38	100	
2025-064	148	Mission500		051 051	051 051		051 - NEGATIVE	133	131	131	100	
2025-064	148	Mission500		051 051	051 051		052 - TRACES	133	2	131	0	
2025-064	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	23	23	23	100	
2025-065	011	AMES NM10S		053 055	053 055		054 - 2+	33	20	33	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-065	011	AMES NM10S		053 055	053 055		053 - 1+	33	1	33	100	
2025-065	011	AMES NM10S		053 055	053 055		055 - 3+	33	12	33	100	
2025-065	013	BAYER CLI		053 055	053 055		054 - 2+	21	14	21	100	
2025-065	013	BAYER CLI		053 055	053 055		055 - 3+	21	7	21	100	
2025-065	067	URISCAN		053 055	053 055		054 - 2+	57	44	56	100	
2025-065	067	URISCAN		053 055	053 055		052 - TRACES	57	1	56	0	
2025-065	067	URISCAN		053 055	053 055		053 - 1+	57	9	56	100	
2025-065	067	URISCAN		053 055	053 055		055 - 3+	57	3	56	100	
2025-065	072	URS-9-TECO		054 056	053 055		054 - 2+	56	23	56	100	
2025-065	072	URS-9-TECO		054 056	053 055		055 - 3+	56	31	56	100	
2025-065	072	URS-9-TECO		054 056	053 055		056 - 4+	56	2	56	100	
2025-065	080	ROCHE (CHE		053 055	053 055		054 - 2+	36	23	35	100	
2025-065	080	ROCHE (CHE		053 055	053 055		051 - NEGATIVE	36	1	35	0	
2025-065	080	ROCHE (CHE		053 055	053 055		055 - 3+	36	12	35	100	
2025-065	089	AIMSTRIP		053 055	053 055		054 - 2+	152	96	150	100	
2025-065	089	AIMSTRIP		053 055	053 055		051 - NEGATIVE	152	1	150	0	
2025-065	089	AIMSTRIP		053 055	053 055		053 - 1+	152	2	150	100	
2025-065	089	AIMSTRIP		053 055	053 055		055 - 3+	152	52	150	100	
2025-065	089	AIMSTRIP		053 055	053 055		056 - 4+	152	1	150	0	
2025-065	094	CLINITEK		053 055	053 055		054 - 2+	104	80	101	100	
2025-065	094	CLINITEK		053 055	053 055		053 - 1+	104	5	101	100	
2025-065	094	CLINITEK		053 055	053 055		055 - 3+	104	16	101	100	
2025-065	094	CLINITEK		053 055	053 055		056 - 4+	104	3	101	0	
2025-065	102	ACON LAB		053 055	053 055		054 - 2+	124	93	122	100	
2025-065	102	ACON LAB		053 055	053 055		051 - NEGATIVE	124	1	122	0	
2025-065	102	ACON LAB		053 055	053 055		053 - 1+	124	5	122	100	
2025-065	102	ACON LAB		053 055	053 055		055 - 3+	124	24	122	100	
2025-065	102	ACON LAB		053 055	053 055		056 - 4+	124	1	122	0	
2025-065	131	iCHEM VELO		053 055	053 055		054 - 2+	34	28	33	100	
2025-065	131	iCHEM VELO		053 055	053 055		051 - NEGATIVE	34	1	33	0	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-065	131	iCHEM VELO		053 055	053 055		053 - 1+	34	1	33	100	
2025-065	131	iCHEM VELO		053 055	053 055		055 - 3+	34	4	33	100	
2025-065	138	URS-10T		053 055	053 055		054 - 2+	10	7	10	100	
2025-065	138	URS-10T		053 055	053 055		055 - 3+	10	3	10	100	
2025-065	140	MISSION A		053 055	053 055		054 - 2+	38	28	38	100	
2025-065	140	MISSION A		053 055	053 055		053 - 1+	38	2	38	100	
2025-065	140	MISSION A		053 055	053 055		055 - 3+	38	8	38	100	
2025-065	145	CLINITEK		054 056	053 055		054 - 2+	43	19	43	100	
2025-065	145	CLINITEK		054 056	053 055		053 - 1+	43	2	43	100	
2025-065	145	CLINITEK		054 056	053 055		055 - 3+	43	21	43	100	
2025-065	145	CLINITEK		054 056	053 055		056 - 4+	43	1	43	100	
2025-065	147	Mission120		053 055	053 055		054 - 2+	38	33	38	100	
2025-065	147	Mission120		053 055	053 055		053 - 1+	38	4	38	100	
2025-065	147	Mission120		053 055	053 055		055 - 3+	38	1	38	100	
2025-065	148	Mission500		053 055	053 055		054 - 2+	133	104	132	100	
2025-065	148	Mission500		053 055	053 055		051 - NEGATIVE	133	1	132	0	
2025-065	148	Mission500		053 055	053 055		053 - 1+	133	9	132	100	
2025-065	148	Mission500		053 055	053 055		055 - 3+	133	19	132	100	
2025-065	151	Clari. Uro		053 055	053 055		054 - 2+	23	20	23	100	
2025-065	151	Clari. Uro		053 055	053 055		053 - 1+	23	1	23	100	
2025-065	151	Clari. Uro		053 055	053 055		055 - 3+	23	2	23	100	
066 URINAL.-UROBILINOGEN												
2025-061	011	AMES NM10S		061 063	061 063		061 - NORMAL,NEG	33	2	33	100	
2025-061	011	AMES NM10S		061 063	061 063		062 - 2	33	16	33	100	
2025-061	011	AMES NM10S		061 063	061 063		063 - 4	33	15	33	100	
2025-061	013	BAYER CLI		061 063	061 063		061 - NORMAL,NEG	21	6	21	100	
2025-061	013	BAYER CLI		061 063	061 063		062 - 2	21	9	21	100	
2025-061	013	BAYER CLI		061 063	061 063		063 - 4	21	6	21	100	
2025-061	067	URISCAN			061 063		061 - NORMAL,NEG	56	18	54	100	
2025-061	067	URISCAN			061 063		062 - 2	56	5	54	100	

**Participant Summary**  
**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-061	067	URISCAN			061 063		063 - 4	56	31	54	100
2025-061	067	URISCAN			061 063		064 - 8	56	1	54	0
2025-061	067	URISCAN			061 063		065 - 12	56	1	54	0
2025-061	072	URS-9-TECO		061 063	061 063		061 - NORMAL,NEG	56	7	55	100
2025-061	072	URS-9-TECO		061 063	061 063		062 - 2	56	35	55	100
2025-061	072	URS-9-TECO		061 063	061 063		063 - 4	56	13	55	100
2025-061	072	URS-9-TECO		061 063	061 063		064 - 8	56	1	55	0
2025-061	080	ROCHE (CHE		061 061	061 063		061 - NORMAL,NEG	36	33	36	100
2025-061	080	ROCHE (CHE		061 061	061 063		062 - 2	36	3	36	100
2025-061	089	AIMSTRIP		061 061	061 063		061 - NORMAL,NEG	153	126	153	100
2025-061	089	AIMSTRIP		061 061	061 063		062 - 2	153	17	153	100
2025-061	089	AIMSTRIP		061 061	061 063		063 - 4	153	10	153	100
2025-061	094	CLINITEK		062 064	061 063		062 - 2	105	38	105	100
2025-061	094	CLINITEK		062 064	061 063		063 - 4	105	52	105	100
2025-061	094	CLINITEK		062 064	061 063		064 - 8	105	1	105	100
2025-061	094	CLINITEK		062 064	061 063		061 - NORMAL,NEG	105	14	105	100
2025-061	102	ACON LAB			061 063		061 - NORMAL,NEG	122	93	122	100
2025-061	102	ACON LAB			061 063		062 - 2	122	26	122	100
2025-061	102	ACON LAB			061 063		063 - 4	122	3	122	100
2025-061	131	iCHEM VELO		062 064	061 063		062 - 2	34	1	34	100
2025-061	131	iCHEM VELO		062 064	061 063		063 - 4	34	33	34	100
2025-061	138	URS-10T		061 063	061 063		061 - NORMAL,NEG	10	1	10	100
2025-061	138	URS-10T		061 063	061 063		062 - 2	10	5	10	100
2025-061	138	URS-10T		061 063	061 063		063 - 4	10	4	10	100
2025-061	140	MISSION A			061 063		061 - NORMAL,NEG	37	29	37	100
2025-061	140	MISSION A			061 063		062 - 2	37	7	37	100
2025-061	140	MISSION A			061 063		063 - 4	37	1	37	100
2025-061	145	CLINITEK		061 063	061 063		061 - NORMAL,NEG	42	3	42	100
2025-061	145	CLINITEK		061 063	061 063		062 - 2	42	39	42	100
2025-061	147	Mission120		061 061	061 063		061 - NORMAL,NEG	38	37	38	100



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-061	147	Mission120		061 061	061 063		062 - 2	38	1	38	100	
2025-061	148	Mission500		061 061	061 063		061 - NORMAL,NEG	134	129	134	100	
2025-061	148	Mission500		061 061	061 063		062 - 2	134	4	134	100	
2025-061	148	Mission500		061 061	061 063		063 - 4	134	1	134	100	
2025-061	151	Clari. Uro			061 063		061 - NORMAL,NEG	23	15	23	100	
2025-061	151	Clari. Uro			061 063		062 - 2	23	6	23	100	
2025-061	151	Clari. Uro			061 063		063 - 4	23	2	23	100	
066 URINAL.-UROBILINOGEN												
2025-062	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2025-062	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	21	21	21	100	
2025-062	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	56	56	56	100	
2025-062	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	56	56	56	100	
2025-062	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	36	36	36	100	
2025-062	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	153	153	153	100	
2025-062	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	105	105	105	100	
2025-062	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	122	121	121	100	
2025-062	102	ACON LAB		061 061	061 061		062 - 2	122	1	121	0	
2025-062	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	34	34	34	100	
2025-062	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100	
2025-062	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	37	36	36	100	
2025-062	140	MISSION A		061 061	061 061		062 - 2	37	1	36	0	
2025-062	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	42	42	42	100	
2025-062	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2025-062	148	Mission500		061 061	061 061		061 - NORMAL,NEG	134	133	133	100	
2025-062	148	Mission500		061 061	061 061		062 - 2	134	1	133	0	
2025-062	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	23	22	22	100	
2025-062	151	Clari. Uro		061 061	061 061		062 - 2	23	1	22	0	
2025-063	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-063	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	21	21	21	100	
2025-063	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	56	56	56	100	
2025-063	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	56	56	56	100	
2025-063	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	36	36	36	100	
2025-063	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	153	153	153	100	
2025-063	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	105	105	105	100	
2025-063	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	122	121	121	100	
2025-063	102	ACON LAB		061 061	061 061		062 - 2	122	1	121	0	
2025-063	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	34	34	34	100	
2025-063	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100	
2025-063	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	37	36	36	100	
2025-063	140	MISSION A		061 061	061 061		062 - 2	37	1	36	0	
2025-063	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	42	42	42	100	
2025-063	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2025-063	148	Mission500		061 061	061 061		061 - NORMAL,NEG	134	133	133	100	
2025-063	148	Mission500		061 061	061 061		062 - 2	134	1	133	0	
2025-063	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	23	22	22	100	
2025-063	151	Clari. Uro		061 061	061 061		062 - 2	23	1	22	0	
066 URINAL.-UROBILINOGEN												
2025-064	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2025-064	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	21	21	21	100	
2025-064	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	56	56	56	100	
2025-064	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	56	56	56	100	
2025-064	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	36	36	36	100	
2025-064	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	153	153	153	100	
2025-064	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	105	105	105	100	
2025-064	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	122	121	121	100	
2025-064	102	ACON LAB		061 061	061 061		062 - 2	122	1	121	0	
2025-064	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	34	34	34	100	
2025-064	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-064	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	37	36	36	100	
2025-064	140	MISSION A		061 061	061 061		062 - 2	37	1	36	0	
2025-064	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	42	42	42	100	
2025-064	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2025-064	148	Mission500		061 061	061 061		061 - NORMAL,NEG	134	133	133	100	
2025-064	148	Mission500		061 061	061 061		062 - 2	134	1	133	0	
2025-064	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	23	22	22	100	
2025-064	151	Clari. Uro		061 061	061 061		062 - 2	23	1	22	0	
066 URINAL.-UROBILINOGEN												
2025-065	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2025-065	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	21	21	21	100	
2025-065	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	56	56	56	100	
2025-065	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	56	56	56	100	
2025-065	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	36	36	36	100	
2025-065	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	153	153	153	100	
2025-065	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	105	105	105	100	
2025-065	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	122	121	121	100	
2025-065	102	ACON LAB		061 061	061 061		062 - 2	122	1	121	0	
2025-065	131	ICHEM VELO		061 061	061 061		061 - NORMAL,NEG	34	34	34	100	
2025-065	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	10	10	10	100	
2025-065	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	37	36	36	100	
2025-065	140	MISSION A		061 061	061 061		062 - 2	37	1	36	0	
2025-065	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	42	42	42	100	
2025-065	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2025-065	148	Mission500		061 061	061 061		061 - NORMAL,NEG	134	133	133	100	
2025-065	148	Mission500		061 061	061 061		062 - 2	134	1	133	0	
2025-065	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	23	22	22	100	
2025-065	151	Clari. Uro		061 061	061 061		062 - 2	23	1	22	0	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
184 URINALYSIS LEUKOCYTE												
2025-061	011	AMES NM10S		001	001	001	001	001 - Negative	33	33	33	100
2025-061	013	BAYER CLI		001	001	001	001	001 - Negative	21	21	21	100
2025-061	067	URISCAN		001	001	001	001	001 - Negative	56	56	56	100
2025-061	072	URS-9-TECO		001	001	001	001	001 - Negative	52	52	52	100
2025-061	080	ROCHE (CHE		001	001	001	001	001 - Negative	33	33	33	100
2025-061	089	AIMSTRIP		001	001	001	001	001 - Negative	151	150	150	100
2025-061	089	AIMSTRIP		001	001	001	001	002 - Traces	151	1	150	0
2025-061	094	CLINITEK		001	001	001	001	001 - Negative	104	104	104	100
2025-061	102	ACON LAB		001	001	001	001	001 - Negative	117	117	117	100
2025-061	131	iCHEM VELO		001	001	001	001	001 - Negative	33	33	33	100
2025-061	138	URS-10T		001	001	001	001	001 - Negative	10	10	10	100
2025-061	140	MISSION A		001	001	001	001	001 - Negative	42	42	42	100
2025-061	145	CLINITEK		001	001	001	001	001 - Negative	41	41	41	100
2025-061	147	Mission120		001	001	001	001	001 - Negative	37	37	37	100
2025-061	148	Mission500		001	001	001	001	001 - Negative	136	136	136	100
2025-061	151	Clari. Uro		001	001	001	001	001 - Negative	23	23	23	100
2025-062	011	AMES NM10S		002	004	003	005	002 - Traces	33	1	33	100
2025-062	011	AMES NM10S		002	004	003	005	003 - Small	33	27	33	100
2025-062	011	AMES NM10S		002	004	003	005	004 - Moderate	33	5	33	100
2025-062	013	BAYER CLI		002	004	003	005	003 - Small	21	18	21	100
2025-062	013	BAYER CLI		002	004	003	005	004 - Moderate	21	3	21	100
2025-062	067	URISCAN		004	005	003	005	003 - Small	56	7	56	100
2025-062	067	URISCAN		004	005	003	005	004 - Moderate	56	20	56	100
2025-062	067	URISCAN		004	005	003	005	005 - Large	56	29	56	100
2025-062	072	URS-9-TECO		002	004	003	005	002 - Traces	52	4	52	100
2025-062	072	URS-9-TECO		002	004	003	005	003 - Small	52	29	52	100
2025-062	072	URS-9-TECO		002	004	003	005	004 - Moderate	52	18	52	100

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-062	072	URS-9-TECO		002 004	003 005		005 - Large	52	1	52	100	
2025-062	080	ROCHE (CHE		004 005	003 005		004 - Moderate	33	1	33	100	
2025-062	080	ROCHE (CHE		004 005	003 005		005 - Large	33	32	33	100	
2025-062	089	AIMSTRIP		002 004	003 005		004 - Moderate	151	15	149	100	
2025-062	089	AIMSTRIP		002 004	003 005		001 - Negative	151	2	149	0	
2025-062	089	AIMSTRIP		002 004	003 005		002 - Traces	151	27	149	100	
2025-062	089	AIMSTRIP		002 004	003 005		003 - Small	151	107	149	100	
2025-062	094	CLINITEK		002 004	003 005		002 - Traces	104	2	104	100	
2025-062	094	CLINITEK		002 004	003 005		003 - Small	104	97	104	100	
2025-062	094	CLINITEK		002 004	003 005		004 - Moderate	104	4	104	100	
2025-062	094	CLINITEK		002 004	003 005		005 - Large	104	1	104	100	
2025-062	102	ACON LAB		002 004	003 005		002 - Traces	117	14	117	100	
2025-062	102	ACON LAB		002 004	003 005		003 - Small	117	73	117	100	
2025-062	102	ACON LAB		002 004	003 005		004 - Moderate	117	30	117	100	
2025-062	131	iCHEM VELO		004 005	003 005		004 - Moderate	33	3	33	100	
2025-062	131	iCHEM VELO		004 005	003 005		005 - Large	33	30	33	100	
2025-062	138	URS-10T		002 004	003 005		003 - Small	10	6	10	100	
2025-062	138	URS-10T		002 004	003 005		004 - Moderate	10	4	10	100	
2025-062	140	MISSION A		002 004	003 005		001 - Negative	42	1	41	0	
2025-062	140	MISSION A		002 004	003 005		002 - Traces	42	4	41	100	
2025-062	140	MISSION A		002 004	003 005		003 - Small	42	22	41	100	
2025-062	140	MISSION A		002 004	003 005		004 - Moderate	42	14	41	100	
2025-062	140	MISSION A		002 004	003 005		005 - Large	42	1	41	100	
2025-062	145	CLINITEK		003 005	003 005		004 - Moderate	41	41	41	100	
2025-062	147	Mission120		002 004	003 005		002 - Traces	37	10	37	100	
2025-062	147	Mission120		002 004	003 005		003 - Small	37	27	37	100	
2025-062	148	Mission500		002 004	003 005		005 - Large	136	1	136	100	
2025-062	148	Mission500		002 004	003 005		002 - Traces	136	26	136	100	
2025-062	148	Mission500		002 004	003 005		003 - Small	136	76	136	100	
2025-062	148	Mission500		002 004	003 005		004 - Moderate	136	33	136	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-062	151	Clari. Uro		002 004	003 005		002 - Traces	23	2	23	100	
2025-062	151	Clari. Uro		002 004	003 005		003 - Small	23	16	23	100	
2025-062	151	Clari. Uro		002 004	003 005		004 - Moderate	23	5	23	100	
184 URINALYSIS LEUKOCYTE												
2025-063	011	AMES NM10S		001 001	001 001		001 - Negative	33	33	33	100	
2025-063	013	BAYER CLI		001 001	001 001		001 - Negative	21	21	21	100	
2025-063	067	URISCAN		001 001	001 001		001 - Negative	56	56	56	100	
2025-063	072	URS-9-TECO		001 001	001 001		001 - Negative	52	52	52	100	
2025-063	080	ROCHE (CHE		001 001	001 001		001 - Negative	33	32	32	100	
2025-063	080	ROCHE (CHE		001 001	001 001		002 - Traces	33	1	32	0	
2025-063	089	AIMSTRIP		001 001	001 001		001 - Negative	151	151	151	100	
2025-063	094	CLINITEK		001 001	001 001		001 - Negative	104	104	104	100	
2025-063	102	ACON LAB		001 001	001 001		001 - Negative	117	117	117	100	
2025-063	131	iCHEM VELO		001 001	001 001		001 - Negative	33	33	33	100	
2025-063	138	URS-10T		001 001	001 001		001 - Negative	10	10	10	100	
2025-063	140	MISSION A		001 001	001 001		001 - Negative	42	42	42	100	
2025-063	145	CLINITEK		001 001	001 001		001 - Negative	41	41	41	100	
2025-063	147	Mission120		001 001	001 001		001 - Negative	37	37	37	100	
2025-063	148	Mission500		001 001	001 001		001 - Negative	136	136	136	100	
2025-063	151	Clari. Uro		001 001	001 001		001 - Negative	23	23	23	100	
2025-064	011	AMES NM10S		001 001	001 001		001 - Negative	33	33	33	100	
2025-064	013	BAYER CLI		001 001	001 001		001 - Negative	21	21	21	100	
2025-064	067	URISCAN		001 001	001 001		001 - Negative	56	56	56	100	
2025-064	072	URS-9-TECO		001 001	001 001		001 - Negative	52	52	52	100	
2025-064	080	ROCHE (CHE		001 001	001 001		001 - Negative	33	32	32	100	
2025-064	080	ROCHE (CHE		001 001	001 001		002 - Traces	33	1	32	0	
2025-064	089	AIMSTRIP		001 001	001 001		001 - Negative	151	151	151	100	
2025-064	094	CLINITEK		001 001	001 001		001 - Negative	104	104	104	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-064	102	ACON LAB		001 001	001 001		001 - Negative	117	117	117	100	
2025-064	131	iCHEM VELO		001 001	001 001		001 - Negative	33	33	33	100	
2025-064	138	URS-10T		001 001	001 001		001 - Negative	10	10	10	100	
2025-064	140	MISSION A		001 001	001 001		001 - Negative	42	42	42	100	
2025-064	145	CLINITEK		001 001	001 001		001 - Negative	41	41	41	100	
2025-064	147	Mission120		001 001	001 001		001 - Negative	37	37	37	100	
2025-064	148	Mission500		001 001	001 001		001 - Negative	136	136	136	100	
2025-064	151	Clari. Uro		001 001	001 001		001 - Negative	23	23	23	100	
184 URINALYSIS LEUKOCYTE												
2025-065	011	AMES NM10S		001 001	001 001		001 - Negative	33	33	33	100	
2025-065	013	BAYER CLI		001 001	001 001		001 - Negative	21	21	21	100	
2025-065	067	URISCAN		001 001	001 001		001 - Negative	56	56	56	100	
2025-065	072	URS-9-TECO		001 001	001 001		001 - Negative	52	52	52	100	
2025-065	080	ROCHE (CHE		001 001	001 001		001 - Negative	33	32	32	100	
2025-065	080	ROCHE (CHE		001 001	001 001		002 - Traces	33	1	32	0	
2025-065	089	AIMSTRIP		001 001	001 001		001 - Negative	151	151	151	100	
2025-065	094	CLINITEK		001 001	001 001		001 - Negative	104	104	104	100	
2025-065	102	ACON LAB		001 001	001 001		001 - Negative	117	116	116	100	
2025-065	102	ACON LAB		001 001	001 001		005 - Large	117	1	116	0	
2025-065	131	iCHEM VELO		001 001	001 001		001 - Negative	33	33	33	100	
2025-065	138	URS-10T		001 001	001 001		001 - Negative	10	10	10	100	
2025-065	140	MISSION A		001 001	001 001		001 - Negative	42	42	42	100	
2025-065	145	CLINITEK		001 001	001 001		001 - Negative	41	41	41	100	
2025-065	147	Mission120		001 001	001 001		001 - Negative	37	37	37	100	
2025-065	148	Mission500		001 001	001 001		001 - Negative	136	136	136	100	
2025-065	151	Clari. Uro		001 001	001 001		001 - Negative	23	23	23	100	

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 80 PREGNANCY TEST						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
063 URI-PREGNANCY TEST												
2025-061	091	AIM STEP		002	002	002	002	002 - POSITIVE	34	34	34	100
2025-061	101	HCG Alere		002	002	002	002	002 - POSITIVE	23	23	23	100
2025-062	091	AIM STEP		001	001	001	001	001 - NEGATIVE	34	34	34	100
2025-062	101	HCG Alere		001	001	001	001	001 - NEGATIVE	23	23	23	100
2025-063	091	AIM STEP		001	001	001	001	001 - NEGATIVE	34	34	34	100
2025-063	101	HCG Alere		001	001	001	001	001 - NEGATIVE	23	23	23	100
2025-064	091	AIM STEP		001	001	001	001	001 - NEGATIVE	34	34	34	100
2025-064	101	HCG Alere		001	001	001	001	001 - NEGATIVE	23	23	23	100
2025-065	091	AIM STEP		002	002	002	002	002 - POSITIVE	34	34	34	100
2025-065	101	HCG Alere		002	002	002	002	002 - POSITIVE	23	23	23	100

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 75 URINALYSIS SEDIMENT						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
150 URINAL.- SEDIMENT												
2025-071					029	029			915	0	915	0
2025-071					029	029	029 - BACTERIA		915	915	915	100
2025-072					027	027	014 - CA. OXALAT		915	2	884	0
2025-072					027	027	015 - CA. SULFAT		915	9	884	0
2025-072					027	027	018 - HIPPURIC		915	1	884	0



## Participant Summary

MONTH 2 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS			GRP: 75 URINALYSIS SEDIMENT						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-072					027 027		021 - SULFANAM.	915	1	884	0
2025-072					027 027		022 - TYROSINE	915	11	884	0
2025-072					027 027		023 - URIC ACID	915	1	884	0
2025-072					027 027		024 - AMMONIUM B	915	1	884	0
2025-072					027 027		025 - AMORPHOUS	915	1	884	0
2025-072					027 027		026 - CA. CARBO.	915	1	884	0
2025-072					027 027		027 - CA. PHOSP.	915	884	884	100
2025-072					027 027		028 - TRIPLE PH.	915	3	884	0
150 URINAL.- SEDIMENT											
2025-073					038 038		032 - MUCOUS TH.	915	3	911	0
2025-073					038 038		036 - STARCH CR.	915	1	911	0
2025-073					038 038		038 - YEAST/FUN.	915	911	911	100
2025-074					036 036		036 - STARCH CR.	915	914	914	100
2025-074					036 036		038 - YEAST/FUN.	915	1	914	0
2025-075							001 - E.C. CAST	916	100	916	0
2025-075							002 - FATTY CAST	916	662	916	0
2025-075							003 - GRANULAR C	916	4	916	0
2025-075							004 - HYALINE C.	916	1	916	0
2025-075							005 - RED CELL C	916	1	916	0
2025-075							006 - WAXY CAST	916	2	916	0
2025-075							007 - WHITE CELL	916	107	916	0
2025-075							010 - RENAL TUB.	916	31	916	0
2025-075							033 - OVAL FAT B	916	8	916	0

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPE: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 98 OCCULT BLOOD						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
154 FECAL OCCULT BLOOD												
2025-081	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	356	356	356	100
2025-081	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	755	755	755	100
2025-082	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	356	356	356	100
2025-082	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	755	755	755	100
2025-083	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	356	356	356	100
2025-083	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	755	755	755	100
2025-084	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	356	356	356	100
2025-084	002	INMMUASSAY		002	002	002	002	001 - NEGATIVE	755	1	754	0
2025-084	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	755	754	754	100
2025-085	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	356	355	355	100
2025-085	001	PEROXIDASE		001	001	001	001	002 - POSITIVE	356	1	355	0
2025-085	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	755	753	753	100
2025-085	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	755	2	753	0

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 90 SPECIAL TEST					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
068 CARCINOE. ANTIG. CEA											
CLIA TEST ID #: 352											
EVALUATION CRITERIA: TARGET VALUE 15 % OR 1.00 {GREATER}											
2025-031	29	VITROS		10	8.580	0.462	5.39	7.300	9.900		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-031	38	ROCHE E		18	8.111	0.418	5.15	6.900	9.300
2025-031	44	BECK.COUL.		18	9.606	0.900	9.37	8.200	11.000
2025-031	50	ARC		10	10.050	0.372	3.70	8.500	11.600
068 CARCINOE. ANTIG. CEA			CLIA TEST ID #: 352	EVALUATION CRITERIA: TARGET VALUE 15 % OR 1.00 {GREATER}					
2025-032	29	VITROS		10	20.850	0.970	4.65	17.700	24.000
2025-032	38	ROCHE E		18	18.417	0.957	5.20	15.700	21.200
2025-032	44	BECK.COUL.		18	22.833	2.023	8.86	19.400	26.300
2025-032	50	ARC		10	23.570	0.948	4.02	20.000	27.100
2025-033	29	VITROS		10	28.190	1.390	4.93	24.000	32.400
2025-033	38	ROCHE E		18	24.311	1.253	5.15	20.700	28.000
2025-033	44	BECK.COUL.		18	30.583	3.021	9.88	26.000	35.200
2025-033	50	ARC		10	30.870	1.563	5.06	26.200	35.500
2025-034	29	VITROS		10	4.230	0.307	7.25	3.200	5.200
2025-034	38	ROCHE E		18	4.306	0.244	5.66	3.300	5.300
2025-034	44	BECK.COUL.		18	4.911	0.432	8.79	3.900	5.900
2025-034	50	ARC		10	5.210	0.295	5.66	4.200	6.200
2025-035	29	VITROS		10	0.410	0.030	7.32	0	1.400
2025-035	38	ROCHE E		18	0.728	0.099	13.59	0	1.700
2025-035	44	BECK.COUL.		18	0.561	0.059	10.52	0	1.600
2025-035	50	ARC		10	1.120	0.487	43.52	0.100	2.100
069 PROS. SPEC-ANTIG-PSA			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}					
2025-031	29	VITROS		44	3.941	0.171	4.34	3.200	4.700
2025-031	29	VITROS		44	5.386	0.270	5.00	4.600	6.200
2025-031	38	ROCHE E		52	7.949	0.562	7.07	6.400	9.500
2025-031	44	BECK.COUL.		45	8.167	0.476	5.82	6.500	9.800
2025-031	50	ARC		21	6.305	0.726	11.52	5.000	7.600
2025-031	57	S. EXL 200		57	7.886	0.430	5.45	6.300	9.500

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2025-031	58	ATELLICA		19	6.816	0.339	4.98	5.500	8.200		
069	PROS. SPEC-ANTIG-PSA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}								
2025-032	29	VITROS		44	12.457	0.707	5.67	10.300	14.600		
2025-032	29	VITROS		44	9.175	0.390	4.25	7.300	11.000		
2025-032	38	ROCHE E		52	19.186	1.479	7.71	15.300	23.000		
2025-032	44	BECK.COUL.		45	19.466	1.137	5.84	15.600	23.400		
2025-032	50	ARC		21	15.845	1.146	7.23	12.700	19.000		
2025-032	57	S. EXL 200		57	19.134	1.050	5.49	15.300	23.000		
2025-032	58	ATELLICA		19	16.142	0.911	5.64	12.900	19.400		
2025-033	29	VITROS		44	16.843	0.918	5.45	14.100	19.600		
2025-033	29	VITROS		44	12.205	0.448	3.67	9.800	14.600		
2025-033	38	ROCHE E		52	24.994	1.457	5.83	20.000	30.000		
2025-033	44	BECK.COUL.		45	25.611	1.401	5.47	20.500	30.700		
2025-033	50	ARC		21	21.180	1.186	5.60	16.900	25.400		
2025-033	57	S. EXL 200		57	25.275	1.557	6.16	20.200	30.300		
2025-033	58	ATELLICA		19	21.000	1.116	5.31	16.800	25.200		
2025-034	29	VITROS		44	2.030	0.093	4.57	1.600	2.400		
2025-034	29	VITROS		44	2.543	0.118	4.63	2.200	2.900		
2025-034	38	ROCHE E		52	3.963	0.669	16.88	3.200	4.800		
2025-034	44	BECK.COUL.		45	3.923	0.205	5.24	3.100	4.700		
2025-034	50	ARC		21	3.010	0.371	12.34	2.400	3.600		
2025-034	57	S. EXL 200		57	3.743	0.200	5.34	3.000	4.500		
2025-034	58	ATELLICA		19	3.316	0.203	6.13	2.700	4.000		
2025-035	29	VITROS		44	0.086	0.035	40.82	0.100	0.100		
2025-035	29	VITROS		44	0.100	0.000	0.00	0	0.300		
2025-035	38	ROCHE E		52	0.118	0.110	93.27	0	0.300		
2025-035	44	BECK.COUL.		45	0.100	0.000	0.00	0	0.300		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2025-035	50	ARC		21	0.000	0.000	0.00	0	0.200		
2025-035	57	S. EXL 200		57	0.086	0.044	50.82	0	0.300		
2025-035	58	APELLICA		19	0.100	0.000	0.00	0	0.300		
071 VITAMIN B 12			CLIA TEST ID #: 600	EVALUATION CRITERIA: TARGET VALUE 25 % OR 30.00 {GREATER}							
2025-031	29	VITROS		28	481.607	25.805	5.36	361.000	602.000		
2025-031	38	ROCHE E		39	492.395	38.928	7.91	369.000	615.000		
2025-031	44	BECK.COUL.		25	374.040	29.942	8.01	281.000	468.000		
2025-031	50	ARC		21	487.050	37.693	7.74	365.000	609.000		
2025-031	57	S. EXL 200		21	498.286	33.932	6.81	374.000	623.000		
2025-031	58	APELLICA		15	411.733	44.564	10.82	309.000	515.000		
2025-032	29	VITROS		28	816.500	44.162	5.41	612.000	1021.000		
2025-032	38	ROCHE E		39	874.079	82.299	9.42	656.000	1093.000		
2025-032	44	BECK.COUL.		25	644.958	42.660	6.61	484.000	806.000		
2025-032	50	ARC		21	884.381	59.413	6.72	663.000	1105.000		
2025-032	57	S. EXL 200		21	857.048	51.584	6.02	643.000	1071.000		
2025-032	58	APELLICA		15	747.800	85.490	11.43	561.000	935.000		
2025-033	29	VITROS		28	853.000	43.690	5.12	640.000	1066.000		
2025-033	38	ROCHE E		39	1116.432	67.176	6.02	837.000	1396.000		
2025-033	44	BECK.COUL.		25	766.500	49.957	6.52	575.000	958.000		
2025-033	50	ARC		21	1098.952	77.590	7.06	824.000	1374.000		
2025-033	57	S. EXL 200		21	1058.952	52.806	4.99	794.000	1324.000		
2025-033	58	APELLICA		15	872.000	136.859	15.69	654.000	1090.000		
2025-034	29	VITROS		28	340.704	9.767	2.87	256.000	426.000		
2025-034	38	ROCHE E		39	368.216	52.189	14.17	276.000	460.000		
2025-034	44	BECK.COUL.		25	266.280	20.571	7.73	200.000	333.000		
2025-034	50	ARC		21	357.667	23.598	6.60	268.000	447.000		
2025-034	57	S. EXL 200		21	373.095	34.282	9.19	280.000	466.000		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2025-034	58	ATELLICA		15	277.067	36.428	13.15	208.000	346.000		
071 VITAMIN B 12		CLIA TEST ID #: 600	EVALUATION CRITERIA: TARGET VALUE 25 % OR 30.00 {GREATER}								
2025-035	29	VITROS		28	236.321	8.852	3.75	177.000	295.000		
2025-035	38	ROCHE E		39	241.553	41.104	17.02	181.000	302.000		
2025-035	44	BECK.COUL.		25	175.560	16.082	9.16	132.000	219.000		
2025-035	50	ARC		21	250.238	26.396	10.55	188.000	313.000		
2025-035	57	S. EXL 200		21	263.619	37.402	14.19	198.000	330.000		
2025-035	58	ATELLICA		15	161.067	29.467	18.30	121.000	201.000		

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
146 GLYCOHEMOGLOBIN		CLIA TEST ID #: 420	EVALUATION CRITERIA: TARGET VALUE 8 %								
2025-041	12	COBAS/INT.		26	5.838	0.210	3.59	5.400	6.300		
2025-041	14	IMMUNOTUR.		15	5.820	0.229	3.93	5.400	6.300		
2025-041	14	IMMUNOTUR.		15	6.025	0.164	2.72	5.500	6.500		
2025-041	22	VITROS		56	6.133	0.125	2.03	5.600	6.600		
2025-041	22	VITROS		56	5.656	0.155	2.74	5.200	6.100		
2025-041	31	IMMUNOTURB		51	5.520	0.203	3.68	5.100	6.000		
2025-041	40	SIEMENS DI		74	5.790	0.171	2.96	5.300	6.300		
2025-041	46	ARCHITECT		18	5.733	0.160	2.79	5.300	6.200		
2025-041	48	ATELLICA		18	5.728	0.115	2.00	5.300	6.200		
2025-041	50	CS400DIRUI		10	5.960	0.250	4.19	5.500	6.400		
2025-042	12	COBAS/INT.		26	8.131	0.263	3.23	7.500	8.800		
2025-042	14	IMMUNOTUR.		15	8.625	0.286	3.32	7.900	9.300		
2025-042	14	IMMUNOTUR.		15	8.260	0.393	4.76	7.600	8.900		
2025-042	22	VITROS		56	8.098	0.242	2.99	7.500	8.700		
2025-042	22	VITROS		56	8.500	0.163	1.92	7.800	9.200		

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-042	31	IMMUNOTURB		51	8.135	0.165	2.03	7.500	8.800
2025-042	40	SIEMENS DI		74	8.255	0.213	2.58	7.600	8.900
2025-042	46	ARCHITECT		18	7.906	0.201	2.55	7.300	8.500
2025-042	48	ATELLICA		18	8.000	0.170	2.12	7.400	8.600
2025-042	50	CS400DIRUI		10	8.540	1.469	17.20	7.900	9.200
146	GLYCOHEMOGLOBIN		CLIA TEST ID #: 420	EVALUATION CRITERIA: TARGET VALUE 8 %					
2025-043	12	COBAS/INT.		26	5.852	0.214	3.65	5.400	6.300
2025-043	14	IMMUNOTUR.		15	5.753	0.182	3.16	5.300	6.200
2025-043	14	IMMUNOTUR.		15	6.075	0.249	4.09	5.600	6.600
2025-043	22	VITROS		56	6.067	0.170	2.80	5.600	6.600
2025-043	22	VITROS		56	5.667	0.168	2.97	5.200	6.100
2025-043	31	IMMUNOTURB		51	5.543	0.210	3.79	5.100	6.000
2025-043	40	SIEMENS DI		74	5.837	0.170	2.91	5.400	6.300
2025-043	46	ARCHITECT		18	5.712	0.102	1.79	5.300	6.200
2025-043	48	ATELLICA		18	5.761	0.106	1.84	5.300	6.200
2025-043	50	CS400DIRUI		10	5.940	0.291	4.89	5.500	6.400
2025-044	12	COBAS/INT.		26	5.850	0.231	3.95	5.400	6.300
2025-044	14	IMMUNOTUR.		15	6.200	0.346	5.59	5.700	6.700
2025-044	14	IMMUNOTUR.		15	5.864	0.277	4.72	5.400	6.300
2025-044	22	VITROS		56	5.638	0.172	3.05	5.200	6.100
2025-044	22	VITROS		56	6.033	0.047	0.78	5.600	6.500
2025-044	31	IMMUNOTURB		51	5.518	0.232	4.20	5.100	6.000
2025-044	40	SIEMENS DI		74	5.840	0.177	3.04	5.400	6.300
2025-044	46	ARCHITECT		18	5.718	0.098	1.72	5.300	6.200
2025-044	48	ATELLICA		18	5.767	0.120	2.08	5.300	6.200
2025-044	50	CS400DIRUI		10	5.960	0.284	4.76	5.500	6.400
2025-045	12	COBAS/INT.		26	5.096	0.195	3.83	4.700	5.500
2025-045	14	IMMUNOTUR.		15	5.021	0.126	2.52	4.600	5.400

**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-045	14	IMMUNOTUR.		15	5.450	0.229	4.20	5.000	5.900
2025-045	22	VITROS		56	5.233	0.125	2.38	4.800	5.700
2025-045	22	VITROS		56	4.873	0.127	2.61	4.500	5.300
2025-045	31	IMMUNOTURB		51	4.804	0.167	3.48	4.400	5.200
2025-045	40	SIEMENS DI		74	5.005	0.120	2.40	4.600	5.400
2025-045	46	ARCHITECT		18	5.017	0.167	3.34	4.600	5.400
2025-045	48	ATELLICA		18	4.983	0.090	1.80	4.600	5.400
2025-045	50	CS400DIRUI		10	5.060	0.420	8.30	4.700	5.500

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
178	Vitamin D	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-261	3	VITROS		45	124.614	2.806	2.25	100.000	150.000
2025-261	5	ROCHE E		36	88.229	7.578	8.59	71.000	106.000
2025-261	9	BECK.COUL.		42	94.190	6.127	6.50	75.000	113.000
2025-261	11	ARC		19	82.167	3.609	4.39	66.000	99.000
2025-261	25	S. DIME		32	77.188	5.604	7.26	62.000	93.000
2025-261	27	ATELLICA		18	137.389	6.139	4.47	110.000	165.000
2025-262	3	VITROS		45	20.205	3.402	16.84	16.000	24.000
2025-262	5	ROCHE E		36	6.294	0.749	11.90	5.000	8.000
2025-262	9	BECK.COUL.		42	14.810	1.880	12.70	12.000	18.000
2025-262	11	ARC		19	10.889	0.875	8.03	9.000	13.000
2025-262	25	S. DIME		32	14.906	1.444	9.69	12.000	18.000
2025-262	27	ATELLICA		18	19.389	3.918	20.21	16.000	23.000
2025-263	3	VITROS		45	82.614	5.989	7.25	66.000	99.000
2025-263	5	ROCHE E		36	43.629	4.799	11.00	35.000	52.000



**Participant Summary**

**MONTH 2 OF YEAR 2025**

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D				
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-263	9	BECK.COUL.		42	59.857	4.470	7.47	48.000	72.000
2025-263	11	ARC		19	46.611	2.215	4.75	37.000	56.000
2025-263	25	S. DIME		32	48.125	4.407	9.16	39.000	58.000
2025-263	27	APELLICA		18	89.778	5.202	5.79	72.000	108.000
178 Vitamin D			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %					
2025-264	3	VITROS		45	109.250	4.618	4.23	87.000	131.000
2025-264	5	ROCHE E		36	65.114	9.665	14.84	52.000	78.000
2025-264	9	BECK.COUL.		42	78.756	4.509	5.73	63.000	95.000
2025-264	11	ARC		19	65.889	3.725	5.65	53.000	79.000
2025-264	25	S. DIME		32	63.563	4.975	7.83	51.000	76.000
2025-264	27	APELLICA		18	114.500	5.315	4.64	92.000	137.000
2025-265	3	VITROS		45	52.467	4.529	8.63	42.000	63.000
2025-265	5	ROCHE E		36	22.057	3.070	13.92	18.000	26.000
2025-265	9	BECK.COUL.		42	37.905	3.228	8.52	30.000	45.000
2025-265	11	ARC		19	28.316	2.153	7.60	23.000	34.000
2025-265	25	S. DIME		32	31.531	2.806	8.90	25.000	38.000
2025-265	27	APELLICA		18	56.333	5.406	9.60	45.000	68.000